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ABSTRACT 
Li, Jian-Yuan Ph.D., Purdue University, December 2014. The Modification of Brucine 
Derivatives as Chiral Ligands and Its Application in the Asymmetric Synthesis. Major 
Professor: Robert Minto. 
 
 
        The modification of brucine derivatives as chiral ligands and the use of a 
multifaceted chiral ligand, brucine diol, under different reaction conditions to produce 
various optical isomers is described. In Chapter 1, the generation of a number of brucine 
derivatives is described. Taking the advantage of brucine-diol’s excellent molecular 
recognition capability for multiple organic functional groups, we focused on the synthetic 
modifications of brucine-diol and the synthesis of brucine N-oxide. We also produced 
various brucine derivatives with different functional moieties in good yields and 
selectivities.  
        In Chapter 2, we described the investigation of brucine N-oxide catalyzed Morita-
Baylis-Hillman (MBH) reaction of alkyl/aryl ketones. Brucine N-oxide was used as a 
nucleophilic organic catalyst in the MBH reaction of alkyl vinyl ketone. In addition, 
asymmetric MBH reactions of alkyl vinyl ketones with aldehydes were investigated using 
a dual catalysis of brucine N-oxide and proline. In this dual catalyst system, proline was 
found to form iminium intermediates with electron-deficient aryl aldehydes, while the N-
oxide activated vinyl ketones provided enolates through the conjugate addition. Our dual 
catalysis approach also allowed the development of MBH reaction of aryl vinyl ketones.
xiii 
 
        In Chapter 3, brucine diol-copper complex catalyzed asymmetric conjugate addition 
of glycine (ket)imines to nitroalkenes is discussed. Stereodivergent catalytic asymmetric 
conjugate reactions for glycine (ket)imines with nitroalkenes were achieved using various 
chiral catalysts derived from a single chiral source, brucine diol. Both syn- and anti-
conjugate addition products were obtained with high diastereoselectivity and 
enantioselectivity.  
        In Chapter 4, enantiodivergent production of endo-pyrrolidines from glycine 
(ket)imines using brucine diol-copper complex is described. The [3+2] cycloaddition 
reaction of glycine imines and activated alkenes was performed to produce endo-
pyrrolidines. The reversal of enantioselectivity was observed for endo-pyrrolidines 
between concerted and stepwise reaction pathways. 
        The three new brucine derivatives produced in this study would potentially work as 
organocatalysts and chiral ligands with metal ion in asymmetric synthesis. The brucine 
diol-metal complex catalyzed reactions laid a good foundation for catalytic asymmetric 
reactions, where a single chiral source was used to control the absolute and the relative 
stereochemical outcomes of reactions. Understanding the molecular-level interactions 
between catalyst and substrates will provide insightful mechanistic details for the 
stereodivergent approaches in asymmetric catalysis. 
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CHAPTER 1. THE MODIFICATION OF BRUCINE AND ITS DERIVATIVES 
1.1 Introduction 
        The objective of this research was to prepare brucine derivatives that function as 
versatile chiral catalysts in conjunction with a variety of metal salts. 
        Brucine is a natural product with an intriguing structural complexity (Figure 1). It is 
known to possess excellent molecular recognition capability, thus widely utilized in 
chiral resolution of small molecules.1 Motivated by its wide availability as well as the 
ability to interact with multiple organic functional groups, we modified its structure and 
investigated its use in asymmetric catalysis. Our structural modification strategy of 
brucine was based on the facile functionalization of the alkene moiety at C21-C22. 
 
Figure 1. Brucine 1.1 
        Nitrogen-containing ligands are useful in asymmetric catalysis.2 A great number of 
amino alcohols have been used as chiral building blocks and chiral auxiliaries in organic 
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synthesis.3,4 The nitrogen and oxygen containing functional groups typically allow for 
multiple types of binding to metals. For example, Wan and Lu described that reverse 
enantioselectivity could be achieved by adding Ti(OiPr)4 to the diethylzinc addition to 
aldehydes in the presence of an L-prolinol-backbone ligand.5 Oh et al. modified brucine 
1.1 to 1,2-amino alcohol 1.2 by dihydroxylation (Scheme 1) and used it in the 1,3-dipolar 
cycloaddition reactions of azomethine ylides to produce chiral pyrrolidines with both 
forms of optical isomers.6 However, other types of brucine derivatives have not been 
investigated. 
N
N
O
O
H
H
H
OMe
OMe
N
N
O
O
H
H
H
OMe
OMe
OH
Acetone/t-BuOH/H2O
> 95%
HO
Cat. OsO4
NMO
1.1 1.2  
Scheme 1. Synthesis of 1.2 
        Chiral diamine ligands are also one of the most common types of nitrogen 
containing ligands that can be used for catalytic asymmetric synthesis.7,8 Although many 
types of 1,2-diamine ligands have been investigated in numerous enantioselective 
reactions,9,10 the use of 1,3-diamines has not reached the level of stereoselectivity 
commonly found for 1,2-diamine ligands.   
        Chiral N-oxides have been shown to promote a few synthetic transformations. For 
instance, in the Sakurai-Hosomi reaction of aldehydes with allyltrichlorosilanes, chiral N-
oxides are utilized as Lewis base catalysts.11,12 The application of N-oxides as chiral 
ligands has been reported by Sinn and Carlin with some limited success.13 In the Oh’s 
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group, brucine N-oxide 1.3 was used as an asymmetric oxidant for epoxidation of ,-
unsaturated ketones14 as well as a dual catalyst component for the Morita-Baylis-Hillman 
(MBH) reaction.15  
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1.2 Results and Discussion  
1.2.1 Synthesis of 1.4 
 
Scheme 2. Synthesis of 1.4 
        Recently, our group reported the use of 1.2 as a chiral ligand for catalytic 
enantioselective 1,3-dipolar cycloaddition reactions of azomethine ylides to produce both 
optical forms of pyrrolidines.6 The tertiary amine and hydroxyl groups on 1.2 provided 
different binding modes in the presence of metals with different atomic radii, the basis for 
excellent reversal of enantioselectivity. In order to investigate the binding ability of the 
tertiary amine in 1.2 and the synthesis of diamine ligand derived from 1.4 to various 
metal ions, we designed the synthesis of brucine-derived 1,3-diamine ligand by 
converting the secondary hydroxyl group on 1.2 to an amine group. Inspired by the 
Staudinger reduction of azides to desired amines, we synthesized 1.4 as a precursor for 
the desired diamine. Following the protocol of Soos et al.,16  we mixed 1.2 with PPh3 (1.2 
eq.), DIAD (1.2 eq.), and DPPA (1.2 eq.) in THF to produce 1.4 with a 20 % yield after 
40 h of reaction at ambient temperature. To improve the yield, the reaction time was 
increased to 60 h, but the yield of 1.4 only improved to 25% (Scheme 2). To determine 
whether this incomplete reaction was due to insufficient amount of DPPA, the quantity of 
DPPA was increased to 2.5 eq., but the yield of 1.4 remained at 25%. While other 
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experimental parameters were also investigated, the further optimization of reaction did 
not yield positive outcomes. Based on our incapability to drive the reaction to completion, 
it is tempting to speculate that the tertiary amine moiety of brucine might act as a 
nucleophile, competing for the consumption of DIAD where the salt form of 
intermediates (Figure 2) releases back brucine diol during the column chromatography 
purification process. 
 
Figure 2. Proposed Structure of Brucine Diol-DIAD Salt 
 
1.2.2 Synthesis of 1.5 
N
N
O
O
H
H
H
OMe
OMe
H2O2, MeOH
N
N
O
O
H
H
H
OMe
OMe
O
40 °C, > 95 %
1.1 1.3  
Scheme 3. Synthesis of 1.3 
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        We have previously shown that the MBH reaction of alkyl/aryl vinyl ketone could 
be enhanced by either 1.3 alone or 1.3 and proline.15 1.3 could be easily produced by 
oxidation of 1.1 with H2O2 as shown in Scheme 3. 
 
Scheme 4. Synthesis of 1.5 
        We hypothesized that the synthesis of 1.5 from the oxidation of 1.2 would reveal the 
nucleophilicity of brucine-derived N-oxides that might work as a chiral N-oxide ligand in 
asymmetric reactions (Scheme 4).17 The one-pot oxidation protocol of 1.1 was 
investigated using mCPBA. While the synthesis of 1.3 as well as brucine epoxide was 
anticipated upon oxidation, the reaction only yielded 1.3 (Scheme 5) after the addition of 
3.0 eq. of mCPBA at -78 °C and then at 0 °C for 2 h. 
N
N
O
O
H
H
H
OMe
OMe
N
N
O
O
H
H
H
OMe
OMe
O
N
N
O
O
H
H
H
OMe
OMe
O
mCPBA
+
Brucine Epoxide, 0 % 1.3, 95 %1.1
CH2Cl2
 
Scheme 5. Preparation of Brucine Epoxide and 1.3 
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        In an attempt to produce brucine epoxide, we modified the reaction condition from 
0 °C to ambient temperature and then to 40 °C for 2 h. However, only 1.3 was produced; 
the epoxidation of 1.1 to brucine epoxide was not successful. The exact reason to why 
brucine N-oxide 1.3 was not further oxidized was not clear. It was speculated that the 
nucleophilicity of alkene on 1.3 was not strong enough for attack by mCPBA. Upon 
treatment of 1.2 under this oxidation condition with mCPBA in CH2Cl2, the formation of 
1.5 was achieved at 95 % level (Scheme 4). 
1.2.3 Synthesis of 1.6 
        In 2009, Oh’s group published an approach to the reversal of enantioselectivity by 
using 1.2 as a chiral ligand in the asymmetric 1,3-dipolar cycloaddition reactions.6 To 
investigate the binding modes of this chiral amino alcohol, we envisioned the synthesis of 
a secondary hydroxyl brucine derivative (Figure 3) under the hydroboration conditions. 
Difference between the secondary hydroxyl brucine derivative and 1.2, which was a 
tertiary hydroxyl brucine derivative, may provide an explanation for the different binding 
modes of brucine derivatives with metal ions. 
 
Figure 3. Secondary Hydroxyl Brucine Derivative 1.6a 
       In practice, 1.1 in dry THF was added to 1.5 eq. of BH3-THF at 0 °C. The reaction 
mixture was stirred at room temperature for 18 h. After oxidation with hydrogen peroxide, 
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the desired product was isolated by silica gel column chromatography at a 10% yield. 
The structure of 1.6b was confirmed as a tertiary hydroxyl brucine N-oxide derivative by 
DEPT-135 NMR spectroscopy and mass spectrometry (Scheme 6). 
 
 
Scheme 6. Synthesis of 1.6b 
        This type of non-anti-Markovnikov product typically results from the substrate-
directed hydroboration. Examples of the substrate-directed hydroboration were first 
reported in 1967 when Schulte-Elte and Ohloff18 showed that alcohols could be used as a 
directing group in the hydroboration of isopulegol with excellent regioselectivity. Evans 
also showed that phosphinites and amides were useful in substrate-directed hydroboration, 
while phosphinites and amides induced borane to generate regioselective products.19,20 
Amine directed hydroboration was first reported in 2003 when Vedejs used it as a 
directing group in the intramolecular hydroboration of allylic amine.21 After treatment 
with 5.0 eq. of BH3-THF, the yield of 1.6b was increased to 20% (Scheme 6), whereas 
the yield of 1.6b was only 16% using 10.0 eq. of BH3-THF. This low yield of 1.6b was 
probably due to the steric hindrance of brucine-borane intermediates as well as the 
incomplete oxidation of brucine N-oxide-borane complex (Figure 4). In the Vedejs’s 
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research, they used iodine to promote the cleavage of the B-N bond, indicating that iodine 
might be used in the future as an activating agent to improve the yield of 1.6b. 
 
 
Figure 4. Brucine-Borane Intermediates  
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1.3 Experimental Section  
 
(3R,4R,4aR,4a1R,5aS,8aR,8a1S,15aS)-3,4-Dihydroxy-10,11-dimethoxy-
2,3,4,4a,4a1,5,5a,7,8,8a1,15,15a-dodecahydro-14H-4,6-methanoindolo[3,2,1-
ij]oxepino[2,3,4-de]pyrrolo[2,3-h]quinolin-14-one (1.2) The dihydroxylation of brucine 
was performed using modified Upjohn process.22 To a stirred solution of Brucine 
dihydrate (5.00 g, 11.6 mmol) in a mixture of acetone (45 mL), tert-butanol (2.5 mL), 
and water (2.5 mL), 4-methylmorpholine N-oxide monohydrate (1.73 g, 12.8 mmol) was 
added, followed by dropwise addition of osmium tetroxide (0.5 mL, 0.07 mmol/4 wt% in 
water) at ambient temperature. The resulting suspension was stirred at ambient 
temperature for 24 h after which the resulting solids were collected by filtration. The 
solids were washed with dichloromethane (80 mL × 2) and dried under vacuum for 24 h 
to give analytically pure 1.2 (4.74 g, 95%). 1H NMR (CDCl3, 500 MHz): 7.74 (s, 1H), 
6.66 (s, 1H), 6.00 (br, OH), 4.13 (m, 1H), 4.04 (dd, J = 13.0, 3.8 Hz, 1H), 3.99 (d, J = 
10.7 Hz, 1H), 3.89 (s, 3H), 3.87 (s, 3H), 3.58 (m, 1H), 3.48 (m, 1H), 3.41 (m, 1H), 3.18 
(m, 1H), 2.97 (dd, J = 16.0, 8.0 Hz, 1H), 2.82 (m, 3H), 2.67 (dd, J = 16.0, 5.6 Hz, 1H), 
2.51 (d, J = 13.0 Hz, 1H), 2.40 (m, 1H), 2.24 (m, 1H), 2.00 (m, 1H), 1.73 (br, OH), 1.68 
(m, 1H), 1.54 (m, 1H); 13C{1H}NMR (CDCl3, 125 MHz): 168.3, 149.2, 146.6, 134.5, 
124.2, 105.1, 100.4, 75.3, 74.2, 72.4, 68.8, 67.5, 62.0, 58.7, 56.5, 56.1, 53.2, 51.4, 50.6, 
11 
 
44.9, 40.5, 33.0, 26.4; IR (neat, cm-1): 3563, 3466, 2960, 2937, 2887, 1650, 1501, 1468, 
1450, 1414, 1287, 1194, 1132, 1092, 1014, 865; mp throughout: 147-149 °C; HRMS-CI: 
m/z 429.2016 [(M+H)+; calcd for C23H29N2O6: 429.2026]. 
N
N
O
O
H
H
H
OMe
OMe
O  
(4aR,4a1R,5aS,6R,8aS,8a1S,15aS)-10,11-Dimethoxy-14-oxo-2,4a,4a1,5,5a,7,8,8a1,15,15a-
decahydro-6H,14H-4,6-methanoindolo[3,2,1-ij]oxepino[2,3,4-de]pyrrolo[2,3-h]quinoline 
6-Oxide (1.3) The synthesis of N-oxides was adopted from the method of Resnati et al.23 
To a stirred solution of brucine dihydrate (20.0 g, 46 mmol) in dry methanol (120 ml), 
H2O2 (30% in water, 10.53 ml, 93 mmol) was added drop by drop at ambient temperature. 
The resulting mixture was stirred at 40 °C for 4 h, after which the solvent was removed 
under reduced pressure to give a white solid product. The product was further purified 
using flash column chromatography on silica gel (eluted with ethyl acetate and methanol) 
as a white solid of brucine N-oxide 1.3 (18.0 g, >95%). The spectroscopic data were 
consistent with those reported in the literature (in CDCl3).23 1H NMR (500 MHz, CDCl3): 
δ 7.72 (s, 1H), 6.91 (s, 1H), 6.25 (s, 1H), 4.33 (s, 1H), 4.27 (d, J = 8.5 Hz, 1H), 4.19 (dd, 
J = 14.0, 7.0 Hz, 1H), 4.10 (d, J = 13.0 Hz, 1H), 4.05-4.01(m, 1H), 3.91-3.80 (m ,2H), 
3.85 (s, 3H), 3.82 (s, 3H), 3.68-3.65 (m, 1H), 3.20 (s, 1H), 3.09-3.05 (m, 2H), 2.73 (d, J = 
15.0 Hz, 1H), 2.68-2.58 (m, 2H), 1.96-1.92 (m, 1H), 1.63 (d, J = 15.0 Hz, 1H), 1.32 (d, J 
= 10.0 Hz, 1H); 13C{1H} NMR (125 MHz, CDCl3): δ 168.3, 150.0, 146.5, 135.6, 135.2, 
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133.5, 119.8, 104.6, 100.8, 83.1, 77.4, 71.8, 68.1, 64.1, 58.6, 56.3, 56.1, 53.2, 47.6, 42.0, 
38.8, 30.3, 25.0. In DMSO, the 1H NMR (500 MHz, DMSO) spectroscopic data were the 
following:24 δ 7.58 (s, 1H), 7.03 (s, 1H), 6.22 (s, 1H), 4.25-3.76 (m, 8H), 3.73 (s, 3H), 
3.68 (s, 3H), 3.35-3.31 (m, 1H), 3.13 (s, 1H), 2.85-2.82(m, 1H), 2.56-2.46 (m, 2H), 2.34-
2.28 (m, 1H), 1.84-1.82 (m, 1H), 1.46 (d, J = 14.4 Hz, 1H), 1.28 (d, J = 10.4 Hz, 1H); 13C 
{1H} NMR (125 MHz, DMSO): δ 169.3, 150.1, 147.0, 137.0, 136.1, 133.6, 122.3, 107.4, 
101.4, 82.9, 77.4, 71.5, 68.5, 64.4, 59.2, 56.9, 56.6, 53.5, 49.4, 42.2, 39.2, 30.5, 25.3. 
 
(3S,4R,4aR,4a1R,5aS,8aR,8a1S,15aS)-3-Azido-4-hydroxy-10,11-dimethoxy-
2,3,4,4a,4a1,5,5a,7,8,8a1,15,15a-dodecahydro-14H-4,6-methanoindolo[3,2,1-
ij]oxepino[2,3,4-de]pyrrolo[2,3-h]quinolin-14-one (1.4) brucine diol 1.2 (214mg, 0.5 
mmol) and triphenylphosphine (157 mg, 0.6 mmol) were dissolved in 5.0 mL of dry THF, 
and the solution was cooled to 0 °C. Diisopropyl azodicarboxylate (0.12 mL, 0.6 mmol) 
was then added, followed by addition of diphenyl phosphoryl azide (0.13 mL, 0.6 mmol) 
in 1.0 mL of dry THF at 0 °C. The mixture was allowed to warm up to room temperature. 
After being stirred for 40 h, the solvent was removed in vacuo, and the residue was 
purified by column chromatography on silica gel (CH2Cl2 / MeOH / conc. aq. NH4OH = 
90 / 9 / 1 as eluant) as a brown powder (57 mg, 25%). 1H NMR (500 MHz, CDCl3): δ 
7.69 (s, 1H), 6.68 (s, 1H), 4.31-4.27 (m, 1H), 4.14 (d, J = 11.0 Hz, 1H), 3.91 (d, J = 12.0 
13 
 
Hz, 1H), 3.82 (s, 6H), 3.82 – 3.73 (m, 2H), 3.53 (d, 1H), 3.27 (d, J = 9.5 Hz, 1H), 2.90-
2.84 (m, 3H), 2.73-2.69 (m, 1H), 2.51-2.47 (m, 3H), 2.40-2.34 (m, 1H), 1.96 (t, J = 11.0 
Hz, 1H), 1.76-1.72 (m, 1H), 1.60 (d, J = 13.5 Hz, 1H); 13C{1H} NMR (125 MHz, CDCl3): 
δ 168.2, 149.3, 146.7, 134.5, 123.6, 105.3, 100.4, 75.2, 72.5, 67.6, 67.0, 66.7, 61.4, 56.5, 
56.1, 53.8, 53.3, 51.3, 49.8, 44.3, 40.5, 29.3, 26.2; IR (neat, cm-1): 3395, 3000, 2933, 
2096, 1668, 1499, 1468, 1464, 1444, 1411, 1283, 1223, 1194, 1140, 1117, 1091, 1042, 
1009, 947, 857, 758;  mp: 260-264 °C; HRMS-CI: m/z 454.2054 [(M+H)+; calcd for 
C23H28N5O5: 454.2090]. 
 
(3R,4R,4aR,4a1R,5aS,6R,8aS,8a1S,15aS)-3,4-Dihydroxy-10,11-dimethoxy-14-oxo-
2,3,4,4a,4a1,5,5a,7,8,8a1,15,15a-dodecahydro-6H,14H-4,6-methanoindolo[3,2,1-
ij]oxepino[2,3,4-de]pyrrolo[2,3-h]quinoline 6-Oxide (1.5) To a stirred solution of brucine 
diol 1.2 (214 mg, 0.5 mmol) in 5.0 mL of CH2Cl2, mCPBA (259 mg, 1.5 mmol) was 
added at 0 °C. The solution was warmed up to room temperature for 18 h. After the 
solvent was removed under reduced pressure, the residue was purified using flash column 
chromatography on silica gel (eluent ethyl acetate then methanol) to the title compound 
1.5 (212 mg, >95%) as a white solid. 1H NMR (500 MHz, CDCl3): δ 7.68 (s, 1H), 6.72 (s, 
1H), 4.21 (dd, J = 13.0, 6.0 Hz, 1H), 4.11-4.06 (m, 2H), 3.99 (s, 1H), 3.88 (s, 3H), 3.86(s, 
3H), 3.81 – 3.77 (m, 1H), 3.70-3.66 (m, 1H), 3.65-3.59 (m, 2H), 3.51 (dd, J = 13.0, 8.0 
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Hz, 1H), 3.36 (d, J = 13.0 Hz, 1H), 3.19-3.16 (m, 1H), 3.06 (dd, J = 17.0, 8.5 Hz, 1H), 
2.60 (dd, J = 17.0, 4.0 Hz, 1H), 2.51 – 2.50 (m, 1H), 2.39 (d, J = 5.5 Hz, 1H), 2.37 (d, J = 
6.0 Hz, 1H), 1.74-1.71 (m, 1H), 1.56 (d, J = 15.0 Hz, 1H); 13C{1H} NMR (125 MHz, 
CDCl3): δ 168.0, 150.3, 147.1, 134.7, 121.5, 104.7, 100.5, 76.6, 75.6, 73.1, 71.9, 71.9, 
69.0, 67.4, 65.4, 56.4, 56.3, 51.5, 48.6, 41.3, 39.9, 32.7, 22.8; IR (neat, cm-1): 3404, 2971, 
1655, 1503, 1454, 1416, 1334, 1293, 1223, 1198, 1143, 1103, 1066, 1010, 989, 847; mp: 
208-212 °C; HRMS-CI: m/z 445.1954 [(M+H)+; calcd for C23H29N2O7: 445.1975]. 
 
(4R,4aR,4a1R,5aS,6R,8aS,8a1S,15aS)-4-Hydroxy-10,11-dimethoxy-14-oxo-
2,3,4,4a,4a1,5,5a,7,8,8a1,15,15a-dodecahydro-6H,14H-4,6-methanoindolo[3,2,1-
ij]oxepino[2,3,4-de]pyrrolo[2,3-h]quinoline 6-Oxide (1.6b) To a stirred solution of 
Brucine 1.1 (215 mg, 0.5 mmol) in 4.0 mL of dry THF, BH3-THF (2.5 mL, 2.5 mmol) 
was added at 0 °C. The mixture was allowed to warm up to room temperature for 18 
hours and then cooled to 0 °C. 2.0 mL of 1.0 M NaOH (aq.) was then added dropwise, 
followed by addition of 4.0 mL of H2O2 (35% wt in water). The mixture was further 
stirred at 0 °C for 2 h and diluted to 8.0 mL with hexanes / CH2Cl2 = 6 / 2. The aqueous 
layer was extracted 3 times with 10 mL of CH2Cl2. The combined organic layers were 
dried over MgSO4. The solvent was removed in vacuo, and the residue was purified by 
column chromatography on silica gel (CH2Cl2 / MeOH / conc. aq. NH4OH = 90 / 9 / 1 as 
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eluant) as a brown powder (57 mg, 20%). 1H NMR (500 MHz, CDCl3): δ 7.69 (s, 1H), 
6.71 (s, 1H), 4.08-4.04 (m, 2H), 3.95-3.91 (m, 2H), 3.87 (s, 3H), 3.85 (s, 3H), 3.76 – 3.63 
(m, 3H), 3.55 (d, J = 13.0 Hz, 1H), 3.32 (d, J = 13.5 Hz, 1H), 3.18 (d, J = 15.0 Hz, 1H), 
3.02 (q, J = 8.5 Hz, 1H), 2.57 (dd, J = 16.5, 4.5 Hz, 1H), 2.45 (d, J = 2.0 Hz, 1H), 2.37-
2.34 (m, 2H), 2.07-2.00 (m, 2H), 1.72-1.68 (m, 1H), 1.52-1.49 (m, 1H); 13C{1H} NMR 
(125 MHz, CDCl3): δ 168.1, 150.2, 147.0, 134.6, 121.9, 104.6, 100.5, 76.4, 75.4, 71.6, 
69.2, 68.9, 66.4, 65.9, 56.4, 56.2, 51.5, 48.6, 42.9, 41.0, 40.2, 36.2, 23.0; IR (neat): 3417, 
2918, 2849, 1671, 1504, 1446, 1413, 1333, 1281, 1200, 1138, 1126, 1101, 1023, 1009, 
990, 873, 851, 758, 659; mp: 200-204 °C; HRMS-CI: m/z 429.2012 [(M+H)+; calcd for 
C23H29N2O6: 429.2026]. 
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CHAPTER 2.  BRUCINE N-OXIDE CATALYZED MORITA-BAYLIS-HILLMAN 
REACTIONS OF ALKYL/ARYL VINYL KETONES 
2.1 Introduction 
2.1.1 Development of Morita-Baylis-Hillman Reactions 
        The Morita-Baylis-Hillman (MBH) reaction, first reported by Morita et al. in 19681 
and subsequently by A. B. Baylis and M. E. D. Hillman in 1972,2 is one of the most 
important reactions for the carbon-carbon bond formation between electron-deficient 
alkenes and carbonyl compounds. It is typically catalyzed by a nucleophilic tertiary 
amine or phosphine to yield -methylene--hydroxyl-carbonyl derivatives (Scheme 7). 
 
Scheme 7. Morita-Baylis-Hillman Reactions 
 
        The controlled formation of carbon-carbon bonds is of fundamental importance in 
organic chemistry. Many research groups have contributed to the development of
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asymmetric MBH reactions, using one of the following three essential components in a 
chiral form: electrophiles, activated alkenes, and catalysts. While the MBH reactions 
using chiral forms of aldehydes and activated alkenes have been shown to proceed with 
high diastereoselectivities in some cases,3 the precise roles of chiral catalysts for the 
MBH reactions are not well understood. 
2.1.2 Catalytic Asymmetric MBH Reactions 
        Hirama and Marko had independently reported the use of chiral derivatives of 
diazabicyclo[2.2.2]octane,4 quinidine, and cinchonine5 as asymmetric catalysts. However, 
only modest levels of enantioselectivity were observed under elevated pressure. Later, 
Barrett reported the first example of successful asymmetric MBH reactions of ethyl vinyl 
ketone with aryl aldehydes, where a chiral pyrrolidine catalyst induced up to 72% 
enantiomeric excess (ee) under normal atmospheric pressure. In 1999, Hatakeyama et al. 
demonstrated a highly enantioselective MBH reaction of 1,1,1,3,3,3-hexafluoroisopropyl 
acrylate using a catalytic amount of a tricyclic quinidine-derived chiral amine at -55 °C.6 
However, the Hatakeyama’s catalyst failed to promote the asymmetric MBH reaction of 
methyl acrylate, where only 8% ee was observed upon using 4-nitrobenzaldehyde.  
2.1.3 Catalytic Asymmetric MBH Reactions Using a Dual Catalyst System 
        Shi reported the first dual catalyst system for the MBH reaction of methyl vinyl 
ketone (MVK) with arylaldehydes,7 where the respective catalyst, L-proline or imidazole 
did not promote the MBH reaction regardless of the amount of each catalyst. When the 
reaction of MVK with 4-nitrobenzaldehyde was catalyzed by 10 mol% of both L-proline 
and imidazole, the MHB product was obtained in a 60% yield. A further extension to 
asymmetric MBH reactions using such dual catalyst systems was investigated by Shi and 
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Jiang using the Hatakeyama’s catalyst and proline as a co-catalyst. In that study, the 
MBH products with up to 31% ee were achieved using MVK as an electron-deficient 
alkene component.8 Later, Miller et al. reported the development of a new dual catalyst 
system using proline and peptide-derived phosphine for MBH reaction of MVK in 63 – 
81% ee’s.9 Nevertheless, the exact roles of co-catalysts used in the studies of Shi and 
Miller were not well defined. 
        One possible reaction mechanism of proline/NaHCO3-catalyzed MBH reaction was 
recently proposed by Gruttadauria et al., where proline acts as a bifunctional catalyst via 
a bicyclic enaminolactone species.10 However, it still remains unclear if proline functions 
as a bifunctional catalyst for the asymmetric MBH reactions under dual catalyst systems. 
In this chapter, we describe our mechanistic investigation into the dual catalyst system of 
proline and brucine N-oxide (BNO) for the asymmetric MBH reactions of vinyl ketones 
(Figure 5). 
N
N
O
O
H
H
H
OMe
OMe
O
BNO  
Figure 5. Brucine N-Oxide (BNO) 
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2.2 Results and Discussion 
2.2.1 Morita-Baylis-Hillman Reaction with Alkyl Vinyl Ketones 
2.2.1.1 Optimization of BNO-Catalyzed MBH Reaction 
        The MBH reaction has been widely used as one of the key carbon-carbon forming 
processes in synthetic organic chemistry. The reaction features three major components 
involving the coupling of the -position of active alkenes with carbon electrophiles under 
a catalytic amount of tertiary amine. It is a simple and convenient method for the 
synthesis of densely functionalized molecule.11 Although the recent development of 
asymmetric MBH reactions underscores the importance of chiral nucleophilic catalysts, 
the substrate scope of both reaction partners, alkenes and aldehydes, is rather limited, 
perhaps due to the complex nature of MBH reactions. In particular, the substrate scope 
and stereocontrol of the asymmetric MBH reaction of vinyl ketones remain to be further 
developed.8, 9, 12, 13 Although Wu et al. reported the MBH reaction of MVK in the range 
of 90-94% ee’s in the presence of a cyclohexyl aminothiourea, their substrates were 
limited to electron deficient aromatic aldehydes.13 Prior to the Wu’s work, the 
enantioselective MBH reaction of MVK with electron deficient aromatic aldehydes was 
in the range of 63-78% ee’s where the Miller group utilized a dual catalyst system 
involving proline as a co-catalyst.9 The co-catalyst, proline, was first introduced by Shi’s 
group in 2002,7 however, the exact nature of co-catalyst was not understood. Motivated 
by the possibility of new mechanistic insight of dual catalyst systems, we investigated a 
dual catalyst system of BNO and proline for the MBH reaction of vinyl ketones with 
aldehydes.  
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        To study the relative nucleophilicity of both catalysts, we first examined BNO in the 
MBH reaction of MVK with 2-nitrobenzaldehyde 2.1a. As anticipated, BNO promoted 
the MBH reaction of MVK with 2.1a in the presence of 15 mol% of BNO (Scheme 8).14  
 
Scheme 8. BNO-Catalyzed Reaction 
        The yield of 2.2a was less than 10 % after 36 h of reaction, but increased to 41% 
after a total of 110-120 h of reaction. This low reaction yield was due to the depletion of 
MVK by self-dimerization.15 After testing various amounts of MVK, the optimal use of 
MVK was determined to be 3.0 equivalents, yielding 2.2a in 90% yield after 120 h of 
reaction. Interestingly, our investigation into the rate of BNO-promoted MBH reaction 
revealed that while the reaction was influenced by the amount of BNO at the beginning 
of the reaction (i.e. 5-10% conversion), the reaction significantly slowed down regardless 
further additions of BNO. While the more precise kinetic data could not be obtained due 
to the poor solubility of BNO, we concluded that our MBH reaction was promoted by 
BNO at the beginning of the reaction and that beyond a reaction conversion of 10% the 
chemistry involved autocatalysis16 by the MBH product 2.2a.   
2.2.1.2 Substrate Scope of BNO-Promoted MBH Reaction 
        The MBH reactions are typically very slow requiring days to weeks to complete. In 
order to reduce the reaction time of BNO-catalyzed MBH reaction, we used more 
reactive aldehydes. Having established the reaction conditions for the BNO-promoted 
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MBH reaction of MVK with 2.1a, we explored the reactivity of other aldehydes under 
the optimized conditions. As shown in Table 1, electron-deficient aldehydes, in particular 
nitro group-containing aldehydes, readily reacted to generate MBH products with good to 
excellent yields (entry 1-6). Halogen-substituted benzaldehydes were less efficient, 
providing modest yields of MBH products (entry 7-10). Heteroaromatic aldehydes were 
also suitable substrates for our BNO-promoted MBH reactions (entry 11-12), however, 
the yields were low, possibly due to the degradation of products upon isolation process 
(entry 12). The MBH reactions with electron-rich aryl aldehydes such as 4-
methylbenzaldehyde, 4-methoxybenzaldehyde (entry 14-17), and aliphatic aldehydes 
such as cyclohexanecarboxyaldehyde and 1-octanal were sluggish leading to low yields 
of products (entry 18-19). Our attempts to improve the reaction conversion and the 
reaction time by increasing the amounts of BNO were unsuccessful. Surprisingly, 
varying the amount of BNO did not affect reaction yields and time upon using the 
electron-rich aldehydes, not only at the initial stage but also in the overall reaction, 
suggesting the lack of autocatalysis. 
 
 
 
 
 
 
 
26 
 
Table 1. Substrate Scope of BNO-Promoted MBH Reactions 
 
Entry Aldehyde Reaction time (Day) 2.2 Yield (%)
1 2-Nitrobenzaldehyde 5 2.2a 90 
2 3-Nitrobenzaldehyde 3 2.2h 96 
3 4-Nitrobenzaldehyde 5 2.2i 77 
4 1-Nitro-2-naphthaldehyde 5 2.2b 61 
5 2,4-Dinitrobenzaldehyde 4 2.2d 80 
6 3-Methoxy-2-nitrobenzaldehyde 4 2.2c 82 
7 2-Fluorobenzaldehyde 5 2.2g 44 
8 3-Bromobenzaldehyde 5 2.2p 54 
9 4-Chlorobenzaldehyde 6 2.2q 55 
10 2-(Trifluoromethyl)benzaldehyde 6 2.2f 14 
11 2-Furaldehyde 5 2.2r 80 
12 2-Thiophenecarboxaldehyde 5 2.2s 45 
13 Benzaldehyde 6 2.2j 47 
14 4-Methoxybenzaldehyde 6 2.2t 14 
15 6-Nitropiperonal 6 2.2e 23 
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Table 1. Continued 
Entry Aldehyde Reaction time (Day) 2.2 Yield (%) 
16 4-Methylbenzaldehyde 6 2.2u 16 
17 2-Methylbenzaldehyde 6 2.2v 13 
18 Cyclohexanecarboxaldehyde 8 2.2x 6 
19 1-Octanal 7 2.2y 21 
2.2.1.3 Optimization of Asymmetric MBH reaction of Methyl Vinyl Ketone 
        Although our initial postulation regarding the conjugate addition of amine N-oxides 
to MVK was confirmed by the facile MBH reactions with a variety of aldehydes, the 
asymmetric induction using such intermediate species was not possible using our BNO-
promoted MBH reactions. We assumed that the poor asymmetric induction was attributed 
to the slow and non-selective BNO-catalyzed MBH reaction, which was the primary 
reaction pathway at the early stage of reaction in the absence of solvents. In addition, the 
autocatalysis of MBH product was non-selective, which might be the major reaction 
pathway beyond 10-20% reaction conversion. Since we have shown that the autocatalysis 
of MBH product could be slowed down,24 if not completely shut down, in the presence of 
solvents, such as 1,4-dioxane, we further examined the possibility of asymmetric 
induction in the BNO-catalyzed MBH reaction (Table 2). The use of BNO as a chiral 
nucleophilic catalyst led to slow formation of MBH product 2.2a with low ee % (entry 1). 
Although further effort was made to improve enantioselectivity, our optimization 
attempts were unsuccessful despite changing the numerous reaction parameters: 
temperature, solvent, and amounts of BNO. We therefore examined the addition of a co-
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catalyst, such as imidazole, lithium perchlorate, and (L)-proline (entry 2-4). Although 
imidazole and LiClO4 delivered no significant improvement in enantioselectivity, the 
presence of co-catalyst (L)-proline markedly enhanced the enantioselectivity to 57%. 
After confirming that (L)-proline alone did not catalyze the reaction (entry 5), we made 
further optimization efforts using various amounts of both BNO and (L)-proline (entry 6-
13).  
Table 2. MBH Reaction Using a Dual Catalyst System  
 
Entry BNO (eq.) Additive (eq.) ee (%) 
1 0.1 - 8 (R) 
2 0.1 Imidazole (0.1) 8 (R) 
3 0.1 LiClO4 (0.1) NR 
4 0.1 (L)-Proline (0.1) 57 (R) 
5 - (L)-Proline (0.1) NR 
6 0.1 (L)-Proline (0.2) 40 (R) 
7 0.1 (L)-Proline (0.3) 34 (R) 
8 0.1 (L)-Proline (0.4) 27 (R) 
9 0.1 (L)-Proline (0.5) 32 (R) 
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Table 2. Continued 
Entry BNO (eq.) Additive (eq.) ee (%) 
10 0.2 (L)-Proline (0.1) 62 (R) 
11 0.3 (L)-Proline (0.1) 82 (R) 
12 0.4 (L)-Proline (0.1) 83 (R) 
13 0.5 (L)-Proline (0.1) 85 (R) 
         
        While the increasing amount of (L)-proline negatively impacted the observed 
enantioselectivity, larger amounts of BNO led to the further improvement in 
enantioselectivity up to 85%. Considering a cost-benefit analysis of catalysts used versus 
the minimal difference in the observed enantioselectivity (entry 11 vs. 13), the optimal 
catalyst ratio was chosen as a 3:1 between BNO and (L)-proline. While we further 
investigated the potential effect of various solvents and molar ratios of the reagents, no 
further improvement in enantioselectivity was obtained except for increased reaction 
conversion from 12% to 28% upon using 1.5 eq. of BNO and 0.5 eq. of (L)-proline. 
2.2.1.4 Asymmetric MBH Reaction of Alkyl Vinyl Ketones 
        Having established the optimal ratio and amount of BNO and (L)-proline for the 
MBH reaction of MVK and 2-nitrobenzaldehyde 2.1a, we next examined the scope of 
aldehyde substrates with different vinyl ketones (Table 3). As expected, the reactivity and 
enantioselectivity of aldehyde substrates were highly varied at the 24 h mark. For 
example, 2-nitro-substituted aromatic aldehydes collectively showed good 
enantioselectivity with reasonable reactivity (entry 1-5), while other less electron-
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deficient aldehydes showed significantly diminished reactivity and enantioselectivity 
(entry 6-10). The substitution pattern on aryl aldehydes also influenced the ee value of 
MBH products. This may be attributed to the different activation energy barriers for 
proline-catalyzed and the alcohol-catalyzed (autocatalysis) processes. Diminished 
enantioselectivity of MBH products was observed after longer reaction times, probably 
due to the autocatalysis by MBH products. As shown in Table 3, the role of prolines as a 
chirality-inducing component was confirmed by the formation of both optical isomers of 
MBH products using (L)-proline and (D)-proline. Furthermore, the generality of our 
asymmetric MBH reaction using the dual catalysis of BNO and proline was demonstrated 
with of ethyl vinyl ketone (EVK) and 2-nitro-substituted aromatic aldehydes (entry 11-
15). 
Table 3. Asymmetric MBH Reaction of Alkyl Vinyl Ketones 
 
Entry 2.2 Co-catalyst 
ee (%) 
at 24 h 
Reaction 
time / d 
Yield 
(%) 
ee (%) 
1 
 
(L)-proline 74 (R) 4 42 63 (R) 
(D)-proline 56 (S) 5 30 40 (S) 
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Table 3. Continued 
Entry 2.2 Additive 
ee (%) 
at 24 h 
Reaction 
time / d 
Yield 
(%) 
ee (%) 
2 
 
(L)-proline 78 (R) 3 45 44 (R) 
(D)-proline 81 (S) 4 49 39 (S) 
3 
(L)-proline 75 (R) 8 49 49 (R) 
(D)-proline 45 (S) 4 51 21 (S) 
4 
(L)-proline 35 (R) 4 72 55 (R) 
(D)-proline 44 (S) 3 67 32 (S) 
5 
 
(L)-proline 81 (R) 7 20 45 (R) 
(D)-proline 81 (S) 7 27 43 (S) 
6 
 
(L)-proline 60 (R) 6 16 59 (R) 
(D)-proline 84 (S) 6 16 37 (S) 
7 
 
(L)-proline 44 (R) 6 21 50 (R) 
(D)-proline 33 (S) 6 22 29 (S) 
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Table 3. Continued 
Entry 2.2 Additive 
ee (%) 
at 24 h 
Reaction 
time / d 
Yield 
(%) 
ee (%) 
8 
 
(L)-proline 29 (R) 7 38 48 (R) 
(D)-proline 36 (S) 6 43 16 (S) 
9 
 
(L)-proline 20 (R) 5 34 26 (R) 
(D)-proline 49 (S) 4 49 42 (S) 
10 
 
(L)-proline 10 (R) 7 12 8 (R) 
(D)-proline 19 (S) 7 16 11 (S) 
11 
O
Et
OHNO2
2.2k  
(L)-proline 74 (R) 5 38 58 (R) 
(D)-proline 74 (S) 5 30 54 (S) 
12 
 
(L)-proline 79 (R) 5 30 54 (R) 
(D)-proline 82 (S) 5 39 61 (S) 
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Table 3. Continued 
Entry 2.2 Additive 
ee (%) 
at 24 h 
Reaction 
time / d 
Yield 
(%) 
ee (%) 
13 
 
(L)-proline 67 (R) 5 54 72 (R) 
(D)-proline 78 (S) 5 62 64 (S) 
14 
 
(L)-proline 66 (R) 3 47 57 (R) 
(D)-proline 69 (S) 3 61 65 (S) 
15 
 
(L)-proline 80 (R) 8 55 60 (R) 
(D)-proline 87 (S) 8 40 56 (S) 
 
2.2.1.5 Mechanistic Study of MBH Reaction Under the Dual Catalysis 
        McQuade et al. investigated the mechanism of MBH reactions using kinetic isotope 
studies, and revealed that the rate-determining step (RDS) was the elimination of the -
proton by a hemiacetal intermediate (Figure 6 (a)).17,18 Moreover, the kinetic studies by 
Aggarwal and Lloyd-Jones revealed that the -proton-transfer (or RDS) could be 
facilitated in the presence of protic species (Figure 6 (b)).16 Thus, the MBH product was a 
dominant catalyst species for autocatalysis beyond 10-20% conversion. These two 
mechanistic pathways are consistent with our experiments in which iminium intermediate 
2.5 was used to generate N,O-hemiacetal intermediate (Figure 6 (c)) and MBH product 
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with high enantioselectivity after preferential -H elimination (via H-bridged chair-like 
transition state of N,O-acetal 2.7) at the initial stage of the reaction. The presence of three 
stereogenic centers in the transition state of N,O-acetal 2.7 renders 8 possible 
diastereomeric species. However, considering the most stable chair-like transition state, 
where proline, two aromatic, and –CH2O-NR3 groups occupy equatorial positions, the 
transition state would effectively discriminate all possible diastereomers for the one 
shown in Figure 6. Furthermore, the stereochemistry of the iminium intermediate 2.5 
would influence the stereochemical outcome of N,O-acetal 2.7, possibly through a 
preferential dissociative ring opening of exo-oxazolidinone 2.4.  Thus, it is postulated that 
the stereoselectivity of the proline-catalyzed MBH reaction was controlled by the proton-
transfer step. As shown in Table 3, we observed the product with opposite absolute 
stereochemistry when (D)-proline was utilized as a co-catalyst (rationalized in Figure 6 
(d)), and the reaction conversion was promoted by protic species (MBH product 2.2). 
However, this autocatalysis by the MBH product was believed to be non-selective as 
lower enantioselectivities were observed after the addition of enantiomerically enriched 
MBH products. The role of BNO could be two-fold: 1) a nucleophilic promoter to 
activate MVK for the generation of enolate or 2) a stabilizing agent for iminium 
intermediate 2.5. Since the synthetic potential of iminium intermediates derived from aryl 
aldehydes and proline in proline catalysis has been well recognized, it will be interesting 
to see if our dual catalyst system is applicable to other asymmetric reactions.  
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Figure 6. Proposed Mechanism of the MBH Reaction via Dual Catalysis 
 
2.2.2 Morita-Baylis-Hillman Reactions with Aryl Vinyl Ketones 
2.2.2.1 MBH Reaction of Aryl Vinyl Ketones with Aldehydes 
        While considerable progress has been made in the development of a variety of 
catalyst systems for MBH reaction, there are still significant challenges to broaden its 
substrate scope, especially the MBH reaction for aryl vinyl ketones with aldehydes. As 
shown in Figure 6, the interactions between the nucleophilic catalyst and its substrates 
during the MBH reaction are achieved through the following: (1) the preferential -H 
36 
 
elimination by hemiacetal anions (McQuade mechanism),17, 18 in which should exhibit 
second order kinetics for aldehydes occurs at the initial stage of the reaction, and (2) the 
preferential -H elimination by MBH products at the later stage of the reaction 
(Aggarwal/Lloyd-Jones mechanism),16, 19 in which a rate acceleration occurs in the 
presence of alcoholic additives or MBH-products. 
        The interplay between a nucleophilic catalyst and electron-deficient alkenes (or 
latent enolates) can lead to the coupling of two Michael acceptors, also known as the 
Rauhut-Currier (RC) reaction.20, 21 Although the RC reaction can be controlled to some 
extent by using excess amounts of aldehydes or by employing weak Michael acceptors, 
self-coupling of Michael acceptors is inevitable under the nucleophilic catalyst systems. 
Because of the high reactivity of aryl vinyl ketones, the MBH reaction of phenyl vinyl 
ketone with aldehydes leads to the formation of a mixture of 1:2 adduct and RC product, 
while the corresponding alkyl vinyl ketones predominantly give rise to normal MBH 
products. Two indirect approaches have been used to access normal MBH products by 
the functionalization of aryl vinyl ketones (Scheme 9). Kataoka et al. developed a two-
step chalcogeno MBH reaction, where 2-(methylchalcogeno)phenyl vinyl ketones were 
subjected to the Lewis acid-promoted intramolecular Michael reaction, followed by aldol 
and elimination reactions to provide the normal MBH products.22 In 2009, Gevorgyan 
reported the sila-MBH reaction using a silylated aryl vinyl ketone, where a 1,3-Brook 
rearrangement was exploited to prevent the formation of the 1,2-adduct and RC product 
in the presence of phosphine catalysts.23 To date, there is no direct approach to produce 
MBH product using unfunctionalized aryl vinyl ketones. 
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Scheme 9. Chalcogeno- and Sila-MBH Reactions of Functionalized Aryl Vinyl Ketones 
        We have previously shown that the asymmetric MBH reaction of alkyl vinyl ketones 
could be catalyzed by a dual catalyst system of BNO and proline.24 After our study of 
cooperative catalyst activity between BNO and proline, we postulated that our dual 
catalyst system could promote the normal MBH reaction of aryl vinyl ketones without the 
formation of 1:2 adducts and RC products. 
2.2.2.2 Optimization of MBH Reaction of Aryl Vinyl Ketones 
        We first examined the MBH reaction of phenyl vinyl ketone (PVK) and 2.1a in the 
presence of various amounts of catalysts (Table 4). In contrast to the successful MBH 
reactions of alkyl vinyl ketones, BNO did not promote the MBH reaction of PVK either 
in the absence or presence of solvent (entry1). The use of (L)-proline as the sole catalyst 
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also failed to provide the desired MBH product 2.3a (entry 2). The desired MBH product 
2.3a was obtained in a low yield when the reaction was performed in the presence of both 
BNO and (L)-proline (entry 3). When the loading of both catalysts was increased to 100 
mol%, the desired normal MBH product was obtained in a 49% yield (entry4-9).  While a 
longer reaction time had a positive effect on the reaction conversion (entry 10), the 
diminished reaction rate led us to look into alternative reaction parameters. The use of 
excess 2.1a resulted in better reaction conversions within 18 h (entry 11), however, a 
significant deceleration in the reaction rate was observed beyond 18 h (entry 12). To our 
delight, the use of excess PVK improved the reaction rate, providing 86% of 2.3a in 42 h. 
Table 4. Dual Catalysis of BNO and L-Proline  
 
Entry BNO (eq.) L-Proline (eq.) Time (h) Yield (%)b 
1a 0.15 - 18 0 
2a - 0.15 18 0 
3a 0.15 0.15 18 2 
4a 0.3 0.15 18 12 
5a 0.15 0.3 18 9 
6a 0.3 0.3 18 15 
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Table 4. Continued 
Entry BNO (eq.) L-Proline (eq.) Time (h) Yield (%)b 
7a 0.6 0.6 18 34 
8a 1.0 1.0 18 49 
9a 1.5 1.5 18 27 
10a 1.0 1.0 42 69 
11c 1.0 1.0 18 55 
12c 1.0 1.0 42 53 
13d 1.0 1.0 18 51 
14d 1.0 1.0 42 86 
a. Reaction condition: PVK (0.33 mmol, 1.0 eq.), 2.1a (0.33 mmol, 1.0 eq.), 1,4-
dioxane (2.5 mL), 50 °C. 
b. Isolated yield of 2.3a after column chromatography. The remaining mass accounts 
for unreacted starting materials (PVK and 2.1a). 
c. Reaction with 2.1a (3.0 eq.). 
d. Reaction with PVK (3.0 eq.) 
2.2.2.3 Substrate Scope of MBH Reaction of Aryl Vinyl Ketones 
        With the optimized conditions established, the scope of the MBH reaction of aryl 
vinyl ketones was investigated (Table 5). Electron-deficient aldehydes typically provided 
excellent yields of MBH products within 42 h (entry 1-6), while other electron-neutral 
and electron-rich aldehydes were less reactive under our dual catalyst conditions (entry 7-
10). Studies using other aryl vinyl ketones, 4-chlorophenyl vinyl ketone and 4-
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methoxyphenyl vinyl ketone, also revealed a similar reactivity pattern, providing 
excellent yields of normal MBH products (entry 11-13). The results described above are 
consistent with our proposed mechanism, where aldehydes are activated by proline to 
generate proline iminium intermediates that subsequently control the rate-determining 
step (-H elimination) of the MBH reaction. 
Table 5. Scope of the Morita-Baylis-Hillman Reaction of Aryl Vinyl Ketones 
 
Entry 2.3  Time (h) Yield (%) 
1 2.3a 
 
42 86 
2 2.3b 
 
42 86 
3 2.3c 
 
42 82 
4 2.3d 
 
18 98 
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Table 5. Continued 
Entry 2.3  Time (h) Yield (%) 
5 2.3e 
 
42 80 
6 2.3f 
 
42 90 
7 2.3g 
 
66 34 
8 2.3h 
 
42 33 
9 2.3i 
 
42 15 
10 2.3j 
 
42 8 
11 2.3k 
 
42 70 
 
42 
 
Table 5. Continued 
Entry 2.3  Time (h) Yield (%) 
12 2.3l 
 
18 98 
13 2.3m 18 98 
2.2.2.4 Mechanistic Study into the Formation of 1:2 MBH Adduct and RC Product 
        To shed light on the mechanistic details of the MBH reaction of PVK, a series of 
experiments were conducted to examine the formation of 1:2 MBH adduct and RC 
product. While the proposed mechanism for the formation of 1:2 MBH adduct involved 
a fast second reaction of the transient normal MBH product 2.3a with PVK,25, 26 our 
control experiments suggested an alternative mechanism (Scheme 10). We first examined 
the reaction rate between PVK and RC product. For 10 mol% DABCO in DMF, PVK 
was completely consumed within 2 h to yield RC product. It was also confirmed that 
depletion of PVK was complete less than 6 h of the reaction with 2.1a, while the 
formation of 1:2 MBH adduct continued to increase beyond 6 h. The above control 
experiments suggested that a major pathway for the formation of 1:2 MBH adduct at the 
later stage of the reaction may not involve PVK.  
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Scheme 10. Formation of 1:2 MBH Adduct and RC Product 
        To delineate the role of RC product in the formation of 1:2 MBH adduct, 2.1a and 
RC product were reacted under the typical MBH reaction conditions (Scheme 11). In 
agreement with earlier report by Shi et al., the formation of 1:2 MBH adduct was not 
observed after 24 h at room temperature. However, we found that the reaction between 
2.1a and RC product could be facilitated by the presence of even a small amount of 
protic additives such as methanol (0.1 eq.) to give 1:2 MBH adduct. This result clearly 
demonstrated that the direct aldol reaction of 1:2 MBH adduct occurred, presumably by 
using 1:2 MBH adduct as a protic source. 
44 
 
 
Scheme 11. Direct Aldol Reaction Pathway of RC Product 
        To understand the reaction of the normal MBH product 2.3a with PVK, an equal 
molar ratio of 2.3a and PVK was subjected to the standard reactions. Our results showed 
that the RC reaction pathway dominated over the reaction of 2.3a with PVK in a ratio of 
2:1 (Scheme 12). In addition, we confirmed that the reaction for 2.3a with PVK did not 
occur under our dual catalyst conditions, implying a unique activation pathway for 
aldehydes by proline. 
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Scheme 12. Reaction of Normal MBH Product 2.3a with PVK 
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2.3 Conclusion 
        In summary, our studies showed that brucine N-oxide BNO is a nucleophilic catalyst 
for the Morita-Baylis-Hillman reaction of methyl vinyl ketone with aldehydes. In 
particular, the both catalysts, BNO and proline, effected the asymmetric Morita-Baylis-
Hillman reactions using electron-deficient aryl aldehydes via the selective formation of 
iminium intermediates. Although the proline-catalyzed MBH reaction appeared to control 
the proton-transfer step with high stereoselectivity, the observed enantioselectivity of the 
products varied depending on the nature of aldehyde substrates. Although our 
investigation revealed that the alcohol-catalyzed reaction pathway (i.e. autocatalysis) 
negatively affected the observed enantioselectivity of products, various MBH products 
with modest to good ee’s could be obtained for electron-deficient aryl aldehydes. In 
addition, our studies also demonstrated for the first time the formation of normal MBH 
products of aryl vinyl ketones under the dual catalysis of BNO and proline. 
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2.4 Experimental Section 
General Procedure for Asymmetric Morita-Baylis-Hillman Reaction of Aryl Aldehydes 
To a stirred solution of 2-nitroaldehyde 2.1a (100 mg, 0.65 mmol), brucine N-oxide BNO 
(404 mg, 0.98 mmol) and (L)-proline (37 mg, 0.32 mmol) in dry 1,4-dioxane (5.0 ml) at 
ambient temperature were added to methyl vinyl ketone (46 mg, 0.65 mmol). The 
resulting suspension was stirred at the same temperature for 4-5 days until the aldehyde 
was completely consumed.  The mixture was then directly loaded into a silica gel packed 
column for flash column chromatography (eluent 33/67 diethyl ether/hexanes) to give the 
Morita-Baylis-Hillman product 2.2a (61 mg, 42% with 63% ee). 
 
3-(Hydroxy(2-nitrophenyl)methyl)but-3-en-2-one (2.2a). The spectroscopic data were 
consistent with those reported in the literature.27 1H NMR (CDCl3, 500 MHz): 7.96 (d, J 
= 8.5 Hz, 1H), 7.77 (d, J = 7.5 Hz, 1H), 7.64 (t, J = 7.7 Hz, 1H), 7.45 (t, J = 7.7 Hz, 1H), 
6.21 (d, J = 4.0 Hz, 1H), 6.16 (s, 1H), 5.78 (d, J = 1.0 Hz, 1H), 3.51 (br, 1H), 2.36 (s, 3H); 
13C {1H} NMR (CDCl3, 125MHz): 199.8, 148.9, 148.1, 136.4, 133.4, 128.8, 128.5, 
126.3, 124.6, 67.6, 25.9. 
 
3-(Hydroxy(1-nitronaphthalen-2-yl)methyl)but-3-en-2-one (2.2b). The spectroscopic data 
were consistent with those reported in the literature.27 1H NMR (CDCl3, 500 MHz): 
7.95 (d, J = 8.5 Hz, 1H), 7.87 (d, J = 7.5 Hz, 1H), 7.74 (d, J = 8.5 Hz, 1H), 7.62-7.56 
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(m, 3H), 6.27 (s, 1H), 6.01 (d, J = 1.0 Hz, 1H), 5.87 (s, 1H), 3.66 (br, 1H), 2.33 (s, 3H); 
13C{1H} NMR (CDCl3, 125 MHz): 199.7, 147.7, 146.5, 133.3, 131.0, 130.6, 128.6, 
127.9, 127.7, 127.4, 124.3, 124.1, 121.8, 68.4, 26.0. 
 
3-(Hydroxy(3-methoxy-2-nitrophenyl)methyl)but-3-en-2-one (2.2c). The spectroscopic 
data were consistent with those reported in the literature.27 1H NMR (CDCl3, 500 MHz): 
7.40 (t, J = 8.0 Hz, 1H), 7.10 (d, J = 8.0 Hz, 1H), 6.97 (d, J = 8.5 Hz, 1H), 6.22 (s, 1H), 
5.96 (d, J = 1.0 Hz, 1H), 5.63 (s, 1H), 3.86 (s, 3H), 3.61 (br, 1H), 2.32 (s, 3H); 13C{1H} 
NMR (CDCl3, 125 MHz): 199.8, 150.8, 147.5, 140.2, 134.4, 131.1, 127.8, 119.4, 112.0, 
68.3, 56.4, 26.0. 
 
3-((2,4-Dinitrophenyl)(hydroxy)methyl)but-3-en-2-one (2.2d). The spectroscopic data 
were consistent with those reported in the literature.27 1H NMR (CDCl3, 500 MHz): 
8.76 (d, J = 2.5 Hz, 1H), 8.45 (dd, J = 8.7, 2.5 Hz, 1H), 8.03 (d, J = 8.5 Hz, 1H), 6.27 (s, 
1H), 6.22 (s, 1H), 5.85 (s, 1H), 3.76 (br, 1H), 2.35 (s, 3H); 13C{1H} NMR (CDCl3, 125 
MHz): 199.5, 148.1, 147.8, 147.1, 143.3, 130.5, 127.2, 127.1, 120.0, 67.1, 25.8. 
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3-(Hydroxy(6-nitrobenzo[d][1,3]dioxol-5-yl)methyl)but-3-en-2-one (2.2e). 1H NMR 
(CDCl3, 500 MHz): 7.53 (s, 1H), 7.20 (s, 1H), 6.19 (s, 1H), 6.13 (s, 1H), 6.13-6.12 (m, 
2H), 5.76 (d, J = 1.0 Hz, 1H), 3.50 (br, 1H), 2.38 (s, 3H); 13C{1H} NMR (CDCl3, 125 
MHz): 200.0, 152.3, 149.0, 147.2, 141.8, 134.1, 126.0, 107.7, 105.5, 103.0, 67.5, 26.0; 
IR (neat, cm-1): 3424, 1675, 1519, 1261; HRMS-CI m/z : 288.0495 [(M+Na )+; calcd for 
C12H11NO6Na: 288.0484]. 
O
Me
OHCF3
 
3-(Hydroxy(2-(trifluoromethyl)phenyl)methyl)but-3-en-2-one (2.2f). The spectroscopic 
data were consistent with those reported in the literature.27 1H NMR (CDCl3, 500 MHz): 
7.69 (d, J = 8.0 Hz 1H), 7.64 (d, J = 8.0 Hz, 1H), 7.58-7.55 (m, 1H), 7.42-7.39 (m, 1H), 
6.17 (s, 1H), 6.04 (d, J = 3.0 Hz, 1H), 5.53 (d, J = 1.0 Hz, 1H), 3.46 (br, 1H), 2.37 (s, 3H); 
13C{1H} (CDCl3, 125 MHz): 200.2, 149.9, 139.3, 132.0, 128.6, 127.8, 127.7, 127.3, 
125.8, 124.1, 67.4, 26.1. 
 
3-((2-Fluorophenyl)hydroxymethyl)but-3-en-2-one (2.2g). The spectroscopic data were 
consistent with those reported in the literature.27 1H NMR (CDCl3, 500 MHz): 7.47-7.44 
(m, 1H), 7.27-7.23 (m, 1H), 7.15-7.12 (m, 1H), 7.02-6.98 (m, 1H), 6.17 (s, 1H), 5.87 (s, 
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1H), 5.86 (s, 1H), 3.59 (br, 1H), 2.34 (s, 3H); 13C{1H} (CDCl3, 125 MHz): 200.3, 159.8 
(d, J = 245.0 Hz), 148.7, 129.2 (d, J = 8.7 Hz), 128.4 (d, J = 11.2 Hz), 128.1 (d, J = 3.7 
Hz), 126.8, 124.1 (d, J = 3.7 Hz), 115.2 (d, J = 21.2 Hz), 66.9 (d, J = 3.7Hz), 26.3. 
 
3-(Hydroxy(3-nitrophenyl)methyl)but-3-en-2-one (2.2h). The spectroscopic data were 
consistent with those reported in the literature.27 1H NMR (CDCl3, 500 MHz): 8.22 (s, 
1H), 8.13-8.11 (m, 1H), 7.73 (d, J = 7.5 Hz, 1H), 7.71 (t, J = 7.7 Hz, 1H), 6.28 (s, 1H), 
6.07 (s, 1H), 5.66 (d, J = 5.5 Hz, 1H), 3.28 (d, J = 5.5 Hz, 1H), 2.36 (s, 3H); 13C{1H} 
(CDCl3, 125 MHz): 200.0, 149.0, 148.4, 143.9, 132.6, 129.3, 127.5, 122.6, 121.4, 72.2, 
26.3. 
 
3-(Hydroxy(4-nitrophenyl)methyl)but-3-en-2-one (2.2i). The spectroscopic data were 
consistent with those reported in the literature.27 1H NMR (CDCl3, 500 MHz): 8.17 (d, J 
= 9.0 Hz, 2H), 7.54 (d, J = 8.5 Hz, 2H), 6.26 (s, 1H), 6.03 (d, J = 1.0 Hz, 1H), 5.67 (d, J 
= 5.0 Hz, 1H), 3.35 (d, J = 5.0 Hz, 1H), 2.34 (s, 3H); 13C{1H} (CDCl3, 125 MHz): 
199.9, 149.1, 148.9, 147.4, 127.5, 127.2, 123.5, 72.1, 26.2. 
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3-(Hydroxy(phenyl)methyl)but-3-en-2-one (2.2j). The spectroscopic data were consistent 
with those reported in the literature.27 1H NMR (CDCl3, 500 MHz): 7.34-7.29 (m, 4H), 
7.26-7.24 (m, 1H), 6.16 (s, 1H), 5.96 (d, J = 1.0 Hz, 1H), 5.58 (d, J = 3.0 Hz, 1H), 3.21 
(br, 1H), 2.30 (s, 3H); 13C{1H} (CDCl3, 125 MHz): 200.2, 149.9, 141.4, 128.3, 127.6, 
126.5, 126.4, 72.6, 26.4. 
 
2-[Hydroxy-(2-nitrophenyl)-methyl]-pent-1-en-3-one (2.2k).28 1H NMR (CDCl3, 500 
MHz): 7.95 (dd, J = 8.0, 1.0 Hz, 1H), 7.77 (dd, J = 8.0, 1.5 Hz, 1H), 7.64 (td, J = 7.7, 
1.0 Hz, 1H), 7.44 (td, J = 7.7, 1.5 Hz, 1H), 6.20 (s, 1H), 6.14 (s, 1H), 5.72 (d, J = 1.0 Hz, 
1H), 3.61 (br, 1H), 2.77-2.71 (m, 2H), 1.07 (t, J = 7.5 Hz, 3H); 13C{1H}  (CDCl3, 125 
MHz): 202.7, 148.3, 147.9, 136.4, 133.4, 128.8, 128.4, 125.1, 124.6, 67.7, 31.1, 8.0; IR 
(neat, cm-1) 3431, 1675, 1525, 1350; HRMS-CI m/z : 258.0729 [(M+Na)+; calcd for 
C12H13NO4Na : 258.0742]. 
 
2-[Hydroxy-(1-nitronaphthalen-2-yl)-methyl]-pent-1-en-3-one (2.2l). 1H NMR (CDCl3, 
500 MHz): 7.96 (d, J = 9.0 Hz, 1H), 7.88 (d, J = 8.0 Hz, 1H), 7.75 (d, J = 8.5 Hz, 1H), 
7.63 (d, J = 8.5 Hz, 1H), 7.63-7.56 (m, 2H), 6.27 (s, 1H), 5.96 (d, J = 1.0 Hz, 1H), 5.87 (s, 
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1H), 3.65 (br, 1H), 2.75-2.70 (m, 2H), 1.04 (t, J = 7.2 Hz, 3H); 13C{1H} (CDCl3, 125 
MHz): 202.5, 147.0, 146.5, 133.2, 131.0, 130.6, 128.6, 127.9, 127.4, 126.6, 124.3, 
124.0, 121.8, 68.8, 31.2, 7.8; IR (neat, cm-1): 3432, 1676, 1526, 1356; HRMS-CI m/z: 
308.0907 [(M+Na )+; calcd for C16H15NO4Na : 308.0899]. 
 
2-[Hydroxy-(3-methoxy-2-nitrophenyl)-methyl]-pent-1-en-3-one (2.2m). 1H NMR 
(CDCl3, 500 MHz): 7.41 (t, J = 8.2 Hz, 1H), 7.12 (d, J = 7.5 Hz, 1H), 6.97 (dd, J = 4.2, 
1.0 Hz, 1H), 6.21 (s, 1H), 5.90 (d, J = 1.0 Hz, 1H), 5.64 (d, J = 4.5 Hz, 1H), 3.87 (s, 3H), 
3.54 (d, J = 5.5 Hz, 1H), 2.71 (q, J = 7.0 Hz, 2H), 1.04 (t, J = 7.2 Hz, 3H); 13C{1H} 
(CDCl3, 125 MHz): 202.7, 150.8, 146.8, 140.1, 134.4, 131.1, 126.6, 119.3, 111.9, 68.8, 
56.4, 31.2, 7.8; IR (neat, cm-1): 3428, 1676, 1606, 1533, 1281; HRMS-CI m/z: 288.0840 
[(M+Na)+; calcd for C13H15NO5Na : 288.0848]. 
 
2-[(2,4-Dinitrophenyl)hydroxymethyl]-pent-1-en-3-one (2.2n). 1H NMR (CDCl3, 500 
MHz): 8.78 (d, J = 2.5 Hz, 1H), 8.46 (dd, J = 8.7, 2.0 Hz, 1H), 8.05 (d, J = 8.5 Hz, 1H), 
6.28 (s, 1H), 6.21 (s, 1H), 5.78 (s, 1H), 3.52 (br, 1H), 2.77-2.72 (m, 2H), 1.08 (t, J = 7.2 
Hz, 3H); 13C{1H} (CDCl3, 125 MHz): 202.3, 147.8, 147.4, 147.1, 143.3, 130.5, 127.3, 
125.8, 120.0, 67.6, 31.0, 7.9; IR (neat, cm-1) 3434, 1675, 1606, 1537, 1348; HRMS-CI 
m/z: 281.0772 [(M+H)+; calcd for C12H13N2O6 : 281.0768]. 
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2-(Hydroxy(6-nitrobenzo[d][1,3]dioxol-5-yl)methyl)pent-1-en-3-one (2.2o). 1H NMR 
(CDCl3, 500 MHz): 7.52 (s, 1H), 7.21 (s, 1H), 6.18 (s, 1H), 6.12 (s, 2H), 6.11 (s, 1H), 
5.70 (d, J = 1.0 Hz, 1H), 3.56 (br, 1H), 2.80-2.71 (m, 2H), 1.10 (t, J = 7.2 Hz, 3H); 
13C{1H} (CDCl3, 125 MHz): 202.8, 152.3, 148.5, 147.2, 141.8, 134.2, 124.7, 107.7, 
105.5, 103.0, 67.9, 31.0, 8.0; IR (neat, cm-1): 3440, 1677, 1520, 1259; HRMS-CI m/z: 
279.0756 [(M)+; calcd for C13H13NO6: 279.0743]. 
Table 6. HPLC Conditions for MBH Products of Alkyl Vinyl Ketones 
2.2 Chiral column 
Eluents 
(Hex: IPA) 
Flow rate 
(ml / min) 
Retention time (min) 
Ref. 
(S)-2.2 (R)-2.2 
2.2a CHIRALPAK AD-H 93:7 0.70 20.38 22.52 26 
2.2b CHIRALPAK AD-H 93:7 0.75 29.15  33.45 26 
2.2c CHIRALPAK AD-H 93:7 0.75 38.13  40.51 26 
2.2d CHIRALPAK AD-H 93:7 0.75 28.90  32.48 a 
2.2e CHIRALPAK AD-H 90:10 0.75 27.57  33.48 b 
2.2f CHIRALPAK AD-H 95:5 0.75 11.93 14.28 26 
2.2g CHIRALPAK AD-H 98:2 0.75 26.39  29.26 26 
2.2h CHIRALPAK AD-H 93:7 0.90 37.33  41.95 26 
2.2i CHIRALPAK OD-H 95:5 1.00 25.77  26.45 8, 28 
2.2j CHIRALPAK AD-H 93:7 0.75 22.05  23.87 26 
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Table 6. Continued 
2.2 Chiral column 
Eluents 
(Hex: IPA) 
Flow rate 
(ml / min) 
Retention time (min) 
Ref. 
(S)-2.2 (R)-2.2 
2.2k CHIRALPAK OD-H 95:5 0.75 23.60  26.21 b 
2.2l CHIRALPAK OD-H 95:5 0.75 25.79  31.24 b 
2.2m CHIRALPAK AD-H 93:7 0.75 31.03  32.52 b 
2.2n CHIRALPAK AD-H 93:7 0.75 23.70  28.16 b 
2.2o CHIRALPAK AD-H 90:10 0.75 24.85  28.56 b 
a. The retention times in the literature were obtained with a different column.27 
b. New compound. 
General Procedure for BNO-catalyzed Morita-Baylis-Hillman Reaction 
To a stirred solution of 2-nitroaldehyde 2.1a (100 mg, 0.65 mmol), brucine N-oxide BNO 
(40 mg, 0.1 mmol) was added to methyl vinyl ketone (138 mg, 1.95 mmol). The resulting 
suspension was stirred at 23 °C for 5 days, after which the mixture was directly loaded 
into a silica gel packed column for flash column chromatography (eluent 33/67 diethyl 
ether/hexanes) to give the Morita-Baylis-Hillman product 2.1a (130 mg, 90%). 
 
3-((3-Bromophenyl)hydroxymethyl)but-3-en-2-one (2.2p). The spectroscopic data were 
consistent with those reported in the literature.10 1H NMR (CDCl3, 500 MHz): 7.49 (t, J 
= 1.7 Hz, 1H), 7.38 (dt, J = 7.8, 1.4 Hz, 1H), 7.27 (d, J = 7.7 Hz, 1H), 7.19 (t, J = 7.8 Hz, 
1H), 6.21 (s, 1H), 6.00 (d, J = 1.0 Hz, 1H), 5.44 (d, J = 5.3Hz, 1H), 3.30 (d, J = 5.4 Hz, 
55 
 
1H), 2.33 (s, 3H); 13C{1H} (CDCl3, 125 MHz): 200.1, 149.9, 143.3, 130.6, 129.9, 129.5, 
127.1, 125.1, 122.5, 72.0, 26.4. 
OH
Cl
Me
O
 
3-((4-Chlorophenyl)hydroxymethyl)but-3-en-2-one (2.2q). The spectroscopic data were 
consistent with those reported in the literature.8 1H NMR (CDCl3, 500 MHz): 7.29 (d, J 
= 4.9 Hz, 4H), 6.19 (s, 1H), 5.97 (d, J = 1.1 Hz, 1H), 5.57 (d, J = 5.1 Hz, 1H), 3.21 (d, J 
= 5.3 Hz, 1H), 2.33 (s, 3H); 13C{1H} (CDCl3, 125 MHz): 200.2, 149.6, 140.0, 133.4, 
128.5, 127.9, 126.9, 72.2, 26.4. 
 
3-((Furan-2-yl)hydroxymethyl)but-3-en-2-one (2.2r). The spectroscopic data were 
consistent with those reported in the literature.27 1H NMR (CDCl3, 500 MHz): 7.31 (dd, 
J = 1.8, 0.7 Hz, 1H), 6.28 (dd, J = 3.2, 1.8 Hz, 1H), 6.21(s, 1H), 6.18 (d, J = 3.3 Hz, 1H), 
6.09 (d, J = 1.2 Hz, 1H), 5.59 (d, J = 6.0 Hz, 1H), 3.56 (d, J = 6.1 Hz, 1H), 2.32 (s, 3H); 
13C{1H} (CDCl3, 125 MHz): 199.7, 154.2, 147.3, 142.0, 127.0, 110.2, 107.0, 66.5, 26.1. 
 
3-(Hydroxy(thiophen-2-yl)methyl)but-3-en-2-one (2.2s).30 1H NMR (CDCl3, 500 MHz): 
7.23 (dd, J = 4.5, 1.8 Hz, 1H), 6.95 (t, J = 3.2 Hz, 1H), 6.94 (d, J = 1.7 Hz, 1H), 6.22 (s, 
1H), 6.11 (d, J = 1.0 Hz, 1H), 5.81 (d, J = 6.0 Hz, 1H), 3.45 (d, J = 6.1 Hz, 1H), 2.37 (s, 
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3H); 13C{1H} (CDCl3, 125 MHz): 200.2, 149.1, 145.8, 126.8, 126.7, 125.1, 124.6, 69.6, 
16.5. HRMS-CI m/z: 182.0396 [(M)+; calcd for C9H10O2NS: 182.0396]. 
 
3-(Hydroxy(4-methoxyphenyl)methyl)but-3-en-2-one (2.2t). 1H NMR (CDCl3, 500 
MHz): 7.28 – 7.26 (m, 2H), 6.87 – 6.85 (m, 2H), 6.18 (s, 1H), 5.99 (d, J = 1.0 Hz, 1H), 
5.57 (d, J = 3.5 Hz, 1H), 3.79 (s, 3H), 3.20 (d, J = 4.5 Hz, 1H), 2.33 (s, 3H); 13C{1H} 
(CDCl3, 500 MHz):  200.4, 159.3, 150.4, 133.9, 128.0, 126.3, 114.0, 72.5, 55.4, 26.7; IR 
(neat, cm-1): 3440, 3040, 3011, 2962, 2933, 2835, 1674, 1611, 1512, 1366, 1303, 1249, 
1175, 1032, 833; HRMS-CI: m/z 205.0874 [(M-H)-; calcd for C12H13O3: 205.0870]. 
 
3-(Hydroxy(p-tolyl)methyl)but-3-en-2-one (2.2u).31 1H NMR (CDCl3, 500 MHz): 7.24 
(d, J = 8.0 Hz, 2H), 7.14 (d, J = 7.9 Hz, 2H), 6.18 (s, 1H), 5.99 (d, J = 1.2 Hz, 1H), 5.58 
(d, J = 4.6 Hz, 1H), 3.03 (d, J = 5.1 Hz, 1H), 2.33 (s, 6H); 13C{1H} (CDCl3, 125 MHz): 
200.3, 150.0, 138.6, 137.3, 129.1, 126.4, 126.4, 72.7, 26.5, 21.1. 
 
4-Hydroxy-3-methyl-4-(o-tolyl)butan-2-one (2.2v). 1H NMR (CDCl3, 500 MHz):7.42 - 
7.40 (m, 1H), 7.24 - 7.18(m, 2H), 7.16 – 7.14 (m, 1H), 6.17 (s, 1H), 5.86 (d, J = 3.5 Hz, 
1H), 5.73 (d, J = 1.0 Hz, 1H), 2.95 (d, J = 4.0 Hz, 1H), 2.39 (s, 3H), 2.28 (s, 3H); 13C{1H} 
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(CDCl3, 500 MHz):  200.7, 150.0, 139.1, 135.6, 130.5, 127.8, 126.9, 126.4, 126.3, 68.8, 
26.6, 19.3; IR (neat, cm-1): 3417, 3066, 3009, 2965, 2917, 2857, 1679, 1384, 1028, 745; 
HRMS-CI: m/z 193.1227 [(M+H)+; calcd for C12H17O2: 193.1229]. 
 
3-(Cyclohexyl(hydroxy)methyl)but-3-en-2-one (2.2x). The spectroscopic data were 
consistent with those reported in the literature.32 1H NMR (CDCl3, 500 MHz): 6.12 (s, 
1H), 5.91 (s, 1H), 4.06 (t, J = 7.5 Hz, 1H), 2.68 (d, J = 7.9 Hz, 1H), 2.35 (s, 3H), 1.92 (m, 
1H), 1.76-1.16 (m, 3H), 1. 53 (m, 1H), 1.43 (m, 1H), 1.24-1.06 (m, 3H), 0.98-0.89 (m, 
2H); 13C{1H} (CDCl3, 125 MHz): 201.0, 148.8, 126.8, 77.4, 42.4, 30.1, 28.4, 26.6, 26.3, 
26.1, 25.9. 
 
4-Hydroxy-3-methyleneundecan-2-one (2.2y). 1H NMR (CDCl3, 500 MHz): 6.08 (s, 
1H), 5.98 (d, J = 0.9 Hz, 1H), 4.39 (q, J = 6.4 Hz, 1H), 2.72 (d, J = 6.5 Hz, 1H), 2.33 (s, 
3H), 1.59 – 1.54 (m, 2H), 1.43 – 1.36 (m, 1H), 1.30 – 1.24 (m, 9H), 0.85 (t, J = 6.95 Hz, 
3H); 13C{1H} (CDCl3, 125 MHz): 200.9, 150.6, 125.6, 71.5, 36.5, 31.9, 29.5, 29.3, 26.6, 
26.0, 22.7, 14.2; IR (neat, cm-1): 3447, 3104, 2003, 2952, 2926, 2856, 1675, 1629, 1466, 
1429, 1366, 1281, 1107, 1069, 1017, 972, 948, 591; HRMS-CI: m/z 199.1686 [(M)+; 
calcd for C12H23O2: 199.1698]. 
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General Procedure for Morita-Baylis-Hillman Reaction of Phenyl Vinyl Ketone 
To a stirred solution of 2.1a (100 mg, 0.65 mmol), BNO (269 mg, 0.65 mmol) and L-
proline (74 mg, 0.65 mmol) in anhydrous 1,4-dioxane (5.0 mL) at ambient temperature 
were added to PVK (0.259 mL, 1.95 mmol). The resulting suspension was stirred at 
50 °C for 42 h, and then loaded directly into a silica gel packed column for flash column 
chromatography (EtOAc–hexanes, 20:80) to give MBH product 2.3a. 
 
2-(Hydroxy(2-nitrophenyl)methyl)-1-phenylprop-2-en-1-one (2.3a). 1H NMR (CDCl3, 
500 MHz): δ 8.01-7.97(m, 2H), 7.73-7.67 (m, 3H), 7.57-7.54 (m, 1H), 7.49-7.42 (m, 3H), 
6.31 (s, 1H), 5.82 (d, J = 0.8 Hz, 1H), 5.77(s, 1H), 4.14 (d, J = 1.8 Hz, 1H); 13C{1H} 
NMR (CDCl3, 125 MHz): δ 198.5, 147.8, 147.6, 136.7, 136.2, 133.6, 133.0, 129.7, 129.0, 
128.6, 128.4, 127.7, 124.7, 69.4; IR (neat, cm-1): 3450, 3064, 2920, 2851, 1650, 1524, 
1345; HRMS-CI: m/z 283.0845 [(M-H)-; calcd for C16H12NO4: 282.0772]; Yellow liquid. 
 
2-(Hydroxy(4-nitrophenyl)methyl)-1-phenylprop-2-en-1-one (2.3b). 1H NMR (CDCl3, 
500M Hz): δ 8.19 (d, J = 8.75 Hz, 2H), 7.68-7.66 (m, 2H), 7.63 (d, J = 8.5 Hz, 2H), 7.58-
7.54 (m, 1H), 7.44-7.41 (m, 2H), 6.12 (s, 1H), 5.88 (s, 1H), 5.84 (s, 1H), 3.74 (s, 1H); 
13C{1H} NMR (CDCl3, 125 MHz): δ 197.9, 148.7, 147.6, 147.4, 136.8, 133.1, 129.5, 
128.5, 128.1, 127.2, 123.7, 73.5; IR (neat, cm-1): 3458, 3066, 2925, 1655, 1519, 1347; 
HRMS-CI: m/z 283.0845 [(M-H)-; calcd for C16H12NO4: 282.0772]; Yellow liquid. 
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2-(Hydroxy(3-nitrophenyl)methyl)-1-phenylprop-2-en-1-one (2.3c). 1H NMR (CDCl3, 
500 MHz): δ 8.34 (s, 1H), 8.15-8.12 (m, 1H), 7.82 (d, J = 7.5 Hz, 1H), 7.70-7.68 (m, 2H), 
7.58-7.51 (m, 2H), 7.45-7.42 (m, 2H), 6.15 (d, J = 1.0 Hz, 1H), 5.92 (s, 1H), 5.84 (d, J = 
5.5 Hz, 1H), 3.67 (d, J = 5.5 Hz, 1H); 13C{1H}  NMR (CDCl3, 125 MHz): δ 198.0, 148.4, 
147.5, 143.7, 136.9, 133.1, 132.6, 129.5, 129.4, 128.5, 128.4, 122.8, 121.4, 73.6; IR (neat, 
cm-1): 3451, 3088, 2922, 1654, 1529, 1351; HRMS-CI: m/z 283.0845 [(M-H)-; calcd for 
C16H12NO4: 282.0772]; Yellow liquid. 
 
2-((2,4-Dinitrophenyl)(hydroxy)methyl)-1-phenylprop-2-en-1-one (2.3d). 1H NMR 
(CDCl3, 500 MHz): δ 8.85(d, J = 2.0 Hz, 1H), 8.52 (dd, J = 8.5 Hz, 2.0 Hz, 1H), 8.26 (d, 
J = 8.5 Hz, 1H), 7.71-7.69 (m, 2H), 7.61-7.58 (m, 1H), 7.48-7.44 (m, 2H), 6.38 (d, J = 
4.4 Hz, 1H), 5.85 (s, 1H), 5.84 (s, 1H), 4.21 (d, J = 4.7 Hz, 1H); 13C{1H}  NMR (CDCl3, 
125 MHz): δ 198.1, 147.7, 147.3, 146.5, 142.9, 136.2, 133.4, 130.8, 129.7, 128.6, 128.6, 
127.5, 120.2, 69.5; IR (neat, cm-1): 3458, 3112, 2926, 1651, 1606, 1535, 1346; HRMS-CI: 
m/z 328.0695 [(M+H)+; calcd for C16H13N2O6: 329.0768]; Yellow liquid. 
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2-(Hydroxy(3-methoxy-2-nitrophenyl)methyl)-1-phenylprop-2-en-1-one (2.3e). 1H NMR 
(CDCl3, 500 MHz): δ 7.73 (d, J = 8.0 Hz, 2H), 7.57-7.54 (m, , 1H), 7.47-7.42 (m, 3H), 
7.31 (d, J = 8.0 Hz, 1H), 6.99 (d, J = 8.5 Hz, ,1H), 6.03 (d, J = 1.0 Hz, 1H), 5.86 (s, 1H), 
5.81 (d, J = 5.9 Hz, 1H), 4.09 (d, J = 5.9 Hz, 1H), 3.90 (s, 3H); 13C{1H}  NMR (CDCl3, 
125 MHz): δ 199.3, 151.0, 145.7, 136.7, 134.1, 133.0, 131.3, 129.7, 129.4, 128.4, 119.5, 
112.12, 70.4, 56.5; IR (neat, cm-1): 3440, 2941, 2851, 1653, 1532, 1282; HRMS-CI: m/z 
313.0950 [(M+H)+; calcd for C17H15NO5: 314.1023]; Yellow liquid. 
 
2-(Hydroxy(1-nitronaphthalen-2-yl)methyl)-1-phenylprop-2-en-1-one (2.3f). 1H NMR 
(CDCl3, 500 MHz): δ 8.02 (d, J = 8.5 Hz, 1H), 7.90 (d, J = 7.5 Hz, 1H), 7.83 (d, J = 8.5 
Hz, 1H), 7.79 (d, J = 8.5 Hz, 1H), 7.74-7.72 (m, 2H), 7.66-7.52 (m, 3H), 7.44-7.42 (m, 
2H), 6.06-6.04 (m, 2H), 5.91 (s, 1H), 4.05 (d, J = 4.5 Hz, 1H); 13C{1H}  NMR (CDCl3, 
125 MHz): δ 198.1, 146.2, 136.8, 133.4, 133.0, 131.2, 130.5, 129.7, 129.1, 129.1, 128.8, 
128.4, 128.0, 127.6, 124.4, 124.1, 121.8, 70.2; IR (neat, cm-1): 3434, 3064, 2922, 1654, 
1527; HRMS-CI: m/z 333.1001 [(M-H)-; calcd for C20H15NO4: 332.0928]; Yellow liquid. 
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2-(Hydroxy(6-nitrobenzo[d][1,3]dioxol-5-yl)methyl)-1-phenylprop-2-en-1-one (2.3g). 1H 
NMR (CDCl3, 500 MHz): δ 7.74 (d, J = 7.5 Hz, 2H), 7.59-7.56 (m , 2H), 7.46-7.42 (m, 
3H), 6.28 (s, 1H), 6.14 (d, J = 4.5 Hz, 2H), 5.80 (s, 1H), 5.73 (s, 1H), 4.12 (s, 1H); 
13C{1H} NMR (CDCl3, 125 MHz): δ 198.8, 152.5, 147.8, 147.3, 141.6, 136.8, 134.1, 
133.0, 129.8, 128.4, 127.1, 108.0, 105.7, 103.1, 69.5; IR (neat, cm-1): 3444, 3086, 2919, 
1652, 1519, 1262, 1035; HRMS-CI: m/z 327.0743 [(M-H)-; calcd for C17H12NO6: 
326.0670]; Yellow liquid. 
 
2-(Hydroxy(2-(trifluoromethyl)phenyl)methyl)-1-phenylprop-2-en-1-one (2.3h). 1H 
NMR (CDCl3, 500 MHz): δ 7.89 (d, J = 8.0 Hz, 1H), 7.75 (d, J = 8.0 Hz, 2H), 7.69 (d, J 
= 7.5 Hz, 1H), 7.63 (t, J = 7.5 Hz, 1H), 7.59-7.56 (m, 1H), 7.47-7.43 (m, 3H), 6.18 (s, 
1H), 5.80 (s, 1H), 5.66 (s, 1H), 3.75 (s, 1H); 13C{1H} NMR (CDCl3, 125 MHz): δ 198.7, 
148.5, 139.1, 137.0, 132.9, 132.2, 129.7, 128.8, 128.4, 125.9, 69.2; IR (neat, cm-1): 3447, 
3067, 2920, 1655, 1313, 1160, 1123; HRMS-CI: m/z 306.0868 [(M+H)+; calcd for 
C17H14F3O2: 307.0940]; Yellow liquid. 
 
2-((2-Fluorophenyl)hydroxymethyl)-1-phenylprop-2-en-1-one (2.3i). 1H NMR (CDCl3, 
500 MHz): δ 7.74-7.72 (m, 2H), 7.60-7.51 (m, 2H), 7.43 (m, 2H), 7.29-7.25 (m, 1H), 
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7.19-7.16 (m, 1H), 7.06-7.02 (m, 1H), 6.00 (s, 2H), 5.80 (s, 1H), 3.76 (s, 1H); 13C{1H} 
NMR (CDCl3, 125 MHz): δ 198.6, 147.6, 139.6, 136.0, 135.0, 133.8, 131.1, 129.0, 128.8, 
128.7, 127.4, 124.9, 69.4; IR (neat, cm-1): 3445, 3065, 2920, 1655, 1489, 1450, 1314, 980, 
760; HRMS-CI: m/z 256.0900 [(M+H)+; calcd for C16H14FO2: 257.0972]; Yellow liquid. 
 
2-(Hydroxy(phenyl)methyl)-1-phenylprop-2-en-1-one (2.3j). 1H NMR (CDCl3, 500 
MHz): δ 7.71-7.69 (m, 2H), 7.55-7.52 (m, 1H), 7.47-7.40 (m, 5H), 7.37-7.33 (m, 2H), 
6.07 (s, 1H), 5.79 (s, 2H), 3.31 (s, 1H); 13C{1H} NMR (CDCl3, 125 MHz): δ 198.3, 148.8, 
141.3, 137.3, 132.7, 129.6, 128.5, 128.3, 127.8, 126.7, 126.5, 74.2; IR (neat, cm-1): 3467, 
3061, 2923, 2852, 1683, 1654, 1449, 979, 700; HRMS-CI: m/z 238.0994 [(M+H)+; calcd 
for C16H15O2:239.1067]; Colorless liquid. 
 
1-(4-Chlorophenyl)-2-(hydroxy(2-nitrophenyl)methyl)prop-2-en-1-one (2.3k). 1H NMR 
(CDCl3, 500 MHz): δ 8.03 (dd, J =  8.2 Hz, 1.1Hz, 1H), 7.97 (d, J = 7.6 Hz, 1H), 7.73-
7.67 (m, 3H), 7.51-7.48 (m, 1H), 7.43-7.42 (m, 2H), 6.29 (s, 1H), 5.80 (s, 1H), 5.74 (s, 
1H), 3.96 (s, 1H); 13C{1H} NMR (CDCl3, 125 MHz): δ 197.2, 147.6, 139.6, 136.0, 135.0, 
133.8, 131.1, 129.0, 128.8, 128.7, 127.4, 124.9, 69.4. IR (neat, cm-1): 3469, 3068, 2924, 
2853, 1680, 1658, 1589, 1525, 1346, 1092; HRMS-CI: m/z 317.0455 [(M+H)+; calcd for 
C16H13ClNO4:318.0528]; Yellow liquid. 
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1-(4-Chlorophenyl)-2-((2,4-dinitrophenyl)(hydroxy)methyl)prop-2-en-1-one (2.3l). 1H 
NMR (CDCl3, 500 MHz): δ 8.86 (d, J = 2.3 Hz, 1H), 8.53 (dd, J = 8.7 Hz, 2.3 Hz, 1H), 
8.26 (d, J = 8.7 Hz, 1H), 7.66 (d, J = 8.5 Hz, 2H), 7.44 (d, J = 8.5 Hz, 1H), 6.36 (s, 1H), 
5.81 (s, 2H), 4.09 (s, 1H); 13C{1H} NMR (CDCl3, 125 MHz): δ 196.8, 147.6, 147.4, 
146.7, 142.8, 140.0, 134.5, 131.1, 130.8, 129.0, 128.3, 127.6, 120.3, 69.3; IR (neat, cm-1): 
3458, 3104, 2923, 1655, 1588, 1535, 1346; HRMS-CI: m/z 326.0306 [(M+H)+; calcd for 
C16H12ClN2O6:363.0378]; Yellow liquid. 
 
2-((2,4-Dinitrophenyl)(hydroxy)methyl)-1-(4-methoxyphenyl)prop-2-en-1-one (2.3m). 
1H NMR (CDCl3, 500 MHz): δ 8.83 (d, J = 2.3 Hz, 1H), 8.51 (dd, J = 8.7 Hz, 2.3 Hz, 
1H), 8.27 (d, J = 8.7 Hz, 1H), 7.74-7.72 (m, 2H), 6.95-6.92 (m, 2H), 6.31 (d, J = 4.2 Hz, 
1H), 5.77 (s, 1H), 5.75 (s, 1H), 4.52 (d, J = 4.8 Hz, 1H), 3.87 (s, 3H); 13C{1H} NMR 
(CDCl3, 125 MHz): δ 196.9, 164.1, 147.7, 147.3, 146.1, 143.0, 132.3, 130.7, 128.7, 127.4, 
127.0, 120.1, 113.9, 70.1, 55.6; IR (neat, cm-1): 3404, 3109, 2923, 2851, 1649, 1599, 
1535, 1346; HRMS-CI: m/z 358.0801 [(M+H)+; calcd for C17H15N2O7:359.0874]; Yellow 
liquid. 
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CHAPTER 3. CATALYTIC ASYMMETRIC CONJUGATE ADDITION OF 
GLYCINE KETIMINE TO NITROALKENES USING BRUCINE DIOL-COPPER 
COMPLEX 
3.1 Introduction 
3.1.1 Conjugate Addition 
        Conjugate addition to ,-unsaturated carbonyl compounds or electron-deficient 
alkenes is one of the most useful carbon-carbon bond-forming reactions in organic 
synthesis.1 As shown in Scheme 13, nucleophiles attack the -carbon position of 
activated alkenes and produce the conjugate addition product. 
 
Scheme 13. Conjugate Addition Reaction 
        Considerable efforts have been devoted to the development of asymmetric conjugate 
addition reactions.2-8 Typically, the reaction involves the use of modified chiral reactants 
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or catalysts in both diastereoselective (Scheme 14) and enantioselective conjugate 
addition reactions (Scheme 15). 
 
Scheme 14. Diastereoselective Conjugate Addition Reaction9 
 
Scheme 15. Enantioselective Conjugate Addition Reaction10 
3.1.2 Conjugate Addition of Glycine Ester Derivatives to Activated Alkenes 
        Glycine ester derivatives have been utilized as nucleophiles in catalytic asymmetric 
carbon-carbon bond-forming reactions to produce optically pure -amino acid derivatives. 
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Thus, highly stereoselective reactions have been developed11-13  since the first report of 
the asymmetric alkylation of glycine esters using a chiral phase-transfer catalyst by 
O’Donnell et al. in 1978.14 Among them, the asymmetric conjugate addition of N-
(diphenylmethylene)glycine tert-butyl ester to ,-unsaturated carbonyl compounds 
provides an efficient route to optically active -alkylamino acid derivatives.15-18 As 
outlined in Scheme 16, (S)-ornithine dihydrochloride could be synthesized from the 
asymmetric conjugate addition of glycine ketimine 3.1 to acrylonitrile using a chiral 
catalyst. Furthermore, a variety of activated alkenes have been investigated to expand the 
scope of substrates such as -alkyl-,-unsaturated esters,19 -aryl nitroalkenes,20 -aryl-
,-unsaturated ketones,21, 22 arylidene malonates,23, 24 and alkylidene bisphosphonates.25 
 
Scheme 16. Synthesis of (S)-Ornithine Using Asymmetric Conjugate Addition Reaction 
        In this chapter, we present our study on the diastereoselective and enantioselective 
conjugate addition of glycine ketimine 3.1 to nitroalkenes to produce a variety of anti-
selective conjugate addition products with excellent ee’s. 
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3.2 Results and Discussion 
3.2.1 Anti-Selective Conjugate Addition Reaction 
        Several research groups have reported the development of catalytic asymmetric 
conjugate additions of glycine imines to a variety of activated alkenes,19-25 all leading to 
anti-selective conjugate reaction products (Scheme 17). In contrast, there are no 
examples of catalytic enantio- and syn-selective conjugate reactions of glycine imines. As 
a consequence, there is a clear void in the development of catalytic asymmetric syn-
selective conjugate reactions.  
 
Scheme 17. anti-Selective and syn-Selective Conjugate Addition Reactions 
        In the pursuit of a solution to this stereodivergence issue, we became interested in 
the stereochemical pathways of [3+2] cycloaddition reactions between glycine imines and 
electron-deficient alkenes. Since the seminal contribution of Grigg in 1911,26 significant 
progress has been made on the catalytic asymmetric [3+2] cycloaddition reactions of N-
metalated azomethine ylides with alkenes.27,28 Both concerted and stepwise 
mechanisms29,30 have been considered as possible pathways. The stepwise mechanism 
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has been suggested in the catalytic asymmetric exo-,31,32 endo-,32,33 and exo’-selective34 
[3+2] cycloaddition reactions of N-metalated azomethine ylides and nitroalkenes 
(Scheme 18). This stepwise reaction process in the [3+2] cycloaddition reactions of N-
metalated azomethine ylides implies the possibility of developing catalytic asymmetric 
systems for the conjugate reaction pathway. 
 
Scheme 18. Stereochemical Pathway of the [3+2] Cycloaddition Reactions 
        We have previously reported that the catalyst-substrate arrangements are controlled 
by multiple binding modes of multidentate amino alcohol, brucine diol (BD), through 
either metal coordination or the hydrogen-binding network.35,36 When glycine imines 
were treated with various ,-unsaturated esters under chiral copper(I) and silver(I) 
catalysis, the exclusive formation of endo-pyrrolidines was observed, possibly through a 
concerted [3 + 2] cycloaddition pathway.35 Given the possibility of different preferential 
interactions between acyclic alkenes and nucleophiles under various chiral catalyst 
conditions, we used nitroalkenes to develop stereodivergent conjugate addition reactions. 
We describe herein the first example of such a switch in selectivity to provide respective 
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anti- and syn-1,4-addition products using the chiral catalyst system derived from a single 
chiral source.37,38 In our preliminary study, we produced the syn-selective conjugate 
addition products and further synthesized exo-pyrrolidines under basic conditions 
(Scheme 19).39 
 
Scheme 19. Stepwise One-Pot [3+2] Cycloaddition Reaction 
        After establishing the facile access to chiral exo-pyrrolidine through a catalytic syn-
selective conjugate addition reaction, we investigated anti-selective conjugate addition 
reaction of glycine imines that potentially leads to diastereomeric endo-pyrrolidines. In 
our preliminary studies of the [3+2] cycloaddition reaction, endo-3.5 could be obtained, 
but the transient nature of the anti-selective conjugate addition product was not observed 
from the reaction of glycine imine 3.2 and nitroalkenes 3.3. However, the use of glycine 
ketimine 3.1 turned out to be a key factor in identifying the anti-selective conjugate 
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addition product (Scheme 20). The emergence of endo-pyrrolidines 3.7 was attributed to 
the base-promoted cyclization of anti-conjugate product 3.6 under the Cu-BD catalyst 
conditions. 
 
Scheme 20. Stepwise Conjugate Addition Reaction and Cyclization 
3.2.2 Optimization of anti-Selective Conjugate Addition Reaction  
        We examined the copper(I)-catalyzed asymmetric conjugate addition of glycine 
ketimine 3.1 to nitroalkene 3.3a in the presence of 10 mol % BD (Table 7). The use of 
CuOAc, CuCl, and CuI led to the endo-selective formation of 3.7a with low reactivity 
and enantioselectivity (entry 1-3). The use of CuOTf was subsequently identified as an 
anti-selective catalyst with 9:1 ratio between anti-3.6a and endo-3.7a (entry 4). The 
Cu(OTf)2 catalyst system was also investigated, however the product ratio between  anti-
3.6a and endo-3.7a was dropped to 1 : 1 (entry 5). To further improve the product ratio 
and enantioselectivity of anti-3.6a, we screened a variety of solvents (entry 6-8) and 
bases (entry 9-14). The coordinating solvent system-THF and the bulky organic base-
DBU were identified as an optimal solvent and a base for the asymmetric conjugate 
addition of glycine ketimine to nitroalkene. The additive effect using protic source, such 
as H2O, PhOH, i-PrOH, t-BuOH, 2,3-dimethyl-2-butanol, 2,2-diphenyl-ethanol, 2-
phenyl-2-propanol was also investigated (entry 15-21). While the use of acidic additive, 
PhOH, and non-bulky protic source, i-PrOH, led to lower enantioselectivity (entry 16) 
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and product ratio (entry 17), t-BuOH and 2-phenyl-2-propanol provided improved 
selectivities (entry 18 and 21). Under our optimized conditions, the combination of 
CuOTf and DBU in THF in the presence of t-BuOH or 2-phenyl-2-propanol, the 
formation of anti-3.6 was achieved in 89 % yield with 90 and 85 % ee, respectively.  
Although the exact role of OTf anion was not clear at the present time, the use of 
coordinating solvent, THF, and bulky base, DBU, were expected to stabilize the 
complexation between reactants and copper(I)/BD complex due to chelating and steric 
effects. The protic additive, t-BuOH, was believed to act as a proton shuttle between the 
complex intermediates and unbound reactants, thus facilitating the faster catalyst turn-
over as evidenced by the improved reaction conversion.  
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Table 7. Optimization of anti-Selective Conjugate Addition Reaction 
 
Entry Metal/Base Additive Solvent Yield (%)a 3.6 : 3.7b ee (%)c 
1 CuOAc/no base - CHCl3 35 1 : 11 48 
2 CuCl/Et3N - CHCl3 45 1 : 6 37 
3 CuI/DBU - CHCl3 45 1 : 10 34 
4 CuOTf/Et3N - CHCl3 90 9 : 1 60 
5 Cu(OTf)2/Et3N - CHCl3 89 1 : 1 67 
6 CuOTf/Et3N - CH2Cl2 99 2 : 1 57 
7 CuOTf/Et3N - PhCH3 90 2 : 1 11 
8 CuOTf/Et3N - THF 95 15 : 1 68 
9 CuOTf/NMM - THF 50 1 : 1 71 
10 CuOTf/Pyridine - THF 50 1 : 1 69 
11 CuOTf/DMAP - THF 35 2 : 1 59 
12 CuOTf/DABCO - THF 65 14 : 1 67 
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Table 7. Continued 
Entry Metal/Base Additive Solvent Yield (%)a 3.6 : 3.7b ee (%)c 
13 CuOTf/DBU - THF 60 10 : 1 75 
14 CuOTf/DBN - THF 50 4 : 1 72 
15 CuOTf/DBU H2O THF 90 15 : 1 77 
16 CuOTf/DBU PhOH THF 95 >25 : 1 10 
17 CuOTf/DBU i-PrOH THF 85 5 : 1 83 
18 CuOTf/DBU t-BuOH THF 89 >25 : 1 90 
19 CuOTf/DBU d THF 93 >25 : 1 71 
20 CuOTf/DBU e THF 90 >25 : 1 73 
21 CuOTf/DBU f THF 89 >25 : 1 85 
a. Isolated yields. 
b. Determined by crude 1H NMR. 
c. Determined by HPLC using a chiral column. 
d. 2,3-Dimethyl-2-butanol. 
e. 2,2-Diphenyl-ethanol. 
f. 2-Phenyl-2-propanol. 
g. CuOTf = (CuOTf)2●C6H6 
3.2.3 Substrate Scope of Anti-Selective Conjugate Reaction 
        Table 8 summarizes the scope of the catalytic anti-selective conjugate addition of 
glycine ketimine 3.1. The formations of anti-3.6 with high enantioselectivities and yields 
were achieved for various nitroalkene derivatives with different electronic (3.6a-3.6d) 
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and steric effects (3.6e-3.6i). Synthetically satisfactory levels of enantioselectivity (i.e. 
80-90% ee’s) were observed, although sterically demanding substrates proved to be less 
selective (3.6g-i). The use of heteroaromatic nitroalkenes also provided satisfactory 
selectivities (3.6j, 3.6k) in the absence of protic additives. This result might imply the 
stronger coordination ability of heteroaromatic nitroalkenes to the catalyst than aryl 
nitroalkenes. Lower reactivity was observed for aliphatic nitroalkenes (3.6l, 3.6m). While 
efforts to improve the reaction yields for aliphatic nitroalkenes were made using more 
than 20 mol % catalyst, due to the facile decomposition of aliphatic nitroalkenes the 
lower yields of products were obtained. The relative and absolute stereochemistry of anti-
3.6 was confirmed to be (2S,3S) by comparison of its HPLC retention times with those 
described previously.20 
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Table 8. Scope of the anti-Selective Conjugate Addition Reaction  
 
Entry R1 anti-3.6 Yield (%) ee (%) 
1a 
 
3.6a 89 90 
2 
 
3.6b 84 88 
3 
 
3.6c 82 84 
4a 
 
3.6d 68 80 
5 
 
3.6e 81 88 
6 
 
3.6f 85 88 
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Table 8. Continued 
Entry R1 anti-3.6 Yield (%) ee (%) 
7 
 
3.6g 83 82 
8 
 
3.6h 73 81 
9b 
 
3.6i 88 80 
10c 
 
3.6j 83 86 
11c 
 
3.6k 83 81 
12b 
 
3.6l 52 80 
13b 
 
3.6m 49 80 
a. Reaction used 60 mol % t-BuOH. 
b. Reaction used 20 mol % catalyst. 
c. No additive was used. 
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3.3 Conclusion 
        In summary, we have developed a stereodivergent catalytic asymmetric conjugate 
reaction for glycine (ket)imine with nitroalkenes. Both syn- and anti-addition products 
were obtained with high diastereoselectivity and enantioselectivity. The stereoselective 
formation of exo-3.5 and endo-3.7 was also achieved from syn-3.4 and anti-3.6, 
respectively, under the base catalysis. These results clearly demonstrated the stepwise 
nature of the [3+2] cycloaddition reaction of N-metalated azomethine ylides. The 
preparation of a diverse array of chiral compounds using various chiral catalyst species, 
particularly those derived from a single chiral source (i.e. BD), should advance our 
molecular level understanding of asymmetric catalysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
83 
 
3.4 Experimental Section 
General Procedure A for the Synthesis of Anti-Conjugated Products 
 
tert-Butyl (2S,3S)-2-((Diphenylmethylene)amino)-4-nitro-3-phenylbutanoate (3.6a). 
(CuOTf)2●C6H6 (10 mol %, 25 mg) and brucine diol (BD) were added to a 10 mL 
Schlenk flask. Dry THF (2.0 mL) was then added to the flask at 0 °C, followed by 
addition of DBU (10 mol %, 7.5 L). The solution was stirred for 4 h at this temperature. 
The resulting solution was cooled to -15 °C, and glycine ketimine 3.1 (0.5 mmol, 148 mg) 
was added and stirred for 10 min. After which, to the resulting solution, 1-((E)-2-
nitrovinyl)benzene (0.5 mmol, 74 mg) was added followed by the addition of tert-butanol 
additive (60 mol%, 28 L). The solution was stirred continuously at -15 °C for 48-60 h. 
The reaction mixture was then subjected to chromatography on a short silica column (5-
10 % ethyl acetate in hexanes); the yield of the title compound was 89%. 1H NMR and 
13C NMR spectra for this compound are consistent with previously reported data in the 
literature.20 1H NMR (CDCl3, 500 MHz):  7.64-7.63 (m, 2H), 7.45-7.42 (m, 1H), 7.38-
7.33 (m, 3H), 7.29-7.26 (m, 2H), 7.25-7.22 (m, 3H), 7.15-7.13 (m, 2H), 6.65 (d, J = 7 Hz, 
2H), 5.15-5.07 (m, 2H), 4.29 (dd, J = 9.5, 4.5 Hz, 1H), 4.17 (d, J = 4.5 Hz, 1H), 1.37 (s, 
9H); 13C{1H} NMR (CDCl3, 125 MHz):  172.3, 168.9, 138.8, 137.5, 135.6, 130.7, 128.8, 
128.6, 128.5, 128.3, 128.2, 128.2, 127.7, 127.4, 82.2, 76.5, 69.2, 46.9, 27.9. 
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tert-Butyl (2S,3S)-2-((Diphenylmethylene)amino)-4-nitro-3-(p-tolyl)butanoate (3.6b). 
Product was prepared with 1-methyl-4-((E)-2-nitrovinyl)benzene (0.5 mmol, 82 mg) by 
General Procedure A except using 2-phenyl-2-propanol (20 mol%, 14 L) as an additive. 
The crude product was subjected to on a short silica column (5-10% ethyl acetate in 
hexanes); the yield of the title compound was 84%. 1H NMR and 13C NMR spectra for 
this compound are consistent with previously reported data in the literature.20 1H NMR 
(CDCl3, 500 MHz):  7.66 -7.64 (m, 2H), 7.45-7.41 (m, 1H), 7.37-7.33 (m, 3H), 7.31 - 
7.25 (m, 2H), 7.06 - 7.02 (m, 4H), 6.69 (d, J = 7.0 Hz, 2H), 5.12 - 5.05 (m, 2H), 4.29 – 
4.26 (m, 1H), 4.18 (d, J = 4.5 Hz, 1H), 2.29 (s, 3H), 1.37 (s, 9H); 13C{1H} NMR (CDCl3, 
125 MHz):  172.1, 168.9, 138.8, 137.2, 135.5, 134.3, 130.6, 129.2, 128.8, 128.5, 128.2, 
128.1, 127.3, 124.3, 82.0, 76.6, 69.2, 46.5, 27.8, 20.9. 
 
tert-Butyl (2S,3S)-3-(4-chlorophenyl)-2-((diphenylmethylene)amino)-4-nitrobutanoate 
(3.6c). Product was prepared with 1-chloro-4-((E)-2-nitrovinyl)benzene (0.5 mmol, 92 
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mg) by General Procedure A except that 2-phenyl-2-propanol (20 mol%, 14 L) was 
used as an additive. The crude product was subjected to chromatography on a short silica 
column (5-10% ethyl acetate in hexanes); the yield of the title compound was 82%. 1H 
NMR and 13C NMR spectra for this compound are consistent with previously reported 
data in the literature.20 1H NMR (CDCl3, 500 MHz):  7.65-7.64 (m, 2H), 7.47-7.43 (m, 
1H), 7.39-7.31 (m, 5H), 7.22 (dd, J = 7.0, 1.5 Hz, 2H), 7.11 (dd, J = 7.0, 1.5 Hz, 2H), 
6.73-6.71 (m, 2H), 5.13-5.07 (m, 2H), 4.30-4.26 (m, 1H), 4.17 (d, J = 4.5 Hz, 1H), 1.39 
(s, 9H); 13C{1H} NMR (CDCl3, 125 MHz):  172.6, 168.6, 138.6, 136.0, 135.4, 133.6, 
130.9, 129.7, 128.8, 128.8, 128.7, 128.3, 128.2, 127.3, 82.4, 76.3, 68.9, 46.2, 27.8. 
 
tert-Butyl (2S,3S)-2-((Diphenylmethylene)amino)-3-(4-fluorophenyl)-4-nitrobutanoate 
(3.6d). Product was prepared with 1-fluoro-4-((E)-2-nitrovinyl)benzene (0.5 mmol, 83 
mg) by General Procedure A. The crude product was subjected to chromatography on a 
short silica column (5-10% ethyl acetate in hexanes); the yield of the title compound was 
68%. 1H NMR and 13C NMR spectra for this compound are consistent with previously 
reported data in the literature.20 1H NMR (CDCl3, 500 MHz):  7.67 (d, J = 8.0  Hz, 2H), 
7.46  – 7.32 (m ,6H), 7.16 (dd, J = 8.0, 5.5 Hz, 2H), 6.96 (t, J = 8.0 Hz, 2H), 6.75 (d, J = 
7.0 Hz, 2H), 5.10 (d, J = 7.5 Hz, 2H), 4.32 (dd, J = 12.0, 7.5 Hz, 1H), 4.19 (d, J = 4.5 Hz, 
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1H), 1.40 (s, 9H); 13C{1H} NMR (CDCl3, 125 MHz):  172.4, 168.6, 162.1 (d, J = 245 
Hz), 138.6, 135.4, 133.2(d, J = 2.95 Hz), 130.8, 129.9(d, J = 8.0 Hz), 128.7, 128.6, 128.3, 
128.1, 127.2, 115.4 (d, J = 21.1 Hz), 82.2, 76.5, 69.0,  46.1, 27.7. 
 
tert-Butyl (2S,3S)-2-((Diphenylmethylene)amino)-4-nitro-3-(m-tolyl)butanoate (3.6e). 
Product was prepared with 1-methyl-3-((E)-2-nitrovinyl)benzene (0.5 mmol, 82 mg) by 
General Procedure A except using 2-phenyl-2-propanol (20 mol%, 14 L) as an additive. 
The crude product was subjected to chromatography on a short silica column (5-10% 
ethyl acetate in hexanes); the yield of the title compound was 81%. 1H NMR (CDCl3, 500 
MHz):  7.65 - 7.63 (m, 2H), 7.41 - 7.40 (m, 1H), 7.36 – 7.33 (m, 3H), 7.29 – 7.26 (m, 
2H), 7.11 (t, J = 7.8 Hz, 1H), 7.03 (d, J = 7.6 Hz, 1H), 6.94 (d, J = 2.0 Hz, 1H), 6.64 (d, J 
= 1.8 Hz, 1H), 5.15 – 5.07 (m, 2H), 4.29 – 4.25 (m, 1H), 4.17 (d, J = 4.5 Hz, 1H), 2.22 (s, 
3H), 1.38 (s, 9H); 13C{1H} NMR (CDCl3, 125 MHz):  172.2, 169.0, 138.9, 138.2, 137.3, 
135.7, 130.7, 129.4, 128.8, 128.6, 128.5, 128.4, 128.2, 128.2, 127.4, 125.0, 82.2, 76.5, 
69.3, 46.8, 27.9, 21.3; IR (neat, cm-1): 3059, 3025, 2978, 2929, 1732, 1533, 1446, 1150, 
701; HRMS-CI m/z: 459.2283 [(M+H)+; calcd for C28H31N2O4: 459.2278]. 
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tert-Butyl (2S,3S)-3-(3-Chlorophenyl)-2-((diphenylmethylene)amino)-4-nitrobutanoate 
(3.6f). Product was prepared with 1-chloro-3-((E)-2-nitrovinyl)benzene (0.5 mmol, 92 
mg) by General Procedure A except using 2-phenyl-2-propanol (20 mol%, 14 L) as an 
additive. The crude product was subjected to chromatography on a short silica column (5-
10% ethyl acetate in hexanes); the yield of the title compound was 85%. 1H NMR (CDCl3, 
500 MHz):  7.64 - 7.62 (m, 2H), 7.46 - 7.42 (m, 1H), 7.39 - 7.35 (m, 3H), 7.33 – 7.30 
(m, 2H), 7.24 – 7.22 (m, 1H), 7.20 – 7.16 (m, 1H), 7.14 – 7.13 (m, 1H), 7.05 (d, J = 7.6 
Hz, 1H), 6.7 (d, J = 6.8 Hz, 2H), 5.09 – 5.08 (m, 2H), 4.28 – 4.24 (m, 1H), 4.15 (d, J = 
4.5 Hz, 1H), 1.38 (s, 9H); 13C{1H} NMR (CDCl3, 125 MHz):  172.7, 168.6, 139.6, 
138.7, 135.5, 134.5, 130.9, 129.9, 128.8, 128.8, 128.7, 128.3, 128.2, 127.9, 127.3, 126.2, 
82.5, 76.1, 68.9, 46.5, 27.9; IR (neat, cm-1): 3060, 2978, 2932, 1733, 1554, 1369, 1151, 
696; HRMS-CI m/z: 479.1729 [(M+H)+; calcd for C27H28ClN2O4 : 479.1732 ]. 
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tert-Butyl (2S,3S)-3-(2-Chlorophenyl)-2-((diphenylmethylene)amino)-4-nitrobutanoate 
(3.6g). Product was prepared with 1-chloro-2-((E)-2-nitrovinyl)benzene (0.5 mmol, 92 
mg) by General Procedure A except using 2-phenyl-2-propanol (20 mol%, 14 L) as an 
additive. The crude product was subjected to chromatography on a short silica column (5-
10% ethyl acetate in hexanes); the yield of the title compound was 83%. 1H NMR and 
13C NMR spectra for this compound are consistent with previously reported data in the 
literature.20 1H NMR (CDCl3, 500 MHz):  7.68 (d, J = 7.4 Hz, 2H), 7.31 (d, J = 7.3 Hz, 
1H), 7.41 – 7.37 (m, 4H), 7.34 - 7.29 (m, 2H), 7.27 – 7.18 (m, 3H), 6.60 (d, J = 6.0 Hz, 
2H), 5.36 – 5.21 (m, 2H), 4.97 – 4.93 (m, 1H), 4.37 (d, J = 4.0 Hz, 1H), 1.46 (s, 9H); 
13C{1H} NMR (CDCl3, 125 MHz):  172.6, 168.7, 138.6, 135.4, 134.8, 134.4, 130.7, 
130.0, 128.7, 128.7, 128.6, 128.2, 128.1, 127.1, 126.7, 124.2, 82.2, 75.0, 66.6, 42.7, 27.8. 
 
tert-Butyl (2S,3S)-2-((Diphenylmethylene)amino)-3-(naphthalen-1-yl)-4-nitrobutanoate 
(3.6h). Product was prepared with 1-((E)-2-nitrovinyl)naphthalene (0.5 mmol, 99 mg) by 
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General Procedure A except using 2-Phenyl-2-propanol (20 mol%, 14 L) as an additive. 
The crude product was subjected to chromatography on a short silica column (5-10% 
ethyl acetate in hexanes); the yield of the title compound was 73%. 1H NMR (CDCl3, 500 
MHz):  8.03 (d, 7.6 Hz, 1H), 7.87 (d, J = 8.3 Hz, 1H), 7.78 (dd, J = 6.8, 2.4 Hz, 1H), 
7.64 (d, J = 7.9 Hz, 2H), 7.49 - 7.42 (m, 3H), 7.38 - 7.35 (m, 4H), 7.14 (t, J = 7.4 Hz, 1H), 
6.97 (t, J = 7.3 Hz, 1H), 6.31 (s, 2H), 5.43 (dd, J = 12.2, 8.6 Hz, 1H), 5.35 - 5.28 (m, 2H), 
4.35 (d, J = 2.8 Hz, 1H), 1.38 (s, 9H); 13C{1H} NMR (CDCl3, 125 MHz):  172.4, 169.1, 
138.7, 135.1, 134.0, 133.0, 131.4, 130.6, 128.8, 128.7, 128.2, 128.1, 128.0, 127.8, 126.8, 
126.5, 125.7, 124.9, 124.3, 122.2, 82.2, 75.6, 67.8, 31.7, 27.8; IR (neat, cm-1): 3058, 2977, 
2931, 1733, 1553, 1151, 781, 697; HRMS-CI m/z: 495.2299 [(M+H)+; calcd for 
C31H31N2O4 : 495.2278]. 
 
tert-Butyl (2S,3S)-2-((Diphenylmethylene)amino)-3-(naphthalen-2-yl)-4-nitrobutanoate 
(3.6i). Product was prepared using (CuOTf)2●C6H6 (20 mol%, 50 mg), BD (20 mol%, 42 
mg), 2-((E)-2-nitrovinyl)naphthalene (0.5 mmol, 99 mg) by General Procedure A except 
using 2-phenyl-2-propanol (20 mol%, 14 L) as an additive. The crude product was 
subjected to chromatography on a short silica column (5-10% ethyl acetate in hexanes); 
the yield of the title compound was 88%. 1H NMR (CDCl3, 500 MHz):  7.85 – 7.68 (m, 
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6H), 7.52 – 7.49 (m, 3H), 7.45 – 7.42 (m, 2H), 7.37 - 7.33 (m, 2H), 7.23 (t, J = 7.9 Hz, 
2H), 6.64 (d, J = 7.0 Hz, 2H), 5.33 – 5.21 (m, 2H), 4.55 – 4.51 (m, 1H), 4.35 (d, J = 4.6 
Hz, 1H), 1.43 (s, 9H); 13C{1H} NMR (CDCl3, 125 MHz):  172.4, 168.9, 138.8, 135.5, 
134.9, 133.2, 132.7, 130.8, 128.8, 128.5, 128.3, 128.2, 128.2, 127.8, 127.5, 127.5, 127.3, 
126.2, 126.0, 125.9, 82.3, 76.5, 69.2, 47.0, 27.9; IR (neat, cm-1): 3058, 3020, 2978, 2930, 
1730, 1553, 1151, 751, 698; HRMS-CI m/z: 495.2291 [(M+H)+; calcd for C31H31N2O4: 
495.2278]. 
 
tert-Butyl (2S,3S)-2-((Diphenylmethylene)amino)-3-(furan-2-yl)-4-nitrobutanoate (3.6j). 
Product was prepared with 2-((E)-2-nitrovinyl)furan (0.5 mmol, 69 mg) by General 
Procedure A without addition of additives. The crude product was subjected to 
chromatography on a short silica column (5-10% ethyl acetate in hexanes); the yield of 
the title compound was 83%. 1H NMR and 13C NMR spectra for this compound are 
consistent with previously reported data in the literature.20 1H NMR (CDCl3, 500 MHz): 
 7.60 (d, J = 8.3 Hz, 2H), 7.45 – 7.33 (m, 6H), 7.27 (dd, J = 2.0, 0.5 Hz, 1H), 6.86 (d, J 
= 6.9 Hz, 2H), 6.26 (dd, J = 3.0, 1.5 Hz, 1H), 6.12 (d, J = 3.0 Hz, 1H), 5.06 – 5.04 (m, 
2H), 4.44 – 4.40 (m, 1H), 4.33 (d, J = 4.0 Hz, 1H), 1.42 (s, 9H); 13C{1H} NMR (CDCl3, 
125 MHz):  172.5, 168.7, 151.1, 142.0, 138.9, 135.6, 130.7, 128.9, 128.7, 128.3, 128.1, 
127.6, 110.5, 107.6, 82.4, 75.1, 67.2, 40.9, 27.9. 
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tert-Butyl (2S,3S)-2-((Diphenylmethylene)amino)-4-nitro-3-(thiophen-2-yl)butanoate 
(3.6k). Product was prepared with 2-((E)-2-nitrovinyl)thiophene (0.5 mmol, 78 mg) by 
General Procedure A without addition of additives. The crude product was subjected to 
chromatography on a short silica column (5-10% ethyl acetate in hexanes); the yield of 
the title compound was 83%. 1H NMR (CDCl3, 500 MHz):  7.69 (d, J = 7.8 Hz, 2H), 
7.48 – 7.44 (m, 1H), 7.40 – 7.33 (m, 5H), 7.18 (dd, J = 5.0, 0.8 Hz, 1H), 6.91 – 6.88 (m, 
2H), 6.84 (d, J = 7.0 Hz, 2H), 5.12 (d, J = 7.2 Hz, 2H), 4.63 – 4.60 (m, 1H), 4.27 (d, J = 
3.6 Hz, 1H), 1.45 (s, 9H); 13C{1H} NMR (CDCl3, 125 MHz):  172.9, 168.6, 140.0, 
138.8, 135.6, 130.8, 128.9, 128.6, 128.3, 128.1, 127.3, 126.6, 126.1, 125.1, 82.4, 77.8, 
69.1, 42.5, 27.8; IR (neat, cm-1): 3061, 3020, 3004, 2979, 2932, 1731, 1554, 1151, 698; 
HRMS-CI m/z: 451.1685 [(M+H)+; calcd for C25H27N2O4S : 451.1629]. 
 
tert-Butyl (2S,3S)-3-Cyclohexyl-2-((diphenylmethylene)amino)-4-nitrobutanoate (3.6l). 
Product was prepared using (CuOTf)2●C6H6 (20 mol%, 50 mg), BD (20 mol%, 42 mg), 
((E)-2-nitrovinyl)cyclohexane (0.5 mmol, 78 mg) and tert-butanol (20 mol%, 9.0 L) by 
General Procedure A. The crude product was subjected to chromatography on a short 
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silica column (5-10% ethyl acetate in hexanes); the yield of the title compound was 52%. 
1H NMR (C6D6, 500 MHz):  7.77 - 7.75 (m, 2H), 7.14 – 7.05 (m, 8H), 5.03 (dd, J = 14.2, 
4.1 Hz, 1H), 4.53 (dd, J = 9.2, 6.8 Hz, 1H), 4.32 (d, J = 2.9 Hz, 1H), 3.12 – 3.08 (m, 1H), 
1.52 – 1.42 (m, 5H), 1.33 (s, 9H), 1.29 – 1.20 (m, 1H), 0.97 – 0.84 (m, 3H), 0.80 – 0.68 
(m, 2H); 13C{1H} NMR (C6D6, 125 MHz):  171.3, 170.5, 139.7, 137.0, 130.9, 129.3, 
128.9, 128.7,  128.5, 127.9, 81.6, 76.3, 66.1, 46.5, 39.9, 30.5, 30.1, 27.9, 26.6, 26.6, 26.4; 
IR (neat, cm-1): 3060, 3020, 2977, 2929, 2854, 1732, 1551, 1448, 1368, 1154, 845, 704; 
HRMS-CI m/z: 451.2594  [(M+H)+; calcd for C27H35N2O4: 451.2591]. 
 
tert-Butyl (2S,3S)-2-((Diphenylmethylene)amino)-4-methyl-3-(nitromethyl)pentanoate 
(3.6m). Product was prepared using (CuOTf)2●C6H6 (20 mol%, 50 mg), BD (20 mol%, 42 
mg), (E)-3-methyl-1-nitrobut-1-ene (0.5 mmol, 58 mg) and tert-butanol (20 mol%, 9.0 
L) by General Procedure A. The crude product was subjected to chromatography on a 
short silica column (5-10% ethyl acetate in hexanes); the yield of the title compound was 
49%. 1H NMR (C6D6, 500 MHz):  7.75 - 7.74 (m, 2H), 7.12 – 7.04 (m, 8H), 5.01 (dd, J 
= 14.2, 4.2 Hz, 1H), 4.48 (dd, J = 14.2, 6.6 Hz, 1H), 4.25 (d, J = 3.0 Hz, 1H), 3.08 – 3.04 
(m, 1H), 1.60 – 1.53 (m, 1H), 1.31 (s, 9H), 0.68 (d, J = 6.8 Hz, 3H), 0.63 (d, J = 6.8 Hz, 
3H); 13C{1H} NMR (C6D6, 125 MHz):  171.3, 170.3, 139.6, 136.9, 130.9, 129.3, 128.8, 
128.7, 128.4, 127.9, 81.7, 76.4, 66.3, 47.1, 30.0, 27.8, 20.0, 19.7; IR (neat, cm-1): 3060, 
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3016, 2967, 2931, 2873, 1731, 1552, 1369, 1152, 697; HRMS-CI m/z: 411.2272 
[(M+H)+; calcd for C24H31N2O4: 411.2278]. 
 
Conditions for Determination of Enantiomeric Excess 
(1) tert-Butyl (2S,3S)-2-((Diphenylmethylene)amino)-4-nitro-3-phenylbutanoate (3.6a): 
tmajor =15.96 min tminor = 17.69 min (AD-H Column, hexanes/2-propanol : 99/1, 0.7 
mL/min) 
(2) tert-Butyl (2S,3S)-2-((Diphenylmethylene)amino)-4-nitro-3-(p-tolyl)butanoate (3.6b): 
tmajor =13.73 min tminor = 15.28 min (AD-H Column, hexanes/2-propanol : 99/1, 0.7 
mL/min) 
(3) tert-Butyl (2S,3S)-3-(4-Chlorophenyl)-2-((diphenylmethylene)amino)-4-
nitrobutanoate (3.6c): tmajor =14.73 min tminor = 19.60 min (AD-H Column, hexanes/2-
propanol : 99/1, 0.7 mL/min) 
(4) tert-Butyl (2S,3S)-2-((Diphenylmethylene)amino)-3-(4-fluorophenyl)-4-
nitrobutanoate (3.6d): tmajor =6.62 min tminor = 7.97 min (AD-H Column, hexanes/2-
propanol : 90/10, 0.7 mL/min) 
(5) tert-Butyl (2S,3S)-2-((Diphenylmethylene)amino)-4-nitro-3-(m-tolyl)butanoate (3.6e): 
tminor =13.45 min tmajor = 14.35 min (AD-H Column, hexanes/2-propanol : 99/1, 0.7 
mL/min) 
(6) tert-Butyl (2S,3S)-3-(3-Chlorophenyl)-2-((diphenylmethylene)amino)-4-
nitrobutanoate (3.6f): tminor =14.24 min tmajor = 15.34 min (AOD-H Column, hexanes/2-
propanol : 99/1, 0.7 mL/min) 
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(7) tert-Butyl (2S,3S)-3-(2-Chlorophenyl)-2-((diphenylmethylene)amino)-4-
nitrobutanoate (3.6g): tminor =9.09 min tmajor = 11.49 min (AD-H Column, hexanes/2-
propanol : 99/1, 0.7 mL/min) 
(8) tert-Butyl (2S,3S)-2-((Diphenylmethylene)amino)-3-(naphthalen-1-yl)-4-
nitrobutanoate (3.6h): tminor =11.63 min tmajor = 13.21 min (AD-H Column, hexanes/2-
propanol : 98/2, 0.5 mL/min) 
(9) tert-Butyl (2S,3S)-2-((Diphenylmethylene)amino)-3-(naphthalen-2-yl)-4-
nitrobutanoate (3.6i): tmajor = 6.97 min tminor = 9.17 min (AD-H Column, hexanes/2-
propanol : 90/10, 0.7 mL/min) 
(10) tert-Butyl (2S,3S)-2-((Diphenylmethylene)amino)-3-(furan-2-yl)-4-nitrobutanoate 
(3.6j): tminor = 6.10 min tmajor = 7.34 min (AD-H Column, hexanes/2-propanol : 90/10, 0.7 
mL/min) 
(11) tert-Butyl (2S,3S)-2-((Diphenylmethylene)amino)-4-nitro-3-(thiophen-2-
yl)butanoate (3.6k): Determined with the product by one further transformation in eq. 1. 
tminor = 11.74 min tmajor = 13.77 min (AD-H Column, hexanes/2-propanol : 80/20, 0.5 
mL/min)  
             
tert-Butyl (2S,3S)-2-Amino-4-nitro-3-(thiophen-2-yl)butanoate (anti-3.6k’): 3.6k (22.5 
mg, 0.05 mmol) was dissolved in THF (0.5 mL), and 1N HCl (0.5 mL) was added at 0 °C. 
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After the mixture was stirred at 0 °C for 1h, THF was removed under reduced pressure. 
The resulting aqueous solution was washed with ether (3 × 10 mL) and neutralized with 
NaHCO3. The mixture was then extracted three times with 10 ml of CH2Cl2 (3 × 10 mL). 
The organic layers of these three extractions were combined and then dried over 
anhydrous Na2SO4. After filtration and concentration under reduced pressure, the desired 
product 3.6k’ (13.3 mg, 93 % yield, dr > 99 : 1, 81 % ee) was obtained. 1H NMR (CDCl3, 
500 MHz):  7.24 (t, J = 3.0 Hz, 1H), 6.95 – 6.93 (m, 2H), 4.95 (dd, J = 13.0, 5.5 Hz, 
1H), 4.71 (dd, J = 13.0, 9.0 Hz, 1H), 4.14 – 4.09 (m, 1H), 3.62 (d, J = 7.0 Hz, 1H), 1.64 
(s, 2H), 1.36 (s, 9H); 13C{1H} NMR (CDCl3, 125 MHz):  172.3, 138.9, 126.8, 126.7, 
125.3, 82.3, 78.1, 58.4, 43.5, 27.7; IR (neat, cm-1): 3391, 3324, 3111, 3078, 2978, 2933, 
1728, 1554, 1371, 1251, 1155, 844, 704;  HRMS-CI m/z: 287.1058 [(M+H)+; calcd for 
C12H19N2O4S: 287.1060]. 
(12) tert-Butyl (2S,3S)-3-Cyclohexyl-2-((diphenylmethylene)amino)-4-nitrobutanoate 
(3.6l): tminor =23.53 min tmajor = 24.49min (OD-H Column, hexanes/2-propanol : 99/1, 0.2 
mL/min) 
(13) tert-Butyl (2S,3S)-2-((Diphenylmethylene)amino)-4-methyl-3-
(nitromethyl)pentanoate (3.6m): tminor =9.81 min tmajor = 10.17 min (OD-H Column, 
hexanes/2-propanol : 99/1, 0.5 mL/min) 
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CHAPTER 4. ENANTIODIVERGENT APPROACHES TO ENDO-PYRROLIDINES 
USING COPPER-BRUCINE DIOL COMPLEXES 
4.1 Introduction 
4.1.1 Synthesis of Chiral Pyrrolidine Derivatives 
        Chiral pyrrolidines are one of the key structural motifs present in many biologically 
important compounds,1-4 and they often constitute as the core structure of many 
organocatalysts.5-7 Among the synthetic strategies developed for chiral pyrrolidines, the 
catalytic asymmetric [3+2] cycloaddition reactions of azomethine ylides and activated 
alkenes directly produce  enantiomeric pyrrolidines with a diverse array of functional 
groups.8-10 The use of both chiral metal catalysts10-13 and organocatalysts14-16 have been 
extensively investigated for the synthesis of chiral pyrrolidines. Furthermore, 
intramolecular Mannich reaction, a powerful method for the preparation of azacyclic 
products from acyclic precursors, has been utilized for the synthesis of pyrrolidine 
derivatives.17,18 Although Mannich reaction is commonly used for the synthesis of 
pyrrolidine derivatives,19 there exists only few Mannich reaction examples that utilize the 
asymmetric conjugate addition products of glycine (ket)imines for the preparation of 
chiral pyrrolidines.20  
4.1.2 Stereodivergent Synthesis of Pyrrolidine Derivatives 
        Theoretically, the [3+2] cycloaddition reactions of azomethine ylides with 
alkenescan provide up to four diastereomers, namely exo-, endo-, exo’-, and endo’-
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products (Scheme 21). The notation endo signifies the “syn” relationship between the R2 
of glycine ester and the electron-withdrawing-group (EWG) of alkene. Consequently, the 
exo implies the “anti” relationship between the R2 of glycine ester and the electron-
withdrawing-group (EWG) of alkene. The notion endo’ and exo’ indicates the “anti” 
relationship between the ester moiety and the R2 of glycine ester. 
 
Scheme 21. The [3+2] Cycloaddition Reaction Pathway to Pyrrolidine Derivatives 
 
        In 2005, Carretero et al. reported the first example of exo-selective pyrrolidine 
synthesis using the catalytic asymmetric [3+2] cycloaddition reaction of azomethine 
ylides and nitroalkenes.21 Subsequently, in 2006 Hou et al. demonstrated the switch of  
endo/exo selectivity by tuning the electron density of a chiral ligand.12 In 2010, Arai et al. 
reported an exo’-selective pyrrolidine synthesis.22 It is interesting to study the relationship 
between the stereochemical outcome and the reaction pathway of [3+2] cycloaddition 
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reactions of glycinates with electron-deficient alkenes since there is not an experimental 
consensus for either a concerted (Scheme 22) or a stepwise (Scheme 23) reaction 
pathway.11,23,24   
 
Scheme 22. Concerted Reaction Pathway25 
 
Scheme 23. Stepwise Reaction Pathway26 
        In this chapter, we present the copper-brucine diol (BD) catalyzed concerted endo-
selective [3+2] cycloaddition reactions between glycine imines and nitroalkenes, leading 
to the discovery of the substrate-controlled enantiodivergent [3+2] cycloaddition 
reactions (Figure 7). 
 
Figure 7. Brucine Diol (BD)  
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4.2 Results and Discussion  
4.2.1 The endo-Selective [3+2] Cycloaddition Reaction 
4.2.1.1 Optimization of endo-Selective [3+2] Cycloaddition Reaction 
        We had previously reported a diastereodivergent catalytic asymmetric conjugate 
addition reaction (Scheme 24).27 Results of that study were consistent with the stepwise 
[3+2] cycloaddition reaction mechanism for exo-pyrrolidines. However, because we 
could not prepare anti conjugate addition products from the reaction between glycine 
imines and nitroalkenes,28,29 thus, a related mechanistic assertion for endo/exo’-
pyrrolidines required further investigation.
 
Scheme 24. Stereodivergent Catalytic Asymmetric Conjugate Addition Reactions 
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        From the substrate-controlled diastereoselective conjugate addition reactions, we 
noted the exclusive formation of anti-products from glycine ketimine and syn-products 
from glycine imine. Thus, we investigated the reaction outcome of glycine imines 4.1a-c 
under our anti-selective conjugate addition reaction conditions (Table 9). Since the ester 
moiety of glycine imines 4.1 had a great influence on the enantioselectivity of products 
(Entries 1-3), the use of tert-butyl glycine imine 4.1a produced 4.3Ba with the lowest 
enantiomeric excess (ee) of 52%, while the use of methyl glycine imine 4.1c produced 
4.3Ma at 77% ee (Entry 3) and 72% ee (Entry 4) under another anti-selective conjugate 
addition condition as described previously.27 In addition, the preferential formation of 
endo-4.3 instead of exo-4.3 was observed. Thus, glycine imine 4.1c was chosen for 
further optimization efforts. Since the effect of protic additives to the observed selectivity 
was minimal (entry 5), we examined solvent effect in the absence of additives (entries 6-
8). No significant advantage in stereoselectivity was observed using other solvent 
systems; therefore, we screened the effect of base (entries 9-10). Although the use of 
DBN as base improved the enantioselectivity of endo-4.3Ma to 82% ee with 13 : 1 ratio 
of diastereoselectivity (dr) (entry 10), the oxidation state of copper ion did not have much 
influence to the observed stereoselectivity (entries 11-12). Furthermore, elevated reaction 
temperatures showed much faster reaction conversions, but with reduced 
enantioselectivity and diastereoselectivity of endo-4.3Ma (entry 13). Finally, the catalyst 
loading was investigated, and the use of 20 mol% of CuOTf and BD was identified as the 
optimal condition to provide the diastereoselective formation of endo-4.3Ma in 84% ee 
with > 25 : 1 dr (entry 14). 
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Table 9. Optimization of endo-Selective [3+2] Cycloaddition Reactions 
 
Entry Metal/Base Solvent Additive dr (endo : exo)b ee (%)c 
1d CuOTf/DBU THF t-BuOH 4.3Ba (4 : 1) 52 
2d CuOTf/DBU THF t-BuOH 4.3Ea (14 : 1) 70 
3d CuOTf/DBU THF t-BuOH 4.3Ma (10 : 1) 77 
4e CuCl/Et3N TCE EtOH 4.3Ma (25 : 1) 72 
5 CuOTf/DBU THF - 4.3Ma (9 : 1) 74 
6 CuOTf/DBU 2-MeTHF - 4.3Ma (9 : 1) 66 
7 CuOTf/DBU PhCH3 - NRi - 
8 CuOTf/DBU CHCl3 - 4.3Ma (20 : 1) 77 
9 CuOTf/ Et3N THF - 4.3Ma (4 : 1) 28 
10 CuOTf/DBN THF - 4.3Ma (13 : 1) 82f 
11 Cu(OTf)2/DBN THF - 4.3Ma (7 : 1) 80 
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Table 9. Continued 
Entry Metal/Base Solvent Additive dr (endo : exo)b ee (%)c 
12 Cu(NTf2)2/DBN THF - 4.3Ma (10 : 1) 80 
13g CuOTf/DBN THF - 4.3Ma (1 : 1) 26 
14h CuOTf/DBN THF - 4.3Ma (25 : 1) 84 
a. Reaction using 4.1 (0.5 mmol) and 4.2 (0.5 mmol) in 0.25 M solution (all reactions 
have conversion ≥ 50%). 
b. Determined by crude 1H NMR. 
c. Determined by HPLC using chiral column.  
d. 60 mol% t-BuOH. 
e. 20 mol% EtOH. 
f. exo-4Ma (45% ee). 
g. Reaction at 0 °C for 8 h. 
h. 20 mol% of Cu-BD. 
i. NR = No Reaction.  
4.2.1.2 Substrate Scope of endo-Selective [3+2] Cycloaddition Reactions 
        The optimized endo-selective [3+2] cycloaddition conditions were further 
investigated using other glycine imines and nitroalkenes (Table 10). A wide range of 
imino esters 4.1 with different electronic and steric effect provided the desired endo-
4.3Ma-h in high yields with good to excellent enantio- and diastereoselectivity. The 
reaction was also applicable to other nitroalkenes with slightly reduced enantioselectivity 
(endo-4.3Mi-j). However, a trend in the substrate-selectivity relationship was not found 
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because the combinations of different substituents on the glycine imines and the 
nitroalkenes generally provided excellent selectivity (endo-4.3Mk-n). Although the 
isolation yield of endo-4.3Mo from -methyl glycine imine was reduced to 76%, the 
enantioselectivity was observed at 94%. Thus, the additional substituent at the -carbon 
of glycine imine did not affect the stereoselectivity, implying that the present method 
could be further utilized to produce chiral pyrrolidines with a quaternary center. The 
relative and absolute stereochemistry of endo-4.3M was confirmed to be (2R,3S,4R,5R) 
by comparison of its HPLC retention time with those described previously.12,13 
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Table 10. Scope of endo-Selective [3+2] Cycloaddition Reaction 
 
Entry 
endo-
4.3M 
R2 R3 
Yield 
(%)a 
dr 
(endo : exo)d 
ee (%)e
1b 4.3Ma 
  
97 > 25 : 1 84 
2b 4.3Mb 
  
92 > 25 : 1 93 
3b 4.3Mc 
 
92 > 25 : 1 90 
4b 4.3Md 
  
89 10 : 1 81 
5b 4.3Me 
  
99 > 25 : 1 86 
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Table 10. Continued 
Entry endo-4.3M R2 R3 
Yield 
(%)a 
dr 
(endo : exo)d 
ee 
(%)e 
6b 4.3Mf 
 
 
95 20 : 1 81 
7b 4.3Mg 
 
99 > 25 : 1 93 
8b 4.3Mh 
  
94 18 : 1 84 
9b 4.3Mi 
  
92 20 : 1 86 
10b 4.3Mj 
  
95 20 : 1 80 
11b 4.3Mk 
  
89 20 : 1 90 
12b 4.3Ml 
  
92 > 25 : 1 94 
13b 4.3Mm 
  
94 > 25 : 1 93 
14b 4.3Mn 
  
90 20 : 1 94 
15c 4.3Mo 
  
76 > 25 : 1 94 
a. Isolated yield of endo-4.3M after column chromatography. 
b. R1 = H 
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c. R1 = methyl 
d. Determined by crude 1H NMR. 
e. Determined by HPLC using chiral column. 
 
4.2.2 Stepwise [3+2] Cycloaddition Pathway 
4.2.2.1 Optimization of Intramolecular Mannich Reaction of Conjugate Addition 
Product anti-4.4 
        The stereochemical outcome of the endo-selective [3+2] cycloaddition reactions 
provided insightful mechanistic information. Upon close inspection of various reaction 
conditions listed in Table 9 and Table 10, we observed the exclusive formation of endo-
4.3M and exo-4.3M with 50 – 99 % reaction conversions. The absence of other 
pyrrolidines such as endo’-4.3M27 and exo’-4.3M22 strongly suggested a concerted [3+2] 
cycloaddition pathway. Previously, we reported asymmetric anti-conjugate addition 
products with absolute chemistry of (2S,3S).27 The results suggested that the endo-
pyrrolidines derived from the stepwise reaction pathway of our anti-conjugate addition 
products would have opposite absolute chemistry to that of endo-4.3M from the 
concerted reaction pathway. To verify this hypothesis, we investigated the intramolecular 
Mannich reaction of anti-4.4. We first removed the benzophenone imine moiety of anti-
4.4 under acidic conditions,30 and condensed the primary amine intermediates with 
aldehydes under basic conditions (Table 11). With different solvents and reaction 
temperatures, the preferential formation of endo-4.3Ba was observed with an 
accompanying by-product, C4-epi-endo-4.3Ba as the only detectable minor product. 
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Table 11. Optimization of Intramolecular Mannich Reaction for anti-4.4 
 
Entry PhCHO (eq.) Et3N (eq.) Solvent 
dr 
(endo : epi-endo)a 
Yield (%)b 
1 2.0 2.0 CH2Cl2 14 : 1 57 
2 2.0 2.0 MeOH 14 : 1 99 
3 2.0 2.0 EtOH 12 : 1 99 
4 2.0 2.0 i-PrOH 12 : 1 99 
5 1.0 1.0 MeOH 12 : 1 90 
6 4.0 2.0 MeOH 13 : 1 99 
7 2.0 4.0 MeOH 13 : 1 99 
8 4.0 4.0 MeOH 7 : 1 99 
9c 2.0 2.0 MeOH 1 : 1 99 
a. Determined by crude 1H NMR. 
b. Isolated yield of combined endo-4.3Ba and 4C-epi-endo-4.3Ba.  
c. Reaction at 23 °C. 
4.2.2.2 Substrate Scope of Stepwise [3+2] Cycloaddition Pathway 
        With the optimized conditions for the intramolecular Mannich reaction of conjugate 
adducts in hand, we further investigated the synthetic utility of the stepwise [3+2] 
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cycloaddition pathway to get access to endo-4.3B. Results of substrate scope are shown 
in Table 12. With anti-4.4, the stereoselective formation of endo-4.3B was readily 
achieved with good to excellent yields in three steps. In all cases, the formation of minor 
products 4C-epi-endo-4.3B was observed, but no other byproducts such as exo’-4.3B 
(Figure 8) were detected.31 While the observed diastereoselectivity of endo-4.3B varied 
among substrates (> 25 : 1 to 3 : 1 dr’s), a synthetically useful level of enantioselectivity 
was obtained using various nitroalkenes and aldehydes (80 – 90% ee’s). 
 
Figure 8. exo’-4.3B 
        To confirm the opposite stereochemical outcome of endo-4.3M from the concerted 
[3+2] cycloaddition reaction pathway, the stepwise synthesis of endo-4.3Ma from anti-
4.4Ba was performed (Scheme 25).  We first removed the benzophenone moiety of anti-
4.4Ba, followed by transesterification to produce anti-4.5Ma. Finally, endo-4Ma was 
obtained by performing the intramolecular Mannich reaction of anti-4.5Ma with 
benzaldehyde. By comparison of the retention times of endo-4.3Ma from both concerted 
and stepwise reaction pathways, the stereochemistry of endo-4.3B was confirmed to be 
(2S,3R,4S,5S). 
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Scheme 25. Synthesis of endo-4.3Ma from anti-4.4Ba 
Table 12. Scope of Stepwise [3+2] Cycloaddition Reaction 
 
Entry 
endo-
4.3B 
R1 R2 
Yield 
(%)a 
dr 
(endo : epi-endo)b 
ee 
(%)c 
1 4.3Ba 
  
57 20 : 1 90 
2 4.3Bb 
  
74 10 : 1 84 
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Table 12. Continued 
Entry 
endo-
4.3B 
R1 R2 
Yield 
(%)a 
dr 
(endo : epi-endo)b 
ee 
(%)c 
3 4.3Bc 
 
79 20 : 1 81 
4 4.3Bd 
  
48 20 : 1 81 
5 4.3Be 
  
48 3 : 1 80 
6 4.3Bf 
  
77 > 25 : 1 80 
7 4.3Bg 
  
48 > 25 : 1 86 
8 4.3Bh 
  
44 20 : 1 80 
9 4.3Bi 
  
48 17 : 1 80 
10 4.3Bj 
  
73 13 : 1 81 
11 4.3Bk 
  
67 7 : 1 81 
12 4.3Bl 
  
47 3 : 1 87 
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Table 12. Continued 
Entry 
endo-
4.3B 
R1 R2 
Yield 
(%)a 
dr 
(endo : epi-endo)b 
ee 
(%)c 
13 4.3Bm 
 
71 > 25 : 1 80 
14 4.3Bn 
 
68 5 : 1 80 
15 4.3Bo 
 
55 20 : 1 83 
a. Isolated yield of endo-4.3B in three steps from 4.1d after column chromatography. 
b. Determined by crude 1H NMR. 
c. Determined by HPLC using chiral column. 
4.2.3 Stereomodels for Divergent Reaction Pathways 
        The stereochemical outcome of the Cu-BD catalyzed reactions between glycine 
(ket)imines and nitroalkenes is likely due to the stereoselective generation of enolates 
(Scheme 26).32-35 Thus, the O-metallated azomethine ylides of glycine ketimine, 4.1d, 
possesses an (E)-geometry due to the steric effect of tert-butyl ester moiety and the bulky 
diphenyl groups on 4.1d. The (Z)-geometry is favored for the N,O-metallated azomethine 
ylides of glycine imine 4.1c because of less bulky methyl ester moiety. The geometrical 
difference in the enolates resulted in the divergent reaction pathways for either conjugate 
addition or concerted [3+2] cycloaddition products.36 The proposed stereomodels also 
explain our syn-selective conjugate addition reaction of glycine imine, 4.1c, via (E)-
enolates due to more coordinated ligand effect of (-OAc) than (-OTf) at the copper center 
118 
 
of Cu-BD catalyst.27 The exact difference in the catalyst structure caused by the acetate 
or triflate ligands is not yet understood. While more work is needed to assert the 
kinetic/thermodynamic preferences of glycine (ket)imine enolates under metal catalysis, 
the specific substrate-catalyst interaction is believed to be a crucial diverging factor for 
the reaction of glycine imines and nitroalkenes for either stereoselective concerted [3+2] 
cycloaddition pathway (to endo-4.3M) or syn-selective conjugate reaction pathway. 
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(a) Stepwise Reaction Pathway via (E)-enolates 
 
(b) Concerted Reaction Pathway via (Z)-enolates 
 
Scheme 26. Stereomodels for Divergent Reaction Pathway 
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4.3 Conclusion  
        We have developed stereodivergent synthetic approaches to endo-pyrrolidines based 
on different reaction mechanisms (i.e. concerted and stepwise reaction pathways). The 
use of a single chiral source for the stereodivergent catalytic asymmetric reactions is less 
well developed.37,38 The implementation of catalytic approaches to multiple synthetic 
transformations has been challenging because of the nature of specific factors that affect 
the reversal of stereoselectivity in various reactions and chemotypes. By utilizing the 
substrate-controlled reaction pathways of glycine ketimine (to anti-4.4) and glycine imine 
(to endo-4.3), we demonstrated the reversal of stereoselectivity using a single chiral 
ligand, brucine diol (BD). 
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4.4 Experimental Section 
General Procedure A for Racemic Synthesis of Endo-Selective Cycloaddition Reaction  
Products 
To the solution of methyl (E)-2-(benzylideneamino)acetate (0.5 mmol, 89 mg), 1-((E)-2-
nitrovinyl)benzene (0.5 mmol, 75 mg) and silver(I) acetate (0.5 mmol, 83 mg) in dry 
DCM (1.0 mL) were added to Et3N (0.5 mmol) at ambient temperature. The resulting 
solution was stirred for 18 hours and then concentrated under reduced pressure. The 
resulting reaction mixture was subjected to chromatography on a short silica column (10-
20% ethyl acetate in hexanes), and the yield of the desired endo-4.3Ma cycloaddition 
product was 30%. 
General Procedure B for the Synthesis of endo-Selective [3+2] Cycloaddition Products 
 
(2R,3S,4R,5R)-Methyl 4-Nitro-3,5-diphenylpyrrolidine-2-carboxylate (endo-4.3Ma) 
(CuOTf)2●C6H6 (20 mol%, 50 mg) and brucine diol (BD) (20 mol%, 43 mg) were added 
to a 10 mL Schlenk flask. Dry THF (2.2 mL) was then added to the flask at 0 °C, 
followed by addition of DBN (20 mol%, 12 L). The solution was stirred for 4 h at this 
temperature. The resulting solution was cooled to -15 °C, and methyl (E)-2-
(benzylideneamino)acetate 4.1c (0.5 mmol, 89 mg) was added, with continuous stirring 
for 10 min after which, 1-((E)-2-nitrovinyl)benzene 4.2a (0.5 mmol, 75 mg) was added. 
The solution was stirred continuously at -15 °C for 48-60 h. The reaction mixture was 
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then subjected to chromatography on a short silica column (10-20% ethyl acetate in 
hexanes); the yield of the title compound was 97%. 1H NMR and 13C NMR spectra of 
this compound are consistent with previously reported data in the literature.13 1H NMR 
(CDCl3, 500 MHz): δ 7.42−7.29 (m, 10H), 5.28 (dd, J = 6.5, 3.5 Hz, 1H), 4.92 (d, J = 6.0 
Hz, 1H), 4.22 (dd, J = 7.5, 3.5 Hz, 1H), 4.15 (d, J = 7.5 Hz, 1H), 3.81 (s, 3H), 3.35 (br, 
NH ); 13C{1H} NMR (CDCl3, 125 MHz): δ 171.9, 138.7, 134.5, 129.5, 128.9, 128.9, 
128.3, 127.7, 126.6, 97.2, 68.0, 67.6, 55.6, 52.8; IR (neat, cm-1): 3341, 3066, 3031, 2958, 
2924, 2854, 1742, 1550, 1497, 1455, 1435, 1367, 1331, 1265, 1211, 1130, 759, 699 cm-1; 
HRMS-CI m/z 327.1342 [(M+H)+; calcd for C18H19N2O4 : 327.1339]. Absolute 
stereochemistry of this compound was determined by comparison of its HPLC retention 
time (minor/major peaks) with that of an authentic sample.13 
 
(2R,3S,4R,5R)-Methyl 4-Nitro-3-phenyl-5-(p-tolyl)pyrrolidine-2-carboxylate (endo-
4.3Mb) 
The product endo-4.3Mb was prepared from methyl (E)-2-((4-
methylbenzylidene)amino)acetate (0.5 mmol, 96 mg) and 1-((E)-2-nitrovinyl)benzene 
(0.5 mmol, 75 mg) by General Procedure B. The crude product was subjected to 
chromatography on a short silica column (10 - 20% ethyl acetate in hexanes); the yield of 
the title compound was 92%. 1H NMR and 13C NMR spectra of this compound are 
consistent with previously reported data in the literature.13 1H NMR (CDCl3, 500 MHz): δ 
7.40 (t, J = 7.0 Hz, 2H), 7.35 – 7.31 (m, 1H), 7.30 – 7.28 (m, 2H), 7.25 – 7.22 (m, 2H), 
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7.16 (d, J = 8.0 Hz, 2H), 5.25 (dd, J = 6.5, 3.5 Hz, 1H), 4.88 (d, J = 6.5 Hz, 1H), 4.20 (dd, 
J = 7.5, 3.5 Hz, 1H), 4.13 (d, J = 7.5 Hz, 1H), 3.79 (s, 3H), 2.32 (s, 3H); 13C{1H} NMR 
(CDCl3, 125 MHz): δ171.9, 138.8, 138.7, 131.4, 129.6, 129.4, 128.2, 127.6, 126.4, 97.3, 
67.9, 67.6, 55.6, 52.8, 21.3; IR (neat, cm-1): 3351, 3063, 3022, 2952, 2917, 2851, 1742, 
1550, 1454, 1436, 1367, 1265, 1210, 1130, 823, 758, 701 cm-1; HRMS-CI m/z: 341.1498 
[(M+H)+; calcd for C19H21N2O4 : 341.1496].  
 
(2R,3S,4R,5R)-Methyl 5-(4-Chlorophenyl)-4-nitro-3-phenylpyrrolidine-2-carboxylate 
(endo-4.3Mc) 
The product endo-4.3Mc was prepared from methyl (E)-2-((4-
chlorobenzylidene)amino)acetate (0.5 mmol, 106 mg) and 1-((E)-2-nitrovinyl)benzene 
(0.5 mmol, 75 mg) by General Procedure B. The crude product was subjected to 
chromatography on a short silica column (10 - 20% ethyl acetate in hexanes); the yield of 
the title compound was 92%. 1H NMR and 13C NMR spectra of this compound are 
consistent with previously reported data in the literature.13 1H NMR (CDCl3, 500 MHz): δ 
7.42 − 7.39 (m, 2H), 7.36 – 7.28 (m, 7H), 5.26 (dd, J = 6.5, 4.0 Hz, 1H), 4.89 (d, J = 6.5 
Hz, 1H), 4.23 (dd, J = 7.5, 4.0 Hz, 1H), 4.15 (d, J = 7.5 Hz, 1H), 3.80 (s, 3H); 13C{1H} 
NMR (CDCl3, 125 MHz): δ171.8, 138.4, 134.8, 133.3, 129.5, 129.1, 128.3, 128.1, 127.6, 
96.8, 67.3, 67.0, 55.1, 52.8; IR (neat, cm-1): 3345, 3072, 3031, 3003, 2958, 2920, 2841, 
1741, 1550, 1495, 1366, 1211, 1093, 758, 701 cm-1; HRMS-CI m/z: 361.0945 [(M+H)+; 
calcd for C18H18ClN2O4 : 361.0950].  
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(2R,3S,4R,5R)-Methyl 5-(3-Chlorophenyl)-4-nitro-3-phenylpyrrolidine-2-carboxylate 
(endo-4.3Md) 
The product endo-4.3Md was prepared from methyl (E)-2-((3-
chlorobenzylidene)amino)acetate (0.5 mmol, 106 mg) and 1-((E)-2-nitrovinyl)benzene 
(0.5 mmol, 75 mg) by General Procedure B. The crude product was subjected to 
chromatography on a short silica column (10 - 20% ethyl acetate in hexanes); the yield of 
the title compound was 89%. 1H NMR and 13C NMR spectra of this compound are 
consistent with previously reported data in the literature.12 1H NMR (CDCl3, 500 MHz): δ 
7.43 − 7.40 (m, 3H), 7.37 – 7.33 (m, 1H), 7.33 – 7.28 (m, 4H), 7.27 – 7.24 (m, 1H), 5.28 
(dd, J = 6.5, 4.0 Hz, 1H), 4.88 (d, J = 6.5 Hz, 1H), 4.23 (dd, J = 7.5, 3.5 Hz, 1H), 4.15 (d, 
J = 7.5 Hz, 1H), 3.81 (s, 3H); 13C{1H} NMR (CDCl3, 125 MHz): δ171.7, 138.4, 136.8, 
134.9, 130.1, 129.5, 129.1, 128.4, 127.6, 127.2, 124.8, 96.7, 67.3, 67.0, 55.1, 52.9; IR 
(neat, cm-1): 3383, 3069, 3031, 2952, 2923, 2851, 1740, 1550, 1437, 1369, 1259, 1216, 
753, 698 cm-1; HRMS-CI m/z: 361.0952[(M+H)+; calcd for C18H18ClN2O4 : 361.0950].  
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(2R,3S,4R,5R)-Methyl 4-Nitro-3-phenyl-5-(m-tolyl)pyrrolidine-2-carboxylate (endo-
4.3Me) 
The product endo-4.3Me was prepared from methyl (E)-2-((3-
methylbenzylidene)amino)acetate (0.5 mmol, 96 mg) and 1-((E)-2-nitrovinyl)benzene 
(0.5 mmol, 75 mg) by General Procedure B. The crude product was subjected to 
chromatography on a short silica column (10 - 20% ethyl acetate in hexanes); the yield of 
the title compound was 99%. 1H NMR (CDCl3, 500 MHz): δ 7.42 – 7.39 (m, 2H), 7.36 – 
7.29 (m, 3H), 7.26 – 7.23 (m, 1H), 7.16 – 7.13 (m, 3H), 5.27 (dd, J = 6.5, 3.5 Hz, 1H), 
4.87 (d, J = 6.5 Hz, 1H), 4.20 (dd, J = 7.0, 3.5 Hz, 1H), 4.14 (d, J = 7.0 Hz, 1H), 3.81 (s, 
3H), 2.35 (s, 3H); 13C{1H} NMR (CDCl3, 125 MHz): δ 171.9, 138.8, 138.6, 134.3, 129.7, 
129.5, 128.8, 128.2, 127.6, 127.3, 123.6, 97.2, 68.1, 67.7, 55.8, 52.8, 21.6; IR (neat, cm-1): 
3341, 3066, 3031, 2952, 2930, 2851, 1742, 1550, 1455, 1436, 1366, 1266, 1212, 1181, 
757, 700 cm-1; HRMS-CI m/z: 341.1500 [(M+H)+; calcd for C19H21N2O4 : 341.1496]. 
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(2R,3S,4R,5R)-Methyl 5-(2-Chlorophenyl)-4-nitro-3-phenylpyrrolidine-2-carboxylate 
(endo-4.3Mf) 
The product endo-4.3Mf was prepared from methyl (E)-2-((2-
chlorobenzylidene)amino)acetate (0.5 mmol, 106 mg) and 1-((E)-2-nitrovinyl)benzene 
(0.5 mmol, 75 mg) by General Procedure B. The crude product was subjected to 
chromatography on a short silica column (10 - 20% ethyl acetate in hexanes); the yield of 
the title compound was 95%. 1H NMR (CDCl3, 500 MHz): δ 7.49 − 7.47 (m, 1H), 7.44 – 
7.39 (m, 3H), 7.37 – 7.33 (m, 1H), 7.32 – 7.28 (m, 4H), 5.59 (dd, J = 6.0, 3.0 Hz, 1H), 
5.20 (d, J = 6.0 Hz, 1H), 4.24 (dd, J = 7.5, 3.0 Hz, 1H), 4.09 (d, J = 6.5 Hz, 1H), 3.83 (s, 
3H); 13C{1H} NMR (CDCl3, 125 MHz): δ 171.6, 139.0, 133.3, 132.1, 130.1, 129.7, 129.5, 
128.2, 127.6, 127.5, 127.2, 94.9, 67.7, 65.2, 55.3, 52.8; IR (neat, cm-1): 3335, 3066, 3034, 
2946, 2917, 2854, 1743, 1551, 1437, 1384, 1365, 1210, 758, 700 cm-1; HRMS-CI m/z: 
361.0948 [(M+H)+; calcd for C18H18ClN2O4 : 361.0950].  
 
 
 
127 
 
 
(2R,3S,4R,5R)-Methyl 5-(Naphthalen-2-yl)-4-nitro-3-phenylpyrrolidine-2-carboxylate 
(endo-4.3Mg) 
The product endo-4.3Mg was prepared from methyl (E)-2-((naphthalen-2-
ylmethylene)amino)acetate (0.5 mmol, 114 mg) and 1-((E)-2-nitrovinyl)benzene (0.5 
mmol, 75 mg) by General Procedure B. The crude product was subjected to 
chromatography on a short silica column (10 - 20% ethyl acetate in hexanes); the yield of 
the title compound was 99%. 1H NMR and 13C NMR spectra of this compound are 
consistent with previously reported data in the literature.12 1H NMR (CDCl3, 500 MHz): δ 
7.86 − 7.79 (m, 4H), 7.49 – 7.45 (m, 2H), 7.42 – 7.39 (m, 3H), 7.35 – 7.30 (m, 3H), 5.37 
(dd, J = 6.5, 3.5 Hz, 1H), 5.05 (d, J = 6.5 Hz, 1H), 4.26 (dd, J = 7.5, 3.5 Hz, 1H), 4.19 (d, 
J = 7.5 Hz, 1H), 3.81 (s, 3H), 3.48 (br, NH); 13C{1H} NMR (CDCl3, 125 MHz): δ 171.9, 
138.7, 133.4, 133.3, 131.9, 129.5, 128.7, 128.3, 128.3, 127.8, 127.7, 126.6, 126.6, 125.9, 
124.2, 97.1, 68.0, 67.6, 55.6, 52.8; IR (neat, cm-1): 3335, 3060, 3031, 2949, 2920, 2851, 
1741, 1550, 1435, 1365, 1271, 1212, 1180, 754, 700 cm-1; HRMS-CI m/z: 377.1499 
[(M+H)+; calcd for C22H21N2O4 : 377.1496].  
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(2R,3S,4R,5S)-Methyl 4-Nitro-3-phenyl-5-(thiophen-2-yl)pyrrolidine-2-carboxylate 
(endo-4.3Mh) 
The product endo-4.3Mh was prepared from methyl (E)-2-((thiophen-2-
ylmethylene)amino)acetate (0.5 mmol, 92 mg) and 1-((E)-2-nitrovinyl)benzene (0.5 
mmol, 75 mg) by General Procedure B. The crude product was subjected to 
chromatography on a short silica column (10 - 20% ethyl acetate in hexanes); the yield of 
the title compound was 94%. 1H NMR (CDCl3, 500 MHz): δ 7.42 – 7.39 (m, 2H), 7.36 – 
7.33 (m, 1H), 7.30 – 7.28 (m, 3H), 7.07 (dt, J = 3.5, 1.0 Hz, 1H), 7.01 (dd, J = 5.5, 3.5 Hz, 
1H), 5.27 (dd, J = 6.0, 4.5 Hz, 1H), 5.12 (d, J = 6.0 Hz, 1H), 4.26 (d, J = 7.5, 4.5 Hz, 1H), 
4.14 (d, J = 7.5 Hz, 1H), 3.80 (s, 3H), 3.37 (br, NH); 13C{1H} NMR (CDCl3, 125 MHz): 
δ 171.6, 138.3, 137.4, 129.5, 128.3, 127.7, 127.4, 125.9, 125.5, 96.4, 67.2, 63.5, 54.9, 
52.9; IR (neat, cm-1): 3338, 3107, 3085, 3063, 3031, 3006, 2952, 2920, 2854, 1741, 1551, 
1436, 1384, 1367, 1214, 759, 700 cm-1; HRMS-CI m/z: 333.0906 [(M+H)+; calcd for 
C16H17N2O4S: 333.0904].  
 
 
 
129 
 
 
(2R,3S,4R,5R)-Methyl 4-Nitro-5-phenyl-3-(p-tolyl)pyrrolidine-2-carboxylate (endo-
4.3Mi) 
The product endo-4.3Mi was prepared from methyl (E)-2-(benzylideneamino)acetate (0.5 
mmol, 89 mg) and (E)-1-methyl-4-(2-nitrovinyl)benzene (0.5 mmol, 82 mg) by General 
Procedure B. The crude product was subjected to chromatography on a short silica 
column (10 - 20% ethyl acetate in hexanes); the yield of the title compound was 92%. 1H 
NMR (CDCl3, 500 MHz): δ 7.37 − 7.31 (m, 5H), 7.22 – 7.18 (m, 4H), 5.25 (dd, J = 6.5, 
3.5 Hz, 1H), 4.92 – 4.89 (m, 1H), 4.17 (dd, J = 7.5, 3.5 Hz, 1H), 4.13 (t, J  = 7.0 Hz, 1H), 
3.81 (s, 3H), 3.35 (br, NH), 2.37 (s, 3H); 13C{1H} NMR (CDCl3, 125 MHz): δ 172.0, 
138.1, 135.7, 134.6, 130.1, 128.9, 128.9, 127.5, 126.6, 97.3, 67.9, 67.6, 55.4, 52.8, 21.2; 
IR (neat, cm-1): 3341, 3056, 3025, 2952, 2917, 2847, 1741, 1550, 1435, 1384, 1367, 1208, 
1181, 698 cm-1; HRMS-CI m/z: 341.1500 [(M+H)+; calcd for C19H21N2O4 : 341.1496].  
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(2R,3S,4R,5R)-Methyl 3-(4-Chlorophenyl)-4-nitro-5-phenylpyrrolidine-2-carboxylate 
(endo-4.3Mj) 
The product endo-4.3Mj was prepared from methyl (E)-2-(benzylideneamino)acetate (0.5 
mmol, 89 mg) and (E)-1-chloro-4-(2-nitrovinyl)benzene (0.5 mmol, 92 mg) by General 
Procedure B. The crude product was subjected to chromatography on a short silica 
column (10 - 20% ethyl acetate in hexanes); the yield of the title compound was 95%. 1H 
NMR (CDCl3, 500 MHz): δ 7.39 − 7.32 (m, 7H), 7.24 – 7.23 (m, 2H), 5.23 (dd, J = 7.0, 
4.0 Hz, 1H), 4.89 (d, J = 7.0 Hz, 1H), 4.20 (dd, J = 7.5, 4.0 Hz, 1H), 4.08 (d, J = 8.0 Hz, 
1H), 3.79 (s, 3H), 3.28 (br, NH); 13C{1H} NMR (CDCl3, 125 MHz): δ 171.6, 137.0, 
134.5, 134.3, 129.6, 129.1, 129.0, 128.9, 126.7, 96.9, 67.7, 67.4, 54.6, 52.9; IR (neat, cm-
1): 3341, 3069, 3025, 2955, 2920, 2854, 1742, 1550, 1494, 1436, 1367, 1213, 1093, 758, 
699 cm-1; HRMS-CI m/z 361.0948 [(M+H)+; calcd for C18H18ClN2O4 : 361.0950]. 
 
(2R,3S,4R,5R)-Methyl 4-Nitro-3,5-di-p-tolylpyrrolidine-2-carboxylate (endo-4.3Mk) 
The product endo-4.3Mk was prepared from methyl (E)-2-((4-
methylbenzylidene)amino)acetate (0.5 mmol, 96 mg) and (E)-1-methyl-4-(2-
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nitrovinyl)benzene (0.5 mmol, 82 mg) by General Procedure B. The crude product was 
subjected to chromatography on a short silica column (10 - 20% ethyl acetate in hexanes); 
the yield of the title compound was 89%. 1H NMR (CDCl3, 500 MHz): δ 7.24 – 7.14 (m, 
8H), 5.22 (dd, J = 6.5, 4.0 Hz, 1H), 4.86 (d, J = 6.5 Hz, 1H), 4.15 (dd, J = 7.5, 3.5 Hz, 
1H), 4.10 (d, J = 7.0 Hz, 1H), 3.79 (s, 3H), 2.35 (s, 3H), 2.32 (s, 3H); 13C{1H} NMR 
(CDCl3, 125 MHz): δ 172.0, 138.6, 138.0, 135.8, 131.5, 130.1, 129.6, 127.5, 126.4, 97.4, 
67.8, 67.6, 55.3, 52.7, 21.3, 21.2; IR (neat, cm-1): 3335, 3022, 2952, 2920, 2860, 1742, 
1550, 1516, 1436, 1366, 1264, 1209, 1180, 1129, 813, 757 cm-1; HRMS-CI m/z: 
355.1654 [(M+H)+; calcd for C20H23N2O4 : 355.1652].  
 
(2R,3S,4R,5R)-Methyl 5-(4-Chlorophenyl)-4-nitro-3-(p-tolyl)pyrrolidine-2-carboxylate 
(endo-4.3Ml) 
The product endo-4.3Ml was prepared from methyl (E)-2-((4-
chlorobenzylidene)amino)acetate (0.5 mmol, 106 mg) and (E)-1-methyl-4-(2-
nitrovinyl)benzene (0.5 mmol, 82 mg) by General Procedure B. The crude product was 
subjected to chromatography on a short silica column (10 - 20% ethyl acetate in hexanes); 
the yield of the title compound was 92%. 1H NMR (CDCl3, 500 MHz): δ 7.33 − 7.30 (m, 
4H), 7.22 – 7.16 (m, 4H), 5.24 (dd, J = 6.5, 3.5 Hz, 1H), 4.87 (d, J = 6.5 Hz, 1H), 4.18 
(dd, J = 7.5, 4.0 Hz, 1H), 4.12 (d, J = 7.5 Hz, 1H), 3.80 (s, 3H), 3.24 (br, NH), 2.37 (s, 
3H); 13C{1H} NMR (CDCl3, 125 MHz): δ 171.8, 138.1, 135.4, 134.8, 133.4, 130.1, 129.1, 
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128.1, 127.5, 96.9, 67.3, 66.9, 54.9, 52.8, 21.2; IR (neat, cm-1): 3345, 3022, 2952, 2917, 
2857, 1742, 1550, 1516, 1494, 1436, 1366, 1211, 1181, 1093, 1015, 814, 759 cm-1; 
HRMS-CI m/z: 375.1109 [(M+H)+; calcd for C19H20ClN2O4 : 375.1106].  
 
(2S,3R,4S,5S)-Methyl 3-(4-Fluorophenyl)-4-nitro-5-(p-tolyl)pyrrolidine-2-carboxylate 
(endo-4.3Mm) 
The product endo-4.3Mm was prepared from methyl (E)-2-((4-
methylbenzylidene)amino)acetate (0.5 mmol, 96 mg) and (E)-1-fluoro-4-(2-
nitrovinyl)benzene (0.5 mmol, 84 mg) by General Procedure B. The crude product was 
subjected to chromatography on a short silica column (10 - 20% ethyl acetate in hexanes); 
the yield of the title compound was 94%. 1H NMR (CDCl3, 500 MHz): δ 7.27 − 7.22 (m, 
4H), 7.16 (d, J = 8.0 Hz, 2H), 7.10 – 7.06 (m, 2H), 5.21 (dd, J = 6.5, 4.0 Hz, 1H), 4.86 (d, 
J = 7.0 Hz, 1H), 4.19 (dd, J = 7.5, 3.5 Hz, 1H), 4.07 (d, J = 7.5 Hz, 1H), 3.79 (s, 3H), 
3.27 (br, NH), 2.32 (s, 3H); 13C{1H} NMR (CDCl3, 125 MHz): δ 171.7, 162.5 (d, J = 
246.3 Hz), 138.8, 134.4 (d, J = 3.8 Hz), 131.5, 129.6, 129.3 (d, J = 7.5 Hz), 126.5, 116.4 
(d, J = 22.5 Hz), 97.2, 67.6, 67.6, 54.6, 52.8, 21.3; IR (neat, cm-1): 3342, 3026, 2954, 
2923, 1743, 1607, 1550, 1512, 1436, 1367, 1308, 1227, 1162, 1129, 1101, 1021, 955, 924, 
873, 824, 758, 556, 531 cm-1; HRMS-CI m/z: 359.1400 [(M+H)+; calcd for C19H20FN2O4 : 
359.1402].  
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(2R,3S,4R,5R)-Methyl 5-(4-Chlorophenyl)-4-nitro-3-(m-tolyl)pyrrolidine-2-carboxylate 
(endo-4.3Mn) 
The product endo-4.3Mn was prepared from methyl (E)-2-((4-
chlorobenzylidene)amino)acetate (0.5 mmol, 106 mg) and (E)-1-methyl-3-(2-
nitrovinyl)benzene (0.5 mmol, 82 mg) by General Procedure B. The crude product was 
subjected to chromatography on a short silica column (10 - 20% ethyl acetate in hexanes); 
the yield of the title compound was 90%. 1H NMR (CDCl3, 500 MHz): δ 7.33 – 7.24 (m, 
5H), 7.14 (d, J = 7.5 Hz, 2H), 7.07 (d, J = 6.5 Hz, 2H), 5.23 (dd, J = 6.5, 3.5 Hz, 1H), 
4.87 (d, J = 6.5 Hz, 1H), 4.18 (d, J = 7.5, 3.5 Hz, 1H), 4.13 (d, J = 7.5 Hz, 1H), 3.79 (s, 
3H), 3.24 (br, NH), 2.37 (s, 3H); 13C{1H} NMR (CDCl3, 125 MHz): δ 171.8, 139.2, 
138.3, 134.7, 133.3, 129.3, 129.0, 129.0, 128.3, 128.1, 124.6, 96.9, 67.2, 67.0, 55.1, 52.8, 
21.6; IR (neat, cm-1): 3345, 3025, 2952, 2917, 2866, 1742, 1550, 1492, 1436, 1365, 1211, 
1094, 1015, 759 cm-1; HRMS-CI m/z: 375.1107 [(M+H)+; calcd for C19H20ClN2O4 : 
375.1106].  
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(2R,3R,4R,5R)-Methyl 2-Methyl-4-nitro-3,5-diphenylpyrrolidine-2-carboxylate (endo-
4.3Mo) 
The product endo-4.3Mo was prepared from methyl (E)-2-(benzylideneamino)propanoate 
(0.5 mmol, 96 mg) and 1-((E)-2-nitrovinyl)benzene (0.5 mmol, 75 mg) by General 
Procedure B. The mixture was stirred at 0 °C for 18 h. The crude product was subjected 
to chromatography on a short silica column (10 - 20% ethyl acetate in hexanes); the yield 
of the title compound was 76%. 1H NMR and 13C NMR spectra of this compound are 
consistent with previously reported data in the literature.13 1H NMR (CDCl3, 500 MHz): δ 
7.40 (d, J = 7.0 Hz, 2H), 7.37 – 7.29 (m, 6H), 7.25 – 7.24 (m, 2H), 5.65 (t, J = 7.0 Hz, 
1H), 5.05 (d, J = 7.5 Hz, 1H), 4.52 (d, J = 6.0 Hz, 1H), 3.85 (s, 3H), 3.42 (br, NH), 1.17 
(s, 3H); 13C{1H} NMR (CDCl3, 125 MHz): δ 174.8, 135.7, 135.5, 128.9, 128.9, 128.8, 
128.7, 128.1, 127.0, 95.7, 68.8, 65.1, 57.0, 53.0, 22.2; IR (neat, cm-1): 3345, 3091, 3064, 
3032, 3002, 2977, 2953, 1734, 1603, 1553, 1498, 1455, 1435, 1370, 1255, 1221, 1141, 
1030, 984, 873, 809, 750, 700, 667 cm-1; HRMS-CI m/z: 341.1506 [(M+H)+; calcd for 
C19H21N2O4: 341.1496]. Absolute stereochemistry of this compound was determined by 
comparison of its HPLC retention time (minor/major peaks) with that of an authentic 
sample.13 
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General Procedure C for Transesterification of anti-4.4 
 
(2S, 3S)-Methyl 2-Amino-4-nitro-3-phenylbutanoate (anti-4.5Ma) 
anti-4.4Ba27 (0.5 mmol, 222 mg) was dissolved in 1M HCl-MeOH solution (5.0 mmol, 
5.0 mL). The mixture was refluxed for 48 hours. HCl and MeOH were then removed 
under reduced pressure. To the resulting solution, 5.0 mL 1M HCl (aq.) was added.  The 
resulting aqueous solution was washed with ether (2 × 10.0 mL) and neutralized with 
NaHCO3 (aq.). The mixture was then extracted with CH2Cl2 (3 × 10 mL). The organic 
layers of these three extractions were combined and then dried over anhydrous Na2SO4. 
After filtration and concentration under reduced pressure, the desired product (anti-
4.5Ma) was obtained. 1H NMR (CDCl3, 500 MHz): δ 7.34 – 7.28 (m, 3H), 7.21 (d, J = 
7.5 Hz, 2H), 5.05 (dd, J = 13.0, 5.0 Hz, 1H), 4.77 (dd, J = 13.0, 9.0 Hz, 1H), 3.82 (d, J = 
6.5 Hz, 1H), 3.69 (d, J = 11.5 Hz, 1H), 3.55 (s, 3H), 1.66 (br, 2NH); 13C{1H} NMR 
(CDCl3, 125 MHz): δ 174.1, 136.6, 129.1, 128.3, 128.1, 58.0, 52.2, 52.2, 47.9; IR (neat, 
cm-1): 3389, 3322, 3063, 3028, 3003, 2954, 2923, 2844, 1733, 1552, 1496, 1456, 1436, 
1383, 1262, 1203, 1174, 1090, 1019, 702 cm-1; HRMS-CI m/z: 239.1025 [(M+H)+; calcd 
for C11H15N2O4 : 239.1032].  
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General Procedure D for Hydrolysis of anti-4.5B 
 
rac-tert-Butyl 3-Amino-5-nitro-2-oxo-4-phenylpentanoate (anti-4.5Ba) 
anti-4.4Ba27 (0.5 mmol, 222 mg) was dissolved in 1M HCl-MeOH solution (5.0 mmol, 
5.0 mL). The mixture was stirred at 0 °C for 4-6 h. HCl and MeOH were then removed 
under reduced pressure. To the resulting solution, 5.0 mL 1M HCl (aq.) was added.  The 
resulting aqueous solution was washed with ether (2 × 10 mL) and neutralized with 
NaHCO3 (aq.). The mixture was then extracted with CH2Cl2 (3 × 10 mL). The organic 
layers of these three extractions were combined and then dried over anhydrous Na2SO4. 
After filtration and concentration under reduced pressure, the desired product (anti-4.5Ba) 
was obtained. 1H NMR and 13C NMR spectra of this compound are consistent with 
previously reported data in the literature.39 1H NMR (CDCl3, 500 MHz): δ 7.33 − 7.22 (m, 
5H), 5.06 (dd, J = 13.0, 5.0 Hz, 1H), 4.72 (dd, J = 13.0, 4.5 Hz, 1H), 3.71 – 3.67 (m, 1H), 
3.60 – 3.54 (m, 1H), 1.62 (br, 2NH), 1.22 (s, 9H); 13C{1H} NMR (CDCl3, 125 MHz): δ 
173.1, 136.8, 128.9, 128.5, 128.3, 82.0, 78.1, 58.4, 48.4, 27.8. 
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General Procedure E for the Synthesis of Stepwise [3+2] Cycloaddition Reaction 
Products 
 
(2S,3R,4S,5S)-tert-Butyl 4-Nitro-3,5-diphenylpyrrolidine-2-carboxylate (endo-4.3Ba) 
The compound anti–4.4Ba was prepared from glycine ketimine (0.5 mmol, 148 mg) and 
1-((E)-2-Nitrovinyl)benzene (0.5 mmol, 75 mg) as described previously.26 The product 
was then hydrolyzed with 1N HCl in MeOH (5.0 mL) at 0 °C for 4-6 h. HCl and MeOH 
were then removed under reduced pressure. Et3N (1.0 mmol) and aldehyde (1.0 mmol) in 
MeOH (1.0 mL) were then added to the isolated reaction residue at –15 °C. The mixture 
was stirred continuously at –15 °C for 18 h. The resulting solution was concentrated 
under reduced pressure and then subjected to chromatography on a short silica column 
(10 – 20 % Ethyl Acetate in Hexanes); the yield of the title compound was 57 %. 1H 
NMR (CDCl3, 500 MHz): δ7.40 – 7.27 (m, 10H), 5.29 (dd, J = 7.0, 4.0 Hz, 1H), 4.93 (d, 
J = 6.5 Hz, 1H), 4.09 (dd, J = 7.5, 4.0 Hz, 1H), 3.99 (d, J = 8.0 Hz, 1H), 3.34(br, NH), 
1.44(s, 9H); 13C{1H} NMR (CDCl3, 125 MHz): δ 170.6, 138.9, 134.8, 129.3, 128.9, 
128.8, 128.1, 127.7, 126.6, 97.2, 82.6, 68.3, 67.9, 56.1, 28.1; IR (neat, cm-1): 3345, 3066, 
3031, 3003, 2974, 2936, 1732, 1550, 1455, 1384, 1369, 1155, 759, 699 cm-1; HRMS-CI 
m/z: 369.1812 [(M+H)+; calcd for C21H25N2O4 : 369.1809].  
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(2S,3R,4S,5S)-tert-Butyl 4-Nitro-3-phenyl-5-(p-tolyl)pyrrolidine-2-carboxylate (endo-
4.3Bb) 
The product endo-4.3Bb was prepared from anti-4.4Ba (0.5 mmol, 222 mg) and 4-
methylbenzaldehyde (1.0 mmol, 120 mg) by General Procedure E. The crude product 
was subjected to chromatography on a short silica column (10 - 20% ethyl acetate in 
hexanes); the yield of the title compound was 74%. 1H NMR (CDCl3, 500 MHz): δ 7.39 – 
7.36 (m, 2H), 7.32 – 7.22 (m, 5H), 7.15 (d, J = 8.0 Hz, 2H), 5.26 (dd, J = 7.0, 4.0 Hz, 1H), 
4.87 (d, J = 6.5 Hz, 1H), 4.08 (dd, J = 7.5, 4.0 Hz, 1H), 3.97 (d, J = 8.0 Hz, 1H), 3.29 (br, 
NH), 2.31 (s, 3H), 1.43 (s, 9H); 13C{1H} NMR (CDCl3, 125 MHz): δ 170.6, 138.9, 138.6, 
131.8, 129.5, 129.2, 128.0, 127.7, 126.5, 97.3, 82.5, 68.3, 67.8, 56.2, 28.1, 21.2; IR (neat, 
cm-1): 3304, 3030, 2978, 2926, 1732, 1550, 1518, 1497, 1477, 1455, 1393, 1369, 1330, 
1257, 1217, 1157, 844, 825, 797, 759, 700 cm-1; HRMS-CI m/z: 383.1962 [(M+H)+; 
calcd for C22H27N2O4 : 383.1965].  
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(2S,3R,4S,5S)-tert-Butyl 5-(4-Methoxyphenyl)-4-nitro-3-phenylpyrrolidine-2-carboxylate 
(endo-4.3Bc) 
The product endo-4.3Bc was prepared from anti-4.4Ba (0.5 mmol, 222 mg) and 4-
anisaldehyde (1.0 mmol, 136 mg) by General Procedure E. The crude product was 
subjected to chromatography on a short silica column (10 - 20% ethyl acetate in hexanes); 
the yield of the title compound was 79%. 1H NMR (CDCl3, 500 MHz): δ 7.39 – 7.36 (m, 
2H), 7.33 – 7.27 (m, 5H), 6.87 (d, J = 9.0 Hz, 2H), 5.25 (dd, J = 6.5, 4.0 Hz, 1H), 4.86 (d, 
J = 6.5 Hz, 1H), 4.09 (dd, J = 8.0, 4.5 Hz, 1H), 3.97 (d, J = 7.5 Hz, 1H), 3.77 (s, 3H), 
3.25 (br, NH), 1.43 (s, 9H); 13C{1H} NMR (CDCl3, 125 MHz): δ 170.7, 160.0, 138.9, 
129.2, 128.0, 127.9, 127.7, 126.8, 114.2, 97.3, 82.5, 68.2, 67.5, 56.0, 55.3, 28.1; IR (neat, 
cm-1): 3339, 3032, 2978, 2932, 2838, 1732, 1613, 1585, 1550, 1517, 1498, 1456, 1369, 
1252, 1157, 1033, 837, 761, 701 cm-1; HRMS-CI m/z: 399.1910 [(M+H)+; calcd for 
C22H27N2O5  : 399.1914].  
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(2S,3R,4S,5S)-tert-Butyl 5-(4-Fluorophenyl)-4-nitro-3-phenylpyrrolidine-2-carboxylate 
(endo-4.3Bd) 
The product endo-4.3Bd was prepared from anti-4.4Ba (0.5 mmol, 222 mg) and 4-
fluorobenzaldehyde (1.0 mmol, 124 mg) by General Procedure E. The crude product was 
subjected to chromatography on a short silica column (10 - 20% ethyl acetate in hexanes); 
the yield of the title compound was 48%. 1H NMR (CDCl3, 500 MHz): δ 7.39 − 7.30 (m, 
5H), 7.28 – 7.26 (m, 2H), 7.03 (td, J = 8.5, 2.0 Hz, 2H), 5.27 (dd, J = 7.0, 3.5 Hz, 1H), 
4.89 (d, J = 6.5 Hz, 1H), 4.10 (dd, J = 7.5, 4.5 Hz, 1H), 3.98 (d, J = 8.0 Hz, 1H), 3.22 (br, 
NH), 1.43 (s, 9H); 13C{1H} NMR (CDCl3, 125 MHz): δ 170.6, 162.9 (d, J = 246.3 Hz), 
138.6, 130.9 (d, J = 2.5 Hz), 129.3, 128.5 (d, J = 8.8 Hz), 128.1, 127.7, 115.8 (d, J = 28.8 
Hz), 97.0, 82.6, 68.0, 66.9, 55.7, 28.1; IR (neat, cm-1): 3352, 3032, 2979, 2927, 2853, 
1732, 1606, 1551, 1513, 1478, 1455, 1393, 1369, 1230, 1157, 1092, 1015, 950, 841, 800, 
760, 700, 539 cm-1; HRMS-CI m/z: 387.1717 [(M+H)+; calcd for C21H24FN2O4 : 
387.1715]. 
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(2S,3R,4S,5S)-tert-Butyl 5-(4-Chlorophenyl)-4-nitro-3-phenylpyrrolidine-2-carboxylate 
(endo-4.3Be) 
The product endo-4.3Be was prepared from anti-4.4Ba (0.5 mmol, 222 mg) and 4-
chlorobenzaldehyde (1.0 mmol, 141 mg) by General Procedure E. The crude product was 
subjected to chromatography on a short silica column (10 - 20% ethyl acetate in hexanes); 
the yield of the title compound was 48%. 1H NMR (CDCl3, 500 MHz): δ 7.40 − 7.37 (m, 
2H), 7.34 – 7.30 (m, 5H), 7.28 – 7.26 (m, 2H), 5.27 (dd, J = 7.0, 4.5 Hz, 1H), 4.87 (d, J = 
6.5 Hz, 1H), 4.09 (dd, J = 7.5, 4.5 Hz, 1H), 3.99 (d, J = 7.5 Hz, 1H), 3.23 (br, NH), 1.43 
(s, 9H); 13C{1H} NMR (CDCl3, 125 MHz): δ 170.5, 138.6, 134.7, 133.6, 129.3, 129.1, 
128.2, 128.1, 127.7, 96.9, 82.7, 68.0, 67.0, 55.8, 28.1; IR (neat, cm-1): 3352, 3031, 2979, 
2931, 1732, 1602, 1549, 1496, 1455, 1393, 1369, 1299, 1251, 1218, 1157, 1095, 1015, 
952, 933, 840, 758, 700, 668, 510 cm-1; HRMS-CI m/z: 403.1412 [(M+H)+; calcd for 
C21H24ClN2O4 : 403.1419]. 
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(2S,3R,4S,5S)-tert-Butyl 4-Nitro-5-(4-nitrophenyl)-3-phenylpyrrolidine-2-carboxylate 
(endo-4.3Bf) 
The product endo-4.3Bf was prepared from anti-4.4Ba (0.5 mmol, 222 mg) and 4-
nitrobenzaldehyde (1.0 mmol, 151 mg) by General Procedure E. The crude product was 
subjected to chromatography on a short silica column (10 - 20% ethyl acetate in hexanes); 
the yield of the title compound was 77%. 1H NMR (CDCl3, 500 MHz): δ 8.22 (dd, J = 
7.0, 2.0, 2H), 7.60 (d, J = 8.5 Hz, 2H), 7.42 – 7.39 (m, 2H), 7.36 – 7.33 (m, 1H), 7.30 – 
7.28 (m, 2H), 5.36 (dd, J = 7.0, 4.5 Hz, 1H), 5.01 (s, 1H), 4.13 (dd, J = 7.5, 4.5 Hz, 1H), 
4.05 (s, 1H), 3.25 (br, NH), 1.44 (s, 9H); 13C{1H} NMR (CDCl3, 125 MHz): δ 170.3, 
148.2, 142.6, 138.1, 129.4, 128.4, 127.9, 127.7, 124.0, 96.5, 82.9, 67.7, 66.4, 55.4, 28.1; 
IR (neat, cm-1): 3380, 3031, 2977, 2924, 2853, 1732, 1603, 1553, 1523, 1456, 1369, 1348, 
1256, 1156, 856, 757, 700 cm-1; HRMS-CI m/z: 414.1642 [(M+H)+; calcd for 
C21H24N3O6 : 414.1660]. 
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(2S,3R,4S,5S)-tert-Butyl 5-(3-Bromophenyl)-4-nitro-3-phenylpyrrolidine-2-carboxylate 
(endo-4.3Bg) 
The product endo-4.3Bg was prepared from anti-4.4Ba (0.5 mmol, 222 mg) and 3-
bromobenzaldehyde (1.0 mmol, 185 mg) by General Procedure E. The crude product was 
subjected to chromatography on a short silica column (10 - 20% ethyl acetate in hexanes); 
the yield of the title compound was 48%. 1H NMR (CDCl3, 500 MHz): δ 7.55 (s, 1H), 
7.47 – 7.45 (m, 1H), 7.41 – 7.38 (m, 2H), 7.35 – 7.27 (m, 4H), 7.23 (t, J = 7.5 Hz, 1H), 
5.29 (dd, J = 7.0, 4.0 Hz, 1H), 4.86 (t, J = 7.5 Hz, 1H), 4.10 (dd, J = 7.5, 4.0 Hz, 1H), 
3.99 (t, J = 7.0 Hz, 1H), 3.24 (br, NH), 1.45 (s, 9H); 13C{1H} NMR (CDCl3, 125 MHz): δ 
170.4, 138.5, 137.4, 132.0, 130.4, 130.1, 129.3, 128.2, 127.7, 125.2, 123.0, 96.7, 82.7, 
68.0, 66.9, 55.8, 28.1; IR (neat, cm-1): 3352, 3064, 3031, 2979, 2928, 2854, 1732, 1596, 
1552, 1497, 1476, 1455, 1429, 1393, 1369, 1257, 1218, 1155, 1073, 997, 843, 758, 699, 
668 cm-1; HRMS-CI m/z: 447.0898 [(M+H)+; calcd for C21H24BrN2O4 : 447.0941].  
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(2S,3R,4S,5R)-tert-Butyl 4-Nitro-3-phenyl-5-(thiophen-2-yl)pyrrolidine-2-carboxylate 
(endo-4.3Bh) 
The product endo-4.3Bh was prepared from anti-4.4Ba (0.5 mmol, 222 mg) and 2-
thiophenecarboxaldehyde (1.0 mmol, 112 mg) by General Procedure E. The crude 
product was subjected to chromatography on a short silica column (10 - 20% ethyl 
acetate in hexanes); the yield of the title compound was 44%. 1H NMR (CDCl3, 500 
MHz): δ 7.41 − 7.39 (m, 2H), 7.34 – 7.27 (m, 4H), 7.07 (d, J = 3.5 Hz, 1H), 7.00 (dd, J = 
5.0, 3.5 Hz, 1H), 5.29 (dd, J = 6.5, 5.0 Hz, 1H), 5.11 (d, J = 7.0 Hz, 1H), 4.14 ( dd, J = 
8.0, 5.0 Hz, 1H), 3.99 (d, J = 7.5 Hz, 1H), 3.35 (br, NH), 1.44 (s, 9H); 13C{1H} NMR 
(CDCl3, 125 MHz): δ 170.3, 138.4, 137.9, 129.3, 128.2, 127.8, 127.4, 125.8, 125.5, 96.4, 
82.7, 67.8, 63.4, 55.4, 28.1; IR (neat, cm-1): 3355, 3034, 3002, 2978, 2923, 1732, 1552, 
1456, 1384, 1369, 1246, 1156, 843, 700 cm-1; HRMS-CI m/z: 375.1373 [(M+H)+; calcd 
for C19H23N2O4S: 375.1373]. 
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(2S,3R,4S,5S)-tert-Butyl 4-Nitro-5-phenyl-3-(p-tolyl)pyrrolidine-2-carboxylate (endo-
4.3Bi) 
The product endo-4.3Bi was prepared from anti-4.4Bi (0.5 mmol, 229 mg) and 
benzaldehyde (1.0 mmol, 106 mg) by General Procedure E. The crude product was 
subjected to chromatography on a short silica column (10 - 20% ethyl acetate in hexanes); 
the yield of the title compound was 48%. 1H NMR (CDCl3, 500 MHz): δ 7.36 – 7.32 (m, 
2H), 7.20 – 7.16 (m, 4H), 5.26 (dd, J = 6.5 Hz, 4.0 Hz, 1H), 4.89 (d, J = 6.5 Hz, 1H), 
4.06 (dd, J= 7.5 Hz, 4.0 Hz, 1H), 3.98 (d, J = 7.5 Hz, 1H), 2.36 (s, 3H), 1.45 (s, 9H); 
13C{1H} NMR (CDCl3, 125 MHz): δ 170.7, 137.8, 136.0, 134.8, 129.9, 128.9, 128.8, 
127.6, 126.6, 97.3, 82.6, 68.4, 67.9, 55.9, 28.1, 21.1; IR (neat, cm-1): 3341, 3028, 3003, 
2978, 2923, 1733, 1550, 1516, 1456, 1384, 1368, 1320, 1256, 1156, 746, 698 cm-1; 
HRMS-CI m/z: 383.1969 [(M+H)+; calcd for C22H27N2O4 : 383.1965].  
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(2S,3R,4S,5S)-tert-Butyl 4-Nitro-5-phenyl-3-(m-tolyl)pyrrolidine-2-carboxylate (endo-
4.3Bj) 
The product endo-4.3Bj was prepared from anti-4.4Bj (0.5 mmol, 229 mg) and 
benzaldehyde (1.0 mmol, 106 mg) by General Procedure E. The crude product was 
subjected to chromatography on a short silica column (10 - 20% ethyl acetate in hexanes); 
the yield of the title compound was 73%. 1H NMR(CDCl3, 500 MHz): δ 7.36 − 7.26 (m, 
6H), 7.13 (d, J = 8.0 Hz, 1H), 7.07 (d, J = 8.0 Hz, 2H), 5.29 (dd, J = 6.5, 4.0 Hz, 1H), 
4.90 (d, J = 6.5 Hz, 1H), 4.06 (dd, J = 7.5, 3.5 Hz, 1H), 3.99 (d, J = 7.5 Hz, 1H), 3.39 (br, 
NH), 2.37 (s, 3H), 1.45 (s, 9H); 13C{1H} NMR (CDCl3, 125 MHz): δ 170.7, 139.0, 138.9, 
134.8, 129.2, 128.9, 128.9, 128.8, 128.5, 126.6, 124.7, 97.2, 82.5, 68.3, 67.9, 56.2, 28.1, 
21.6; IR (neat, cm-1): 3338, 3063, 3028, 3006, 2978, 2928, 2870, 1732, 1550, 1456, 1393, 
1368, 1250, 1157, 757, 700 cm-1; HRMS-CI m/z: 383.1969 [(M+H)+; calcd for 
C22H27N2O4 : 383.1965].  
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(2S,3R,4S,5S)-tert-Butyl 3-(3-Chlorophenyl)-4-nitro-5-phenylpyrrolidine-2-carboxylate 
(endo-4.3Bk) 
The product endo-4.3Bk was prepared from anti-4.4Bk (0.5 mmol, 239 mg) and 
benzaldehyde (1.0 mmol, 106 mg) by General Procedure E. The crude product was 
subjected to chromatography on a short silica column (10 - 20% ethyl acetate in hexanes); 
the yield of the title compound was 67%. 1H NMR (CDCl3, 500 MHz): δ 7.37 – 7.29 (m, 
8H), 7.17 (dt, J = 6.5, 2.0 Hz, 1H),  5.29 (dd, J = 7.0, 4.5 Hz, 1H), 4.89 (d, J = 7.0 Hz, 
1H), 4.08 (dd, J = 7.5, 4.5 Hz, 1H), 3.95 (d, J = 7.5 Hz, 1H), 1.45 (s, 9H); 13C{1H} NMR 
(CDCl3, 125 MHz): δ 170.2, 140.7, 135.1, 134.7, 130.6, 128.9, 128.9, 128.3, 128.1, 126.7, 
125.9, 96.7, 82.9, 68.1, 67.8, 55.4, 28.1; IR (neat, cm-1): 3310, 3056, 3037, 2999, 2979, 
2930, 2873, 1732, 1551, 1479, 1456, 1384, 1369, 1250, 1155, 784, 754, 697 cm-1; 
HRMS-CI m/z: 403.1424 [(M+H)+; calcd for C21H24ClN2O4 : 403.1419].  
 
(2S,3R,4S,5S)-tert-Butyl 3-(Furan-2-yl)-4-nitro-5-phenylpyrrolidine-2-carboxylate (endo-
4.3Bl) 
The product endo-4.3Bl was prepared from anti-4.4Bl (0.5 mmol, 217 mg) and 
benzaldehyde (1.0 mmol, 106 mg) by General Procedure E. The crude product was 
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subjected to chromatography on a short silica column (10 - 20% ethyl acetate in hexanes); 
the yield of the title compound was 47%. 1H NMR(CDCl3, 500 MHz): δ 7.42 – 7.41 (m, 
1H), 7.37 – 7.31 (m, 5H), 6.36 (dd, J = 3.5, 2.0 Hz, 1H), 6.26 (d, J = 3.5 Hz, 1H), 5.34 
(dd, J = 6.5, 3.5 Hz, 1H), 4.85 (d, J = 6.5 Hz, 1H), 4.20 (dd, J = 7.0, 3.0 Hz, 1H), 4.06 (d, 
J = 7.0 Hz, 1H), 3.31 (br, NH), 1.50 (s, 9H); 13C{1H} NMR (CDCl3, 125 MHz): δ 170.2, 
151.2, 142.9, 134.3, 128.8, 128.8, 126.5, 110.8, 107.8, 94.2, 82.7, 67.8, 65.7, 49.6, 28.1; 
IR (neat, cm-1): 3303, 3113, 3063, 3037, 2979, 2927, 2841, 1733, 1550, 1456, 1384, 1369, 
1251, 1157, 742, 698 cm-1; HRMS-CI m/z: 359.1605 [(M+H)+; calcd for C19H23N2O5 : 
359.1601].  
 
(2S,3R,4S,5S)-tert-Butyl 3,5-Bis(4-chlorophenyl)-4-nitropyrrolidine-2-carboxylate (endo-
4.3Bm) 
The product endo-4.3Bm was prepared from anti-4.4Bm (0.5 mmol, 239 mg) and 4-
chlorobenzaldehyde (1.0 mmol, 141 mg) by General Procedure E. The crude product was 
subjected to chromatography on a short silica column (10 - 20% ethyl acetate in hexanes); 
the yield of the title compound was 71%. 1H NMR (CDCl3, 500 MHz): δ 7.37 – 7.35 (m, 
2H), 7.34 – 7.29 (m, 4H), 7.21 (dd, J = 6.5, 1.5 Hz, 2H), 5.23 (dd, J = 7.0, 4.5 Hz, 1H), 
4.86 (d, J = 7.0 Hz, 1H), 4.08 (dd, J = 8.0, 4.5 Hz, 1H), 3.94 (d, J = 8.0 Hz, 1H), 1.44 (s, 
9H); 13C{1H} NMR (CDCl3, 125 MHz): δ 170.2, 136.9, 134.9, 134.1, 133.5, 129.5, 129.1, 
129.1, 128.1, 96.6, 82.9, 67.8, 66.7, 54.8, 28.1; IR (neat, cm-1): 3355, 3028, 2980, 2926, 
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1732, 1550, 1494, 1384, 1369, 1250, 1156, 1093, 1015, 822 cm-1; HRMS-CI m/z: 
437.1018 [(M+H)+; calcd for C21H23Cl2N2O4: 437.1029].  
 
(2S,3R,4S,5S)-tert-Butyl 5-(4-Chlorophenyl)-3-(furan-2-yl)-4-nitropyrrolidine-2-
carboxylate (endo-4.3Bn) 
The product endo-4.3Bn was prepared from anti-4.4Bl (0.5 mmol, 217 mg) and 4-
chlorobenzaldehyde (1.0 mmol, 141 mg) by General Procedure E. The crude product was 
subjected to chromatography on a short silica column (10 - 20% ethyl acetate in hexanes); 
the yield of the title compound was 68%. 1H NMR (CDCl3, 500 MHz): δ 7.41 (t, J = 1.0 
Hz, 1H), 7.33 – 7.26 (m, 4H), 6.36 (dd, J = 3.5, 1.5 Hz, 1H), 6.25 (d, J = 3.5 Hz, 1H), 
5.32 (dd, J = 6.5, 3.5 Hz, 1H), 4.82 (d, J = 6.0 Hz, 1H), 4.20 (dd, J = 7.0, 3.0 Hz, 1H), 
4.04 (d, J = 7.0 Hz, 1H), 3.19 (br, NH), 1.49 (s, 9H); 13C{1H} NMR (CDCl3, 125 MHz): 
δ 170.1, 151.0, 142.9, 134.7, 133.0, 129.1, 128.0, 110.8, 107.9, 93.9, 82.8, 66.9, 65.5, 
49.2, 28.1; IR (neat, cm-1): 3339, 3117, 2979, 2931, 1733, 1550, 1496, 1448, 1384, 1369, 
1299, 1251, 1157, 1094, 1015, 841, 741 cm-1; HRMS-CI m/z: 393.1215 [(M+H)+; calcd 
for C19H22ClN2O5: 393.1212].  
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(2S,3R,4S,5S)-tert-Butyl 5-(4-Chlorophenyl)-3-(naphthalen-1-yl)-4-nitropyrrolidine-2-
carboxylate (endo-4.3Bo) 
The product endo-4.3Bo was prepared from anti-4.4Bo (0.5 mmol, 247 mg) and 4-
chlorobenzaldehyde (1.0 mmol, 141 mg) by General Procedure E. The crude product was 
subjected to chromatography on a short silica column (10 - 20% ethyl acetate in hexanes); 
the yield of the title compound was 55%. 1H NMR (CDCl3, 500 MHz): δ 8.00 (d, J = 8.5 
Hz, 1H), 7.92 – 7.90 (m,1H), 7.85 (dd, J = 7.0, 2.0 Hz, 1H), 7.58 – 7.50 (m, 4H), 7.34 – 
7.30 (td, J = 9.5, 2.5 Hz, 4H), 5.22 (dd, J = 6.5, 3.5 Hz, 1H), 5.07 (dd, J = 6.5, 3.5 Hz, 
1H), 4.97 (d, J = 6.0 Hz, 1H), 4.28 (d, J = 6.0 Hz, 1H), 3.38 (br, NH), 1.32 (s, 9H); 
13C{1H} NMR (CDCl3, 125 MHz): δ 171.0, 135.0, 134.8, 134.2, 133.5, 131.5, 129.3, 
129.1, 128.9, 128.1, 127.2, 126.4, 125.6, 124.1, 122.7, 97.1, 82.7, 67.8, 67.2, 50.5, 27.9; 
IR (neat, cm-1): 3345, 3069, 3044, 3005, 2979, 2930, 1731, 1598, 1550, 1512, 1495, 1456, 
1394, 1369, 1332, 1256, 1217, 1157, 1094, 1015, 841, 799, 778, 757 cm-1; HRMS-CI m/z: 
453.1591 [(M+H)+; calcd for C25H26ClN2O4 : 453.1576].  
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General Procedure F for the Synthesis of exo’-4.3M 
 
rac-Methyl 4-Nitro-3,5-diphenylpyrrolidine-2-carboxylate (exo’-4.3Ma) 
To the solution of methyl (E)-2-(benzylideneamino)acetate (0.5 mmol, 89 mg), 1-((E)-2-
nitrovinyl)benzene (0.5 mmol, 75 mg) in dry acetonitrile (2.5 mL) and nickel(II) 
acetylacetonate (0.05 mmol) were added at ambient temperature. The resulting solution 
was stirred for 18 h. The crude product was subjected to chromatography on a short silica 
column (10% ethyl acetate in hexanes); the yield of the title compound was 30%. 1H 
NMR and 13C NMR spectra of this compound are consistent with previously reported 
data in the literature.21 1H NMR (CDCl3, 500 MHz): δ 7.48 – 7.46 (m, 2H), 7.43 – 7.28 
(m, 8H), 4.91 – 4.86 (m, 2H), 4.21 – 4.19 (m, 1H), 4.14 (d, J = 5.0 Hz, 1H), 3.81 (s, 3H), 
2.98 (br, NH); 13C{1H} NMR (CDCl3, 125 MHz): δ 173.8, 139.4, 138.6, 129.4, 129.0, 
128.9, 128.2, 127.5, 126.9, 98.6, 67.3, 65.9, 54.2, 52.9; IR (neat, cm-1): 3338, 3060, 3031, 
3015, 2955, 2911, 2847, 1738, 1552, 1495, 1456, 1436, 1367, 1332, 1220, 1129, 757, 700 
cm-1; HRMS-CI m/z: 327.1329 [(M+H)+; calcd for C18H19N2O4 : 327.1339].  
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rac-tert-Butyl 4-Nitro-3,5-diphenylpyrrolidine-2-carboxylate (exo’-4.3Ba) 
The product exo’-4Ba was prepared from 4.1a (0.5 mmol, 110 mg) and 1-((E)-2-
nitrovinyl)benzene (0.5 mmol, 75 mg) by General Procedure F. The crude product was 
subjected to chromatography on a short silica column (10% ethyl acetate in hexanes); the 
yield of the title compound was 30%. 1H NMR (CDCl3, 500 MHz): δ 7.49 (d, J = 7.5 Hz, 
2H), 7.42 – 7.28 (m, 8H), 4.94 – 4.90 (m, 2H), 4.14 – 4.12 (m, 1H), 4.01 (d, J = 6.0 Hz, 
1H), 3.01 (br, NH), 1.47 (s, 9H); 13C{1H} NMR (CDCl3, 125 MHz): δ 172.2, 139.4, 
139.2, 129.2, 129.0, 128.7, 128.0, 127.6, 126.8, 98.8, 82.6, 67.2, 66.7, 55.1, 28.1; IR 
(neat, cm-1): 3335, 3066, 3031, 3006, 2974, 2923, 1729, 1552, 1502, 1456, 1369, 1248, 
1157, 758, 700 cm-1; HRMS-CI m/z: 369.1814 [(M+H)+; calcd for C21H25N2O4 : 
369.1809]. 
 
Conditions for Determination of Enantiomeric Excess 
The enantiomeric excess values for the products were determined by chiral HPLC 
analysis using Chiralcel OD-H, AS-H, and AD-H columns. 
(1) (2R,3S,4R,5R)-Methyl 4-Nitro-3,5-diphenylpyrrolidine-2-carboxylate (endo-4.3Ma): 
tminor = 17.93 min tmajor = 27.60 min (OD-H Column, hexanes/2-propanol : 80/20, 1.0 
mL/min) 
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(2) (2R,3S,4R,5R)-Methyl 4-Nitro-3-phenyl-5-(p-tolyl)pyrrolidine-2-carboxylate (endo-
4.3Mb): tminor = 15.13 min tmajor = 17.64 min (OD-H Column, hexanes/2-propanol : 80/20, 
1.0 mL/min) 
(3) (2R,3S,4R,5R)-Methyl 5-(4-Chlorophenyl)-4-nitro-3-phenylpyrrolidine-2-carboxylate 
(endo-4.3Mc): tminor = 21.70 min tmajor = 25.62 min (OD-H Column, hexanes/2-propanol : 
80/20, 1.0 mL/min) 
(4) (2R,3S,4R,5R)-Methyl 5-(3-Chlorophenyl)-4-nitro-3-phenylpyrrolidine-2-carboxylate 
(endo-4.3Md): tminor = 33.76 min tmajor = 36.69 min (OD-H Column, hexanes/2-propanol : 
90/10, 0.8 mL/min) 
(5) (2R,3S,4R,5R)-Methyl 4-Nitro-3-phenyl-5-(m-tolyl)pyrrolidine-2-carboxylate (endo-
4.3Me): tminor = 21.01 min tmajor = 33.68 min (OD-H Column, hexanes/2-propanol : 85/15, 
0.8 mL/min) 
(6) (2R,3S,4R,5R)-Methyl 5-(2-Chlorophenyl)-4-nitro-3-phenylpyrrolidine-2-carboxylate 
(endo-4.3Mf): tmajor = 19.15 min tminor = 21.47 min (OD-H Column, hexanes/2-propanol : 
90/10, 0.8 mL/min) 
(7) (2R,3S,4R,5R)-Methyl 5-(Naphthalen-2-yl)-4-nitro-3-phenylpyrrolidine-2-carboxylate 
(endo-4.3Mg): tmajor = 41.95 min tminor = 52.73 min (OD-H Column, hexanes/2-propanol : 
85/15, 0.8 mL/min) 
(8) (2R,3S,4R,5S)-Methyl 4-Nitro-3-phenyl-5-(thiophen-2-yl)pyrrolidine-2-carboxylate 
(endo-4.3Mh): tmajor = 29.53 min tminor = 33.84 min (AD-H Column, hexanes/2-propanol : 
90/10, 0.7 mL/min) 
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(9) (2R,3S,4R,5R)-Methyl 4-Nitro-5-phenyl-3-(p-tolyl)pyrrolidine-2-carboxylate (endo-
4.3Mi): tminor = 16.76 min tmajor = 26.42 min (OD-H Column, hexanes/2-propanol : 80/20, 
1.0 mL/min) 
(10) (2R,3S,4R,5R)-Methyl 3-(4-Chlorophenyl)-4-nitro-5-phenylpyrrolidine-2-
carboxylate (endo-4.3Mj): tmajor = 26.12 min tminor = 30.47 min (OD-H Column, 
hexanes/2-propanol : 80/20, 1.0 mL/min) 
(11) (2R,3S,4R,5R)-Methyl 4-Nitro-3,5-di-p-tolylpyrrolidine-2-carboxylate (endo-4.3Mk): 
tminor = 33.03 min tmajor = 37.56 min (OD-H Column, hexanes/2-propanol : 90/10, 0/8 
mL/min) 
(12) (2R,3S,4R,5R)-Methyl 5-(4-Chlorophenyl)-4-nitro-3-(p-tolyl)pyrrolidine-2-
carboxylate (endo-4.3Ml): tmajor = 12.29 min tminor = 15.90 min (OD-H Column, 
hexanes/2-propanol : 80/20, 1.0 mL/min) 
(13) (2S,3R,4S,5S)-Methyl 3-(4-Fluorophenyl)-4-nitro-5-(p-tolyl)pyrrolidine-2-
carboxylate (endo-4.3Mm): tmajor = 18.22 min tminor = 23.94 min (OD-H Column, 
hexanes/2-propanol : 80/20, 1.0 mL/min) 
(14) (2R,3S,4R,5R)-Methyl 5-(4-Chlorophenyl)-4-nitro-3-(m-tolyl)pyrrolidine-2-
carboxylate (endo-4.3Mn): tmajor = 22.89 min tminor = 26.17 min (OD-H Column, 
hexanes/2-propanol : 90/10, 0.8 mL/min) 
(15) (2R,3R,4R,5R)-Methyl 2-Methyl-4-nitro-3,5-diphenylpyrrolidine-2-carboxylate 
(endo-4.3Mo): tmajor = 10.80 min tminor = 16.02 min (AD-H Column, hexanes/2-propanol : 
90/10, 1.0 mL/min) 
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(16) (2S,3R,4S,5S)-tert-Butyl 4-Nitro-3,5-diphenylpyrrolidine-2-carboxylate (endo-
4.3Ba): tminor = 10.17 min tmajor = 14.75 min (OD-H Column, hexanes/2-propanol : 90/10, 
0.8 mL/min) 
(17) (2S,3R,4S,5S)-tert-Butyl 4-Nitro-3-phenyl-5-(p-tolyl)pyrrolidine-2-carboxylate 
(endo-4.3Bb): tminor = 8.98 min tmajor = 11.47 min (OD-H Column, hexanes/2-propanol : 
90/10, 0.8 mL/min) 
(18) (2S,3R,4S,5S)-tert-Butyl 5-(4-Methoxyphenyl)-4-nitro-3-phenylpyrrolidine-2-
carboxylate (endo-4.3Bc): tminor = 13.97 min tmajor = 24.64 min (OD-H Column, 
hexanes/2-propanol : 90/10, 0.8 mL/min) 
(19) (2S,3R,4S,5S)-tert-Butyl 5-(4-Fluorophenyl)-4-nitro-3-phenylpyrrolidine-2-
carboxylate (endo-4.3Bd): tminor = 10.04 min tmajor = 11.00 min (OD-H Column, 
hexanes/2-propanol : 90/10, 0.8 mL/min) 
(20) (2S,3R,4S,5S)-tert-Butyl 5-(4-Chlorophenyl)-4-nitro-3-phenylpyrrolidine-2-
carboxylate (endo-4.3Be): tminor = 18.59 min tmajor = 52.36 min (AD-H Column, 
hexanes/2-propanol : 90/10, 0.7 mL/min) 
(21) (2S,3R,4S,5S)-tert-Butyl 4-Nitro-5-(4-nitrophenyl)-3-phenylpyrrolidine-2-
carboxylate (endo-4.3Bf): tmajor = 25.12 min tminor = 34.37 min (OD-H Column, 
hexanes/2-propanol : 90/10, 0.8 mL/min) 
(22) (2S,3R,4S,5S)-tert-Butyl 5-(3-Bromophenyl)-4-nitro-3-phenylpyrrolidine-2-
carboxylate (endo-4.3Bg): tminor = 11.48 min tmajor = 15.82 min (OD-H Column, 
hexanes/2-propanol : 90/10, 0.8 mL/min) 
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(23) (2S,3R,4S,5R)-tert-Butyl 4-Nitro-3-phenyl-5-(thiophen-2-yl)pyrrolidine-2-
carboxylate (endo-4.3Bh): tmajor = 15.03 min tminor = 24.95 min (AD-H Column, 
hexanes/2-propanol : 90/10, 0.7 mL/min) 
(24) (2S,3R,4S,5S)-tert-Butyl 4-Nitro-5-phenyl-3-(p-tolyl)pyrrolidine-2-carboxylate 
(endo-4.3Bi): tminor = 9.53 min tmajor = 14.32 min (OD-H Column, hexanes/2-propanol : 
90/10, 0.8 mL/min) 
(25) (2S,3R,4S,5S)-tert-Butyl 4-Nitro-5-phenyl-3-(m-tolyl)pyrrolidine-2-carboxylate 
(endo-4.3Bj): tminor = 8.94 min tmajor = 12.65 min (OD-H Column, hexanes/2-propanol : 
90/10, 0.8 mL/min) 
(26) (2S,3R,4S,5S)-tert-Butyl 3-(3-Chlorophenyl)-4-nitro-5-phenylpyrrolidine-2-
carboxylate (endo-4.3Bk): tminor = 10.75 min tmajor = 17.13 min (OD-H Column, 
hexanes/2-propanol : 90/10, 0.8 mL/min) 
(27) (2S,3R,4S,5S)-tert-Butyl 3-(Furan-2-yl)-4-nitro-5-phenylpyrrolidine-2-carboxylate 
(endo-4.3Bl): tminor = 13.16 min tmajor = 16.41 min (OD-H Column, hexanes/2-propanol : 
95/5, 0.8 mL/min) 
(28) (2S,3R,4S,5S)-tert-Butyl 3,5-Bis(4-chlorophenyl)-4-nitropyrrolidine-2-carboxylate 
(endo-4.3Bm): tminor = 12.78 min tmajor = 19.63 min (OD-H Column, hexanes/2-propanol : 
90/10, 0.8 mL/min) 
(29) (2S,3R,4S,5S)-tert-Butyl 5-(4-Chlorophenyl)-3-(furan-2-yl)-4-nitropyrrolidine-2-
carboxylate (endo-4.3Bn): tmajor = 15.16 min tminor = 28.28 min (AD-H Column, 
hexanes/2-propanol : 90/10, 1.0 mL/min) 
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(30) (2S,3R,4S,5S)-tert-Butyl 5-(4-Chlorophenyl)-3-(naphthalen-1-yl)-4-nitropyrrolidine-
2 carboxylate (endo-4.3Bo): tminor = 14.28 min tmajor = 17.04 min (OD-H Column, 
hexanes/2 propanol : 90/10, 0.8 mL/min) 
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Appendix A 1H NMR/13C NMR Spectra for Chapter 1  
A-1 1H NMR/13C NMR Spectra 
        1H NMR and 13C NMR spectra of product 1.2 are published in the literature.1 
        1H NMR and 13C NMR spectra of product 1.3 are published in the literature.2 
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Appendix B 1H NMR/13C NMR Spectra for Chapter 2 
B-1 1H NMR/13C NMR Spectra 
        1H NMR and 13C NMR spectra of product 2.2a are published in the literature.1 
        1H NMR and 13C NMR spectra of product 2.2b are published in the literature.1 
        1H NMR and 13C NMR spectra of product 2.2c are published in the literature.1 
        1H NMR and 13C NMR spectra of product 2.2d are published in the literature.1 
        1H NMR and 13C NMR spectra of product 2.2e are published in the literature.1 
        1H NMR and 13C NMR spectra of product 2.2f are published in the literature.1 
        1H NMR and 13C NMR spectra of product 2.2g are published in the literature.1 
        1H NMR and 13C NMR spectra of product 2.2h are published in the literature.1 
        1H NMR and 13C NMR spectra of product 2.2i are published in the literature.1 
        1H NMR and 13C NMR spectra of product 2.2j are published in the literature.1 
        1H NMR and 13C NMR spectra of product 2.2k are published in the literature.1 
        1H NMR and 13C NMR spectra of product 2.2l are published in the literature.1 
        1H NMR and 13C NMR spectra of product 2.2m are published in the literature.1 
        1H NMR and 13C NMR spectra of product 2.2n are published in the literature.1 
        1H NMR and 13C NMR spectra of product 2.2o are published in the literature.1 
        1H NMR and 13C NMR spectra of product 2.2p are published in the literature.1 
        1H NMR and 13C NMR spectra of product 2.2q are published in the literature.1 
        1H NMR and 13C NMR spectra of product 2.2r are published in the literature.1 
        1H NMR and 13C NMR spectra of product 2.2s are published in the literature.1 
        1H NMR and 13C NMR spectra of product 2.2u are published in the literature.1 
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        1H NMR and 13C NMR spectra of product 2.2x are published in the literature.1 
        1H NMR and 13C NMR spectra of product 2.3a are published in the literature.2 
        1H NMR and 13C NMR spectra of product 2.3b are published in the literature.2 
        1H NMR and 13C NMR spectra of product 2.3c are published in the literature.2 
        1H NMR and 13C NMR spectra of product 2.3d are published in the literature.2 
        1H NMR and 13C NMR spectra of product 2.3e are published in the literature.2 
        1H NMR and 13C NMR spectra of product 2.3f are published in the literature.2 
        1H NMR and 13C NMR spectra of product 2.3g are published in the literature.2 
        1H NMR and 13C NMR spectra of product 2.3h are published in the literature.2 
        1H NMR and 13C NMR spectra of product 2.3i are published in the literature.2 
        1H NMR and 13C NMR spectra of product 2.3j are published in the literature.2 
        1H NMR and 13C NMR spectra of product 2.3k are published in the literature.2 
        1H NMR and 13C NMR spectra of product 2.3l are published in the literature.2 
        1H NMR and 13C NMR spectra of product 2.3m are published in the literature.2 
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Appendix C 1H NMR/13C NMR Spectra for Chapter 3 
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Appendix D 1H NMR/13C NMR Spectra for Chapter 4 
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